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Abstract
ATRX is an ATP-dependent chromatin remodeler required to safeguard genomic
integrity. Conditional deletion of Atrx in the mouse embryonic forebrain and anterior
pituitary in AtrxFoxg1Cre mice phenocopies mouse models of progeria which display
increased DNA damage, coupled with reduced lifespan, growth and subcutaneous fat.
These mice also have severely low circulating levels of insulin like growth factor 1 (IGF1) and (T4) which have been reported in models of premature aging. Based on evidence
that Igf1 is activated by the ligand-bound thyroid hormone receptor, I tested whether T4
supplementation could restore IGF-1 levels and ameliorate premature aging phenotypes
in AtrxFoxG1Cre mice. However, restoration of normal serum T4 levels failed to rescue
circulating IGF-1 levels, growth defects or reduced lifespan. This could be explained in
part by an unexpected deletion of ATRX in hepatocytes where ATRX promotes thyroid
hormone receptor mediated Igf1 expression. In the second half of this thesis, I
demonstrated that AtrxFoxG1Cre mice are also characterized by nervous system
hypomyelination,

another

aging-related

phenotype.

Myelin

is

produced

by

oligodendrocytes and ensures rapid propagation of action potentials necessary for higher
cognitive functioning. Systemic thyroxine supplementation improved myelin levels by
promoting oligodendrocyte differentiation. However, myelin restoration was incomplete,
as the number of oligodendrocyte precursor cells (OPCs) was still diminished, pointing to
additional roles of ATRX in the generation or maintenance of these cells. Using directed
inactivation of Atrx in postnatal OPCs or neurons, I established that ablation of ATRX in
the former, but not the latter, results in hypomyelination. ATRX-null OPCs displayed a
more plastic state in vitro and in vivo, allowing a shift from a strict oligodendrocyte
differentiation program toward ectopic astrogliogenesis, ultimately leading to
hypomyelination. Mechanistically, I provide evidence that ATRX associates with the
histone deacetylase HDAC3 in OPCs to promote transcription of the Olig2 fate
specification gene. Collectively this study identified thyroxine-dependent and independent effects of Atrx gene activation on premature aging-like phenotypes in mice.
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Summary for Lay Audience
ATRX is a protein that alters the way DNA is packaged in cells. This function is
necessary to prevent DNA damage and ensure the proper development of many different
cell types and tissues. Mouse models can be used to study the function of ATRX in
development by genetically removing the Atrx gene. Deletion of Atrx from the mouse
brain and pituitary caused symptoms that appear in other mouse models of premature
aging. These abnormalities included a reduction in growth, fat, glucose levels and
lifespan. ATRX deficient mice also exhibited low levels of the thyroid hormone
thyroxine and insulin-like growth factor 1 (IGF-1), as seen in other premature aging
models and both of which are necessary for growth and development. Others have
reported that thyroid hormone can increase IGF-1 levels to promote growth and
development. With this in mind, we thought that supplementing ATRX deficient mice
with thyroid hormone may rescue these harmful developmental symptoms by increasing
IGF-1 levels. However, due to inherent problems with genetic manipulation in mice, we
found that ATRX was unexpectedly absent in the liver. The liver is the primary site for
production of IGF-1 and thyroid hormone was unable to increase IGF-1 levels due to the
absence of ATRX in the liver. Excitingly, thyroid hormone treatment rescued
hypomyelination in ATRX-deficient mice. The cell type in the brain that produces myelin
is the oligodendrocyte which insulates neurons to speed up electrical current in the brain.
However, the rescue in myelin was only partial, leading us to investigate whether ATRX
is important in oligodendrocytes to produce myelin. Using another mouse model, ATRX
was specifically deleted in oligodendrocytes. In this model, we found that ATRX is
necessary for the development of oligodendrocytes and in its absence, these cells become
another brain cell type called astrocytes, ultimately leading to reduced myelin in the
brain. Collectively, this study has identified a role for ATRX in the prevention of
premature aging, both dependent and independent of the thyroid hormone thyroxine.
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Chapter 1

1.1

ATRX is a chromatin remodeling protein essential for
mouse and human development

1.1.1 The ATRX gene and protein
The ATRX gene is located on the long arm of the X chromosome (Xq21.1), contains 36
exons and spans approximately 300 kb of genomic DNA sequence. Mutations in ATRX
were originally identified as the cause of a rare, X-linked syndrome, characterized by
psychomotor delay, characteristic facial features, genital abnormalities, and alphathalassemia (ATR-X Syndrome; OMIM 301040) (Gibbons, Picketts et al. 1995). The
ATRX protein is a large (280 kDa), nuclear protein that specifically localizes to
heterochromatin (McDowell, Gibbons et al. 1999). In addition to the full length 280 kDa
ATRX protein, characterization of ATRX revealed it gives rise to at least two other
alternative transcripts. An alternative splicing of exon 6 results in a 265 kDa protein
(Picketts, Higgs et al. 1996). The third transcript, ATRXt results from a premature stop
codon, failure to remove intron 11 and C-terminal truncation producing a 180 kDa
protein (Bérubé, Smeenk et al. 2000, Garrick, Sharpe et al. 2006). It has been proposed
that ATRXt regulates the full-length ATRX protein as the two interact with one another
(Garrick, Sharpe et al. 2006).
Chromatin remodeling primarily involves histone modifying enzymes and ATPdependent chromatin remodeling complexes that alter chromatin accessibility. ATRX
falls into the latter category, using ATP to change the association between DNA and
histones by removing, replacing or changing the position of nucleosomes. ATRX is a
member of the SNF2 Switch/Sucrose non-fermenting (SWI/SNF) protein superfamily
that often functions within large multi-subunit complexes to remodel chromatin via ATP
hydrolysis (Picketts, Higgs et al. 1996). ATRX shows sequence similarities to Rad54, a
translocase protein involved in nucleotide excision repair and the initiation of
transcription (Stayton, Dabovic et al. 1994), as well as other SWI/SNF proteins involved
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in transcriptional regulation, recombination, replication and DNA repair (Picketts, Higgs
et al. 1996).
ATRX contains two highly conserved domains important for its function (Picketts,
Tastan et al. 1998). The N-terminus of ATRX contains an ADD domain (ATRXDNMT3-DNMT3L) which has a unique combination of a GATA-like zinc finger, a plant
homeodomain and an alpha-helical region that fold to form a single globular domain
(Argentaro, Yang et al. 2007) (Figure 1-1A). Furthermore, the ADD region shows
homology to the DNMT3 DNA methyltransferase family responsible for de novo
methylation during development (Xie, Wang et al. 1999, Aapola, Shibuya et al. 2000).
ADD is able to bind K4me0/K9me3 histone H3 tails within chromatin (Dhayalan, Tamas
et al. 2011, Eustermann, Yang et al. 2011, Iwase, Xiang et al. 2011) (Figure 1-1B). The
C-terminus of ATRX contains a SWI/SNF domain which provides the ATPase and
translocase activity of ATRX necessary for nucleosome remodeling (Xue, Gibbons et al.
2003, Tang, Wu et al. 2004) (Figure 1-1A). ATRX has several other domains that
facilitate its functions at chromatin. ATRX can associate with heterochromatin protein
HP1α via a variant PxVxL motif (LYVKL) (Le Douarin, Nielsen et al. 1996, Bérubé,
Smeenk et al. 2000, Lechner, Schultz et al. 2005) (Figure 1-1A). ATRX has also been
shown to bind enhancer of zeste homolog 2 (EZH2) (Cardoso, Timsit et al. 1998, Sarma,
Cifuentes-Rojas et al. 2014), however, recently their interaction could not be confirmed
(Qadeer, Valle-Garcia et al. 2019). Near the middle of the ATRX protein, there is a death
domain associated protein 6 (DAXX) interacting domain (DID) (Tang, Wu et al. 2004)
(Figure 1-1A). Within the conserved ATPase domain there is a methyl-CpG-binding
protein (MeCP2) binding domain (Nan, Hou et al. 2007) (Figure 1-1A). Lastly, there is a
promyelocytic leukemia nuclear body (PML) targeting domain at the C-terminus of
ATRX (Xue, Gibbons et al. 2003, Berube, Healy et al. 2008) (Figure 1-1A).

1.1.2 ATRX localizes to heterochromatin
Chromatin is a highly ordered structure comprised of DNA, RNA, histones and other
proteins

(Kouzarides

2007).

Euchromatin

contains

transcriptionally

hyperacetylated, hypomethylated chromatin (Kouzarides 2007). In contrast,

active,
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Figure 1-1 The structure and function of the ATRX protein
(a) Structure of the ATRX protein. Conserved domains are displayed in grey and protein
interaction sites are indicated in yellow. (b) ATRX function at chromatin. ATRX is
targeted to chromatin by binding histone H3 containing H3K9me3 and H3K4me0
(orange and green circles) chromatin marks via the N-terminal ADD domain and its
interaction with heterochromatin protein 1 α (HP1α) via the LxVxL motif. ATRX
interacts with the H3.3 chaperone DAXX through the DAXX interacting domain (DID)
and facilitates the deposition of the histone variant H3.3 into chromatin via its C-terminal
ATPase domain.
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heterochromatin is transcriptionally inactive and is in large part hypoacetylated and
hypermethylated (Kouzarides 2007). ATRX is an exclusively nuclear protein and
localizes to the nuclear matrix during interphase (Bérubé, Smeenk et al. 2000). As the
cell enters mitosis, ATRX is phosphorylated (Bérubé, Smeenk et al. 2000) and localizes
to pericentromeric heterochromatin where it interacts with HP1α (McDowell, Gibbons et
al. 1999, Bérubé, Smeenk et al. 2000, Lechner, Schultz et al. 2005). Heterochromatin
contains an abundance of the repressive histone mark H3K9me3 and evidence supports
that the ADD domain and the interaction of ATRX with HP1α contribute to recruitment
to heterochromatin (Eustermann, Yang et al. 2011) (Figure 1-1B). Loss of HP1α results
in delocalized ATRX from pericentric heterochromatin (Kourmouli, Sun et al. 2005). In
addition, mutation of the LxVxL HP1 motif or the ADD domain disrupts ATRX
localization to heterochromatin, suggesting that both interactions contribute to
recruitment (Eustermann, Yang et al. 2011). ATRX can also bind another chromatin
remodeler, MeCP2, through its C-terminal ATPase domain (Nan, Hou et al. 2007)
(Figure 1-1A). In MeCP2-deficient neurons ATRX assumes a dispersed nuclear
distribution, suggesting MeCP2 is required for heterochromatin localization of ATRX in
neurons (Nan, Hou et al. 2007).
ATRX is enriched at heterochromatic repetitive sequences like telomeres, ribosomal
DNA and pericentromeric major satellite repeats (McDowell, Gibbons et al. 1999,
Gibbons, McDowell et al. 2000, Law, Lower et al. 2010). Furthermore, ATRX localizes
to the heterochromatic inactive X chromosome (Baumann and De La Fuente 2009) as
well as the pericentric heterochromatin of the Y chromosome in neonatal spermatogonia
(Baumann, Schmidtmann et al. 2008). ATRX also maintains H3K9me3 levels at atypical
chromatin signatures with high levels of H3K9me3 and H3K36me3 in complex with the
H3K9me3-specific histone methyltransferase SETDB1 as well as TRIM28 and ZNF274
(Valle-Garcia, Qadeer et al. 2016).
ATRX is able to bind G-rich sequences that have a propensity to form bulky secondary
structures called G-quadruplexes (Law, Lower et al. 2010) as well as RNA-DNA hybrids
known as R-loops (Nguyen, Voon et al. 2017). These secondary structures can inhibit
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accurate DNA replication and proper gene expression and tend to form at telomeres
(Law, Lower et al. 2010, Nguyen, Voon et al. 2017). Evidence points to a role for ATRX
in suppressing these secondary structures to allow the replication machinery to easily
access DNA and preserve DNA replication (Law, Lower et al. 2010, Watson, Solomon et
al. 2013, Levy, Kernohan et al. 2015, Nguyen, Voon et al. 2017).

1.1.3 ATRX forms a chromatin remodeling complex with
DAXX
Early proteomics studies reported that DAXX forms a stable, DNA-independent complex
with ATRX and that the majority of both proteins are usually in complex together (Xue,
Gibbons et al. 2003). DAXX was originally identified as a mediator of apoptosis (Yang,
Khosravi-Far et al. 1997) but other studies speculated it may have a role in transcriptional
repression (Torii, Egan et al. 1999). Indeed, DAXX was shown to repress basal gene
expression in HEK293 cells and regulate both gene activation and repression in B cell
lines (Li, Pei et al. 2000, Emelyanov, Kovac et al. 2002).
Together ATRX and DAXX form a complex that deposits histone variant H3.3 at
telomeres, pericentromeric heterochromatin and rDNA (Drane, Ouararhni et al. 2010,
Goldberg, Banaszynski et al. 2010, Lewis, Elsaesser et al. 2010) (Figure 1-1B). ATRX
and DAXX interact through the DID located between the ADD and ATPase domains of
ATRX (Tang, Wu et al. 2004) (Figure 1-1B). DAXX is responsible for targeting ATRX
to PML bodies (Tang, Wu et al. 2004) and acts as a chaperone for H3.3 (Drane,
Ouararhni et al. 2010, Lewis, Elsaesser et al. 2010). ATRX provides the ATPase activity
and is able to alter DNA-histone interactions and stimulate translocation of histones
(Xue, Gibbons et al. 2003, Tang, Wu et al. 2004) (Figure 1-1B). Histone H3.3 is unique
in that it is deposited in a replication-independent manner (Ahmad and Henikoff 2002).
H3.3 can be deposited at actively transcribed genes (Ahmad and Henikoff 2002), aiding
transcription through ease of nucleosome eviction potentially due to the lower energy
cost of H3.3 ejection (Drane, Ouararhni et al. 2010). Additionally, the ATRX-DAXX
complex acts in a specialized chromatin assembly pathway at repetitive regions and
deposition of H3.3 at these sites helps to maintain their repetitive structure (Drane,
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Ouararhni et al. 2010, Goldberg, Banaszynski et al. 2010, Lewis, Elsaesser et al. 2010,
Levy, Kernohan et al. 2015).

1.1.4 ATRX maintains genomic integrity
ATRX is recruited to heterochromatin and telomeres during S phase (Wong, McGhie et
al. 2010, Huh, Price O'Dea et al. 2012, Watson, Solomon et al. 2013). Depletion of
ATRX results in an increased DNA damage response (Watson, Solomon et al. 2013,
Clynes, Jelinska et al. 2014, Valle-Garcia, Qadeer et al. 2016), double strand breaks
(DSBs) at telomeres (Wong, McGhie et al. 2010, Huh, Price O'Dea et al. 2012, Watson,
Solomon et al. 2013) and prolonged S phase (Huh, Price O'Dea et al. 2012, Leung,
Ghosal et al. 2013, Clynes, Jelinska et al. 2014). Telomeres have many kilobases of the
repeat sequence (TTAGGG)n and these tandem repeats have the propensity to form
secondary structures like G-quadruplexes and R-loops which form in the presence of Grich DNA (Parkinson, Lee et al. 2002, Lipps and Rhodes 2009). ATRX is recruited to Rloops and cells deficient for ATRX accumulate R-loops, revealing a role for ATRX in
their suppression (Nguyen, Voon et al. 2017). When G-quadruplexes are drug-stabilized
in ATRX-null neuroprogenitor cells, there is an increase in DNA damage and reduced
cell viability (Watson, Solomon et al. 2013). ATRX-null cells are also hypersensitive to
hydroxyurea (HU) treatment, a drug that inhibits DNA synthesis and causes replication
fork stalling (Watson, Solomon et al. 2013). Treatment of ATRX-deficient cells with HU
results in an increase in stalled replication forks, slow replicating forks and a reduction in
new origin firing (Leung, Ghosal et al. 2013, Clynes, Jelinska et al. 2014) indicating that
ATRX is involved in the restart of stalled replication forks and required for efficient
DNA replication (Clynes, Jelinska et al. 2014).
The MRN complex is essential for DSB repair and the restart of stalled replication forks
(Robison, Elliott et al. 2004). ATRX and DAXX are both able to directly bind three
proteins in the MRN complex: RAD50, MRE11 and NBS1 (Clynes, Jelinska et al. 2014).
Furthermore, ATRX co-localizes with the MRN complex during S phase (Clynes,
Jelinska et al. 2014). Homologous recombination (HR) is required for the removal of Gquadruplexes (Feng and Zhang 2012) and HR proteins RAD51 and BRCA1 are critical
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for the protection of replication forks (Feng and Zhang 2012). In the absence of ATRX,
RAD51 and BRCA1 colocalization is perturbed (Huh, Ivanochko et al. 2016).
Subsequently it was shown that ATRX is required for the sequestration of MRE11
(Clynes, Jelinska et al. 2015) to inhibit its exonuclease activity. In the absence of ATRX,
rampant MRE11 activity may deplete RAD51 pools leading to stalled replication forks,
excessive DNA damage and delayed S phase (Huh, Ivanochko et al. 2016). In addition, it
has been demonstrated that ATRX incorporates H3.3 during extended DNA repair
synthesis, a form of HR during DNA repair (Juhász, Elbakry et al. 2018). This evidence
suggests that ATRX facilitates the replication of complex secondary structures by
depositing H3.3 during post replicative repair (Ray-Gallet, Woolfe et al. 2011, Clynes,
Jelinska et al. 2015, Juhász, Elbakry et al. 2018).
ATRX becomes hyperphosphorylated during mitosis, indicating that it may acquire
specialized functions at the onset of the cell cycle (Bérubé, Smeenk et al. 2000). ATRX is
essential for mitotic (Ritchie, Seah et al. 2008, Ritchie, Watson et al. 2014) and meiotic
(Baumann, Viveiros et al. 2010, De La Fuente, Baumann et al. 2011) integrity. Deletion
of Atrx in neuroprogenitor cells results in micronuclei and dispersed chromosomes
indicating abnormal chromosome segregation (Ritchie, Seah et al. 2008). In addition,
deletion of Atrx in the forebrain causes metaphase chromosome fusions and telomere
defects (Watson, Solomon et al. 2013). Following Atrx deletion in the mouse forebrain,
there is extensive genomic instability that contributes to massive p53-mediated apoptosis
(Berube, Mangelsdorf et al. 2005, Seah, Levy et al. 2008). The cells that survive undergo
premature cell cycle exit during early neurogenesis and premature differentiation,
resulting in irregular neocortical layering (Ritchie, Watson et al. 2014). Similarly,
oocytes lacking ATRX display abnormal meiotic chromosome segregation, and
chromosome instability with a high incidence of aneuploidy (Baumann, Viveiros et al.
2010, De La Fuente, Baumann et al. 2015).

1.1.5 ATRX regulates gene expression
ATRX has been implicated in both the activation and repression of gene expression.
ATRX inhibits the gene expression of several imprinted genes in the brain (Kernohan,
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Jiang et al. 2010, Kernohan, Vernimmen et al. 2014), in the liver (Chatzinikolaou,
Apostolou et al. 2017) and in embryonic stem cells (Voon, Hughes et al. 2015). In the
newborn mouse cortex, the methyl binding protein MeCP2 is required for recruitment of
ATRX, cohesin and the insulator protein CTCF (CCCTC binding factor) to monoallelically suppress several imprinted genes (Kernohan, Jiang et al. 2010). Following
embryonic deletion of Atrx there is an alteration in nucleosome configuration at CTCFbinding sites of the H19 imprinting control region, resulting in reduced CTCF occupancy
and abnormal long-range chromatin interactions within the H19-Igf2 imprinted locus
(Kernohan, Vernimmen et al. 2014). Intriguingly, there is evidence suggesting that
ATRX and CTCF-cohesin also silence imprinted genes in the liver (Chatzinikolaou,
Apostolou et al. 2017). Deletion of Ercc1, part of the ERCC1-XPF complex involved in
nucleotide excision repair (NER), prompts the dissociation of CTCF-cohesin and ATRX
from promoters, resulting in abnormal activation of imprinted genes during liver
development (Chatzinikolaou, Apostolou et al. 2017). This inability to suppress the
expression of imprinted genes in the absence of ATRX may have detrimental effects on
both liver and brain development.
The role of ATRX in gene activation has been studied much more extensively. One of the
first clues to suggest ATRX may activate transcription was observed in ATR-X syndrome
patients, who display mild α-thalassemia, indicating decreased α-globin gene expression
in patients (Gibbons and Higgs 2000). Additionally, somatic mutations in ATRX can
cause α-thalassemia myelodysplasia syndrome (ATMDS) which results in α-thalassemia
in association with a myelodysplasia (Gibbons, Pellagatti et al. 2003, Steensma, Higgs et
al. 2004). ATRX has been shown to negatively regulate the histone variant macroH2A
and Atrx deletion in human erythroleukemic cells results in macroH2A accumulation at
the α-globin gene cluster and a subsequent reduction in α-globin expression (Ratnakumar,
Duarte et al. 2012). Furthermore, the human α-globin cluster is in very close proximity to
the telomere on human chromosome 16 and ATRX is known to bind telomeres (Law,
Lower et al. 2010). Chromatin immunoprecipitation (ChIP) sequencing in human
erythroblasts revealed ATRX binding in the α-globin locus within a variable number
tandem repeat (VNTR) comprised of GC rich DNA (Law, Lower et al. 2010).
Interestingly, the severity of gene repression correlated with increased length of the
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VNTR (Law, Lower et al. 2010) and G-quadruplex formation within the VNTR (Li, Syed
et al. 2016).
Deletion of Atrx in the mouse forebrain embryonically, results in many genes with
decreased expression (Levy, Fernandes et al. 2008). The most severely downregulated
genes in the ATRX-null mouse forebrain are ancestral pseudoautosomal region (aPAR)
genes (Levy, Fernandes et al. 2008) which are rich in repetitive sequence (Gianfrancesco,
Sanges et al. 2001). Two of the most affected aPAR genes, dehydrogenase/reductase
(SDR family) X-linked (Dhrsx) and colony stimulating factor 2 receptor, alpha (Csf2rα),
are located near the subtelomeric regions of mouse chromosomes 4 and 19 respectively,
similar to the α-globin cluster (Levy, Fernandes et al. 2008). Further investigations
showed that in the mouse brain, ATRX and H3.3 are enriched at G-rich regions of several
aPAR genes and deletion of Atrx results in decreased H3.3 incorporation in nucleosomes
of the gene bodies and impairment of RNA polymerase II progression (Levy, Kernohan
et al. 2015). Interestingly, ATRX recruitment to G-rich repeats is dependent on the
presence of R-loops at repeats that are actively being transcribed (Nguyen, Voon et al.
2017). Similar to its function in DNA replication, it appears that ATRX deposits H3.3 to
facilitate transcriptional elongation at G-rich genes prone to G-quadruplex formation that
present challenges for RNA polymerase II progression.
In mouse testes, ATRX is a co-factor for the nuclear hormone receptor androgen receptor
(AR) (Bagheri-Fam, Argentaro et al. 2011). When Atrx is deleted in Sertoli cells there is
a downregulation in the AR target gene Rhox5 (Bagheri-Fam, Argentaro et al. 2011).
Indeed, ATRX can enhance Rhox5 promoter activity in the presence of AR in the TM4
Sertoli cell line (Bagheri-Fam, Argentaro et al. 2011). Comparably, when Atrx is deleted
from the mouse forebrain and anterior pituitary early in development, there is a decrease
in thyroid hormone responsive gene expression indicating that ATRX may play a role in
mediating nuclear hormone receptor gene activation (Watson, Solomon et al. 2013).
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1.1.6 Hypomorphic mutations in ATRX cause ATR-X syndrome
The ATRX gene was originally discovered because mutations cause a rare X-linked
disorder (Weatherall, Higgs et al. 1981, Gibbons, Wilkie et al. 1991) characterized by
intellectual disability, developmental abnormalities and α-thalassemia (ATR-X
syndrome; OMIM #301040) (Gibbons, Picketts et al. 1995). The most recent analysis
reports over 200 cases from 182 families with 113 different mutations (Gibbons, Wada et
al. 2008). The affected individuals are almost exclusively male with female carriers
displaying skewed X-inactivation protecting them from symptoms (Gibbons, Suthers et
al. 1992). Pregnancy occurs normally and birth weight is normal in 90% of patients
(Gibbons and Higgs 2000). During the neonatal period, ATR-X syndrome babies have
severe hypotonia, feeding difficulties, abnormal movement and seizures (Gibbons and
Higgs 2000).
Intellectual disability is the most prevalent symptom in ATR-X syndrome. In a
comprehensive analysis of 145 cases from more than 80 different families, 95% display
intellectual disability, 75% have microcephaly and 35% that have seizures (Gibbons and
Higgs 2000). There tends to be a wide spectrum of severity when it comes to intellectual
delay, however, most patients are characterized by delayed milestones, limited speech,
situational understanding and display a high degree of dependence (Gibbons and Higgs
2000). Brain imaging has allowed the diagnosis of white matter abnormalities (40%)
(Wada, Ban et al. 2013, Lee, Lee et al. 2015) as well as nonspecific brain atrophy in 63%
in patients analyzed (Wada, Ban et al. 2013). There is a high prevalence of facial (94%),
skeletal (91%), genital (80%) and gut (75%) abnormalities (Gibbons and Higgs 2000).
Short stature (66%), cardiac defects (18%) and renal/urinary anomalies (14%) are less
common developmental symptoms of ATR-X syndrome (Gibbons and Higgs 2000).
Lastly, the eponymous α-thalassemia is not present in all patients diagnosed with ATR-X
syndrome (Ion, Telvi et al. 1996, Villard, Lacombe et al. 1996), occurring in 87% of
patients (Gibbons and Higgs 2000).
ATR-X syndrome’s mutation spectrum is diverse, with mutations grouped around the
highly conserved ADD (50%) and ATPase (30%) domains (Gibbons, Wada et al. 2008).
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The majority of the mutations in ATRX are missense (Gibbons, Wada et al. 2008). Two
common mutations 536A>G and 736C>T stand out in 9 and 35 families, respectively
(Gibbons, Wada et al. 2008). It has been speculated that complete absence of ATRX may
be lethal as mutations that cause ATR-X syndrome are hypomorphic (Gibbons, Wada et
al. 2008). Interestingly, even in the case of nonsense mutations, there is mutation
skipping (Howard, Malik et al. 2004) which allows phenotypic rescue and is present for
all stop codons upstream of the ATPase domain (Gibbons, Wada et al. 2008).

1.1.7 ATRX is required for proper development
Abnormal ATRX expression or activity results in severe developmental abnormalities, as
demonstrated by the associated syndrome. Mouse models have allowed the elucidation of
ATRX’s function in specific organ systems. First, gain of function studies allowing over
expression of ATRX resulted in a high lethality with the surviving mice displaying
several

developmental

abnormalities,

including

the

excessive

generation

of

neuroprogenitors (Berube, Jagla et al. 2002). Second, the attempt to delete Atrx using
transgenic approaches did not yield any clones, suggesting ATRX is required for
embryonic stem cell growth and survival (Garrick, Sharpe et al. 2006). In order to
investigate Atrx loss of function, an Atrx floxed allele was generated (Berube,
Mangelsdorf et al. 2005). Deletion of Atrx using the Gata1Cre driver, which removes the
Atrx floxed allele at the morula stage of embryonic development, is embryonic lethal
before embryonic day 9.5 (E9.5) due to trophectoderm failure (Garrick, Sharpe et al.
2006). Embryos lacking Atrx at E7.5 were extremely small as a result of proliferation
defects (Garrick, Sharpe et al. 2006). These data indicate that achieving precise levels of
ATRX is very important, as defects are present in both gain and loss of function studies.
To circumvent embryonic lethality and study ATRX function in a tissue specific manner,
tissue specific Cre lines have been used. Due to the interest in the role of ATRX in the
brain, several conditional mouse models were established by crossing the Atrx floxed
mice with various Cre driver lines. FoxG1Cre and NestinCre, which delete Atrx in all
cells of the forebrain (AtrxFoxG1Cre mice) or central nervous system (CNS) (AtrxNestinCre
mice) respectively, have provided a great deal of information (Berube, Mangelsdorf et al.
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2005). Following deletion of Atrx in either case, there was a drastic increase in cortical
neuroprogenitor

apoptosis

embryonically,

resulting

in

microcephaly

(Berube,

Mangelsdorf et al. 2005, Watson, Solomon et al. 2013). Subsequent studies determined
that ATRX is required to maintain the neuroprogenitor pool, influencing both the timing
of cell cycle exit and neuronal differentiation (Ritchie, Watson et al. 2014). Focusing on
the hippocampus, a brain structure critical in learning and memory, ATRX was found to
be essential for the survival of dentate granule cells and GABAergic interneurons, similar
to what is observed in cortical neural progenitors (Seah, Levy et al. 2008). In line with
research in the brain, ATRX is also important for the proliferation and survival of
embryonic Sertoli cells and the subsequent elongation of the testis cords (Bagheri-Fam,
Argentaro et al. 2011). Deletion of Atrx in skeletal muscle causes reduced myoblast
expansion and increased DNA damage resulting in underdeveloped muscle and kyphosis
postnatally, reiterating the role for ATRX in progenitor maintenance (Huh, Price O'Dea
et al. 2012). Additionally, deletion of Atrx in the limb mesenchyme led to shortened digit
length and brachydactyly due to increased cell death, recapitulating a symptom in ATR-X
syndrome (Solomon, Russell et al. 2013).
Lastly, there may be a role for ATRX in the regulation of insulin like growth factor 1
(IGF-1) that can link ATRX to several developmental pathways. Inactivation of Atrx in
either half the cells of the CNS in heterozygote female AtrxNestinCre mice or in all cells of
the forebrain (AtrxFoxG1Cre mice) results in low levels of circulating IGF-1, skeletal
abnormalities and reduced body size without altering growth hormone (GH) levels
(Watson, Solomon et al. 2013, Tamming, Siu et al. 2017). In target organs, IGF-1 binds
its receptor (IGF-1R) to activate the protein kinase B (AKT) signaling pathway,
promoting stem cell proliferation, growth and development (Guntur and Rosen 2013).
Moreover, there is off-target Cre expression that deletes Atrx in the anterior pituitary of
the AtrxFoxG1Cre mice and results in low levels of the thyroid hormone, thyroxine (T4)
(Watson, Solomon et al. 2013). In addition to the growth and skeletal abnormalities,
AtrxFoxG1Cre mice display several other extremely severe defects which include decreased
lifespan, hypoglycemia, reduced subcutaneous fat, cataracts and small organ size
(Watson, Solomon et al. 2013). Thyroid hormone has been shown to regulate IGF-1
expression during the perinatal and prepubertal period with growth hormone taking over
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at later stages of postnatal development (Xing, Govoni et al. 2012). The RNA transcript
levels of numerous genes involved in thyroid hormone and IGF-1 signaling are altered in
the brain, pituitary and the liver of AtrxFoxG1Cre mice, suggesting that Atrx deletion may
affect liver function (Watson, Solomon et al. 2013).
Intellectual disability, urogenital abnormalities, skeletal deformities and neonatal
hypotonia are all symptoms of ATR-X syndrome. Studying mouse models that
specifically delete Atrx in the brain, testes, muscle and limb mesenchyme has allowed the
identification of the crucial role for ATRX in the development of tissue size by
maintaining progenitor cell proliferation and survival. Interestingly, deletion of Atrx in
chondrocytes did not result in any skeletal defects (Solomon, Li et al. 2009) indicating
that Atrx functions in a tissue and cell type-specific manner during development.

1.2 Premature aging
1.2.1 Theories of aging
Aging is defined as the functional decline in physiological integrity, resulting in an
increased susceptibility to death (López-Otín, Blasco et al. 2013). Degeneration due to
aging gives rise to several pathologies such as atherosclerosis and heart failure,
sarcopenia, osteoporosis, macular degeneration, renal failure, loss of myelin and
neurodegeneration (Campisi 2013). Aging begins to escalate at mid-life (~50 years of age
in humans (Campisi 2013), ~18 months in mice (Flurkey, Currer et al. 2007)) with
degeneration beginning in one or more tissues (Campisi 2013).
Of the several identified hallmarks of aging, genomic instability, telomere attrition and
epigenetic alterations are deemed to be the primary culprits (López-Otín, Blasco et al.
2013). Deregulated nutrient sensing and cellular senescence, although initially intended
as an adaptive response to aging, eventually exacerbate the aging process due to stem cell
exhaustion, altered intercellular communication and functional deterioration (López-Otín,
Blasco et al. 2013). Each of these hallmarks is sufficient on its own to cause aging,
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however, two or more often present at the same time, demonstrating some level of
interconnectedness.
A major cause of aging is excessive DNA damage, such as nucleotide deletions,
insertions or substitutions, single- or double-stranded DNA breaks and telomere
shortening (Moskalev, Shaposhnikov et al. 2013). This genetic damage can be a result of
several exogenous (e.g. chemical, radiation) and endogenous (e.g. DNA replication
errors, reactive oxygen species (ROS)) pressures (López-Otín, Blasco et al. 2013).
Organisms have developed a complex array of DNA repair mechanisms to combat DNA
damage (López-Otín, Blasco et al. 2013, Moskalev, Shaposhnikov et al. 2013). Processes
are also in place to maintain the integrity of mitochondrial DNA (mtDNA) (Kazak, Reyes
et al. 2012). In addition to direct DNA damage, defects in nuclear architecture can result
in genomic instability (Worman 2012). When repair mechanisms can no longer cope with
the level of damage, cells undergo cell cycle arrest, apoptosis or cellular senescence (Erol
2011).
Age-associated DNA damage can occur anywhere in the genome but telomeres are
frequently affected (Blackburn, Greider et al. 2006). Due to the fact that polymerases are
unable to completely replicate the ends of DNA, telomeres of somatic cells are eventually
eliminated from the ends of chromosomes, leading to replicative senescence in vitro and
aging in vivo (Blasco 2007). Telomeres are also unique in that they are bound by the
shelterin complex which is responsible for precluding DNA repair proteins from
telomeres to prevent chromosome fusions (Palm and de Lange 2008). Because of this,
when DNA damage does occur at telomeres it is efficient at inducing senescence or
apoptosis (Fumagalli, Rossiello et al. 2012, Hewitt, Jurk et al. 2012). Embryonic stem
cells have telomerase, the telomere specific DNA polymerase which is able to replicate
telomeric repeats to preserve telomere length and cellular immortality (Hiyama and
Hiyama 2007). Remarkably, if telomerase is activated in mice, aging can be reversed
(Jaskelioff, Muller et al. 2011, Bernardes de Jesus, Vera et al. 2012).
Particular histone modifications (Fraga and Esteller 2007, Han and Brunet 2012) and
decreased maintenance of heterochromatin (Tsurumi and Li 2012) contribute to aging
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pathologies. Therefore, manipulating the epigenome might help to extend lifespan. The
family of NAD-dependent histone deacetylase, Sirtuins (SIRTs), have been implicated in
aging and were first identified as a determinant of lifespan in yeast (Kaeberlein, McVey
et al. 1999). The SIRT regulation of aging is also present in mammals, in particular
SIRT6 which has been shown to be important in maintaining genomic instability
(Mostoslavsky, Chua et al. 2006) and metabolism (Kanfi, Peshti et al. 2010). Mice
deficient in SIRT6 exhibit premature aging (Mostoslavsky, Chua et al. 2006) and those
overexpressing it have a longer lifespan (Kanfi, Naiman et al. 2012). Additionally, SIRT3
has been shown to improve lifespan by reducing oxidative damage (Someya, Yu et al.
2010) and improving the regenerative capacity of hematopoietic stem cells (Brown, Xie
et al. 2013). Global heterochromatin loss is often associated with aging (Tsurumi and Li
2012). All of the epigenetic defects accumulated throughout life contribute to aging and
may specifically affect the integrity of stem cells, thus further contributing to aging by
depletion of the stem cell pool (Pollina and Brunet 2011).
Deregulated nutrient sensing and cellular senescence are two of the responses that
initially alleviate deleterious outcomes of damage but can exacerbate symptoms if left
unrestricted (López-Otín, Blasco et al. 2013). The hypothalamic-pituitary-somatotropic
axis involves the secretion of growth hormone from the somatotropes of the pituitary
gland into circulation, ultimately, stimulating the production of insulin-like growth factor
1 (IGF-1) by several tissues, primarily the liver (Renaville, Hammadi et al. 2002) (Figure
1-2). The intracellular signaling pathway of IGF-1 is the same that is elicited by insulin
and is thus referred to as the insulin and IGF-1 signaling pathway. It is the most
conserved pathway in aging and its attenuation extends lifespan in several model
organisms (Fontana, Partridge et al. 2010, Kenyon 2010). The predominating theory is
that mitigation of the insulin and IGF-1 signaling causes a shift from that of growth and
metabolism to one of cellular maintenance, leading to lower levels of damage and
increased survival (Fontana, Partridge et al. 2010, Kenyon 2010, López-Otín, Blasco et
al. 2013). Cellular senescence is the stable arrest of the cell cycle (Hayflick 1965), which
can occur naturally due to telomere shortening or in response to stress(Campisi and
d'Adda di Fagagna 2007). The number of senescent cells increases with aging (Wang,
Jurk et al. 2009), however, its ultimate purpose is to halt the propagation of damaged
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Figure 1-2 The hypothalamic-pituitary axis controls growth, development,
metabolism and gene expression.
The hypothalamic-pituitary-somatotropic axis (left) results in the production of insulinlike growth factor 1 (IGF-1) from the liver. Whereas the hypothalamic-pituitary-thyroid
axis (right) results in the production of the thyroid hormone thyroxine (T4) from the
thyroid. The hypothalamus synthesizes and secretes growth hormone-releasing hormone
and thyrotropin-releasing hormone that act on anterior pituitary to induce the production
of growth hormone (GH) from somatotropes or thyroid-stimulating hormone (TSH) from
thyrotropes. GH then acts on the liver to stimulate production of IGF-1, leading to growth
and development, and TSH acts on the thyroid to stimulate production of T4, allowing for
thyroid hormone mediated transcription, growth and metabolism.
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cells (López-Otín, Blasco et al. 2013). Removal of senescent cells and proliferation of
progenitors to replace their aged counterparts is critical to maintain the function of aging
organ systems (López-Otín, Blasco et al. 2013). There is evidence that senescent tumour
cells are actively phagocytized (Xue, Zender et al. 2007). As the immune system declines
with age, clearance of senescent cells could become inefficient, leading to their
accumulation (Conboy and Rando 2012, López-Otín, Blasco et al. 2013). Cellular
senescence acts to compensate for accumulated DNA damage that ultimately accelerates
aging when regenerative capacity declines.
Lastly, a combination of DNA damage and the responses to DNA damage lead to stem
cell collapse and altered intercellular communication, which are responsible for the
functional decline seen in aging (López-Otín, Blasco et al. 2013). Decline in the
regenerative ability of tissues is prominent with aging (López-Otín, Blasco et al. 2013) as
is diminished stem cell capacity in several different tissues (Molofsky, Slutsky et al.
2006, Conboy and Rando 2012, López-Otín, Blasco et al. 2013). As mentioned
previously, an increase in senescence and a decrease in serum IGF-1, originally intended
as protective for the stem cell niche, becomes deleterious when there is no longer an
active pool of stem cells for regeneration of aged tissues (López-Otín, Blasco et al. 2013).
The final consequence of DNA damage is altered cellular communication in which
inflammation, decreased immunosurveillance and environmental changes result in a
failure of the immune system to clear damaged or infected cells (López-Otín, Blasco et
al. 2013).

1.2.2 Premature aging syndromes
Progeroid syndromes are rare genetic disorders that mimic the clinical and molecular
aspects of aging prematurely (Navarro, Cau et al. 2006, Vidak and Foisner 2016). The
majority of progeroid syndromes are considered segmental, meaning that multiple tissues
are affected yet they do not fully recapitulate all symptoms of physiological aging
(Navarro, Cau et al. 2006, Vidak and Foisner 2016). Studying the genetic and molecular
aspects of premature aging disorders can give insight into mechanisms contributing to
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natural aging. Premature aging syndromes arise when DNA damage accumulates due to a
compromised nuclear membrane or with defects in DNA repair pathways, highlighting
the importance of genomic integrity in aging (Eriksson, Brown et al. 2003).
Two progeroid syndromes closely echo the features of physiological aging: HutchinsonGilford Progeria Syndrome (HGPS) and Werner Syndrome (WS). HGPS is a premature
aging disease caused by mutations in the LAMIN A (LMNA) gene (Gonzalo, Kreienkamp
et al. 2017). Maintaining the structure of the nuclear membrane is critical for nuclear
architecture and genome stability (Burke and Stewart 2014). The nuclear lamina is made
up of type V intermediate filament lamin proteins whose expression is directly
proportional to the stability of the nucleus (Swift, Ivanovska et al. 2013, Burke and
Stewart 2014). A-type lamins (lamin A/C) are expressed primarily in differentiated cells
(Constantinescu, Gray et al. 2006) and arise from alternative splicing of the LMNA gene
(Burke and Stewart 2014).
The prelamin A protein is a precursor to the mature Lamin A protein. Post-translational
processing of prelamin A by the endoprotease ZMPSTE24 results in a mature lamin A
protein (Davies, Fong et al. 2009). The mutant form of lamin A, termed progerin, induces
abnormalities in nuclear processes leading to decline in cellular functioning and disease
(Davies, Fong et al. 2009). Symptoms of HGPS include, short stature, failure to thrive,
skin abnormalities, alopecia, atherosclerosis, bone and joint abnormalities and
subcutaneous fat loss (Merideth, Gordon et al. 2008). HGPS cells display several of the
hallmarks of aging. Cells derived from patients with HGPS are characterized by loss of
repressive histone marks at heterochromatin (Shumaker, Dechat et al. 2006). There are
also reversals in methylation of CpG sites (Heyn, Moran et al. 2013) and
hypermethylation of ribosomal RNA genes (Osorio, Varela et al. 2010). Interestingly,
expression of progerin and chromatin changes observed in HGPS cells are observed in
cells in normal aging (Scaffidi and Misteli 2006). Unsurprisingly, there are defects in
nuclear morphology in cells that have mutations in LMNA. It has been reported that
HGPS fibroblasts have accelerated telomere shortening (Decker, Chavez et al. 2009) and
undergo premature senescence (Benson, Lee et al. 2010). Furthermore, in a mouse model
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of HGPS, mice exhibit dysregulated IGF-1 signaling with a progressive decline in serum
IGF-1 levels (Mariño, Ugalde et al. 2010).
WS arises due to mutations in the Werner syndrome ATP-dependent helicase (WRN)
gene which encodes a RecQ helicase that uses ATP hydrolysis to unwind double-stranded
DNA (Brosh, Waheed et al. 2002). Symptoms of WS include many of the symptoms of
classic segmental progeria: lack of the pubertal growth spurt (Shamanna, Croteau et al.
2017), greying hair, cataracts, abnormal glucose and lipid metabolism and osteoporosis
(Takemoto, Mori et al. 2013). Mutations in WRN cause several hallmarks of aging. WRN
regulates double strand break repair pathway choice and interacts with several proteins
that are involved in HR, non-homologous end joining (NHEJ) and single-strand
annealing (Croteau, Popuri et al. 2014). There is an excess in DNA damage in WS as
well as telomere fusions (Laud, Multani et al. 2005, Crabbe, Jauch et al. 2007) and
chromosome translocations (Melcher, von Golitschek et al. 2000). WRN is also important
at telomeres and is involved in the replication of secondary structures normally found at
telomeres like g-quadruplexes (Johnson, Cao et al. 2010). Loss of heterochromatin has
been reported in WS cells (Zhang, Li et al. 2015) and is speculated to be the cause of
increased senescence and stem cell exhaustion observed in WS (Norwood, Hoehn et al.
1979).

1.2.3 The role of IGF-1 in premature aging
Paradoxically, studies have shown that reduced IGF-1 signaling occurs in both long-lived
model organisms and progeria models (Garinis, van der Horst et al. 2008). It is
hypothesized that in models of progeria, mutations in genome repair genes result in
increased DNA damage and a switch from a state of growth to one of maintenance,
reducing IGF-1 levels in order to survive the damage (Garinis, van der Horst et al. 2008).
This down regulation of IGF-1 and the resulting reduction in the stem cell pool is
detrimental during the developmental period, leading to premature aging syndromes.
Correspondingly, IGF-1 reduction has been observed in several mouse models of
progeria (de Boer, Andressoo et al. 2002, Mariño, Ugalde et al. 2010, Kanfi, Naiman et
al. 2012).
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Circulating IGF-1 is largely produced by liver hepatocytes (Ohlsson, Mohan et al. 2009),
but small amounts can also be produced in peripheral tissues, including bone (Mohan and
Baylink 1996, Canalis 1997) and brain (Bondy, Werner et al. 1992). IGF-1 is bound by
six IGF binding proteins (IGFBP) that regulate the action of IGF-1 (Jones and Clemmons
1995). IGFBPs transport IGFs from the bloodstream to target tissues (IGFBP-1, 2 and 4),
maintain IGF-1 levels in the serum (IGFBP-3) and can even inhibit the actions of IGF-1
(Jones and Clemmons 1995). Additionally, most of IGF-1 in the serum is in complex
with IGFBP-3, IGFBP-5 and IGF acid-labile subunit (IGFALS) (Boisclair, Rhoads et al.
2001).
In target organs, IGF-1 binding to its receptor results in tyrosine kinase activation
followed by phosphorylation of substrates which include insulin receptor substrates
(IRS1, IRS2) (Fumihiko and Shin-Ichiro 2018). Phosphorylated substrates are recognized
by molecules that contain an Src homology 2 (SH2) domain which is important for
intracellular signal transduction (Fumihiko and Shin-Ichiro 2018). These interactions are
followed by activation of the MAP kinase or PI 3-kinase cascades that mediate many
cellular processes like cell growth, differentiation, survival and protein synthesis
(Fumihiko and Shin-Ichiro 2018).
An example that highlights the detrimental effect of IGF-1 reduction during development
is metallopeptidase Zmpste24-null mice (Mariño, Ugalde et al. 2010). Zmpste24 is a
metallopeptidase involved in processing LMNA from prelamin A (Davies, Fong et al.
2009). Zmpste24-null mice, which phenocopy HGPS, have severely low levels of IGF-1
as well as many of the classic symptoms seen in HGPS (Mariño, Ugalde et al. 2010).
Treatment of Zmpste24-null mice with IGF-1 ameliorates the premature aging features
and extends lifespan, indicating that reduced IGF-1 is causative of premature aging
phenotypes in these mice (Mariño, Ugalde et al. 2010).

1.2.4 The role of thyroid hormone in premature aging
The hypothalamic-pituitary axis is essential for the maintenance of homeostasis,
metabolism, reproduction, growth, and lactation (Scully and Rosenfeld 2002, Mendoza
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and Hollenberg 2017). The synthesis and secretion of trophic hormones is controlled by
the hypothalamus which subsequently signals to the pituitary gland (Scully and
Rosenfeld 2002, Mendoza and Hollenberg 2017) (Figure 1-2). The anterior pituitary is
derived from ectoderm in Rathke’s pouch where organogenesis begins at E8.5 and is
followed by proliferation and patterning of several different cell types (Scully and
Rosenfeld 2002). Thyrotropes in the anterior pituitary produce thyroid-stimulating
hormone (TSH) which stimulates the thyroid to produce the prohormone T4 (Scully and
Rosenfeld 2002, Chiamolera and Wondisford 2009) (Figure 1-2). T4 is then converted to
its active form triiodothyronine (T3) in the target tissue (Scully and Rosenfeld 2002).
Thyroid hormone participates in a positive and negative feedback loop from peripheral
organ systems to both the hypothalamus and pituitary to regulate hormone synthesis in
the hypothalamic-pituitary-thyroid axis (Mendoza and Hollenberg 2017) (Figure 1-2).
Thyroid hormone is essential for proper development, growth, cellular differentiation and
metabolic regulation (Gereben, Zavacki et al. 2008).
Thyroid hormone exerts its effects by binding to the thyroid hormone receptors (TRs) to
control the expression of several genes. TRs act as transcription factors to either enhance
or repress transcription depending on whether T3 is bound or not (Xu, Glass et al. 1999,
Grøntved, Waterfall et al. 2015). The thyroid receptors TRα (Sap, Munoz et al. 1986) and
TRβ (Koenig, Warne et al. 1988) both bind thyroid hormone and recognize the same
thyroid hormone response elements (TREs) (Lazar 1993). There appears to be some
degree of compensation amongst the TR isoforms (Gauthier, Chassande et al. 1999); TRα
is ubiquitously expressed whereas TRβ is restricted to particular tissues, including the
liver, later in development (Bradley, Towle et al. 1992). TRα has been shown to be
important for bone growth (Gauthier, Chassande et al. 1999) with mice null for both
isoforms of TRα exhibiting low levels of thyroid hormone, growth defects and early
postnatal death (Fraichard, Chassande et al. 1997). Deletion of TRβ on its own did not
result in any defects in growth (Forrest, Hanebuth et al. 1996).
The actions of TRs are mediated by both systemic T4 and local T3 availability (Gereben,
Zavacki et al. 2008), transport of thyroid hormone into the cell (Visser, Friesema et al.
2011), the distribution of TR isoforms (Mendoza and Hollenberg 2017) and nuclear
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corepressors and coactivators (Astapova, Lee et al. 2008, Mendoza and Hollenberg
2017). Both T3 and T4 are normally bound to transport molecules in the bloodstream like
albumin, thyroxine binding globulin (TBG) and transthyretin (TTR) (Mendoza and
Hollenberg 2017). Neither of the thyroid hormones are able to passively cross cell
membranes (Mendoza and Hollenberg 2017). T4 is transported from the circulation into
the cytoplasm by monocarboxylate transporters (MCT8 and MCT10), the organic anion
transporter (OATP1) and L-type amino acid transporter (LAT) (Mendoza and Hollenberg
2017). Once T4 enters the cell, it is converted to T3 by type 1 deiodinase (Dio1) or type 2
deiodinase (Dio2) (Mendoza and Hollenberg 2017). The availability of the thyroid
hormones can also be regulated by deiodinase 3 (Dio3), producing reverse T3 (rT3) and
T2 which are the deactivated forms of T4 and T3 respectively (Mendoza and Hollenberg
2017). The action of T3 is dependent on the availability of its receptor, which is mostly
found as a heterodimer with retinoid X receptor (RXR) (Mendoza and Hollenberg 2017).
Following ligand binding, the heterodimer undergoes a conformational change allowing
for differential recruitment of coregulators (Ramadoss, Abraham et al. 2014, Grøntved,
Waterfall et al. 2015, Mendoza and Hollenberg 2017). In the absence of T3 ligand, TRs
bind nuclear receptor corepressor (NCOR1), which forms a corepressor complex with
transducin (beta)-like 1 (Tbl1) and histone deacetylase (HDAC3) (Sun, Feng et al. 2013,
You, Lim et al. 2013, Ramadoss, Abraham et al. 2014, Grøntved, Waterfall et al. 2015,
Mendoza and Hollenberg 2017). Following T3 ligand binding to TRs, the corepressor
complex is replaced by coactivators which include the steroid receptor coactivator (SRC)
family and p300/CBP (CREB-binding protein) leading to histone acetylation and gene
activation (Astapova 2016, Mendoza and Hollenberg 2017). Additionally, liganded TRs
can repress genes (Ramadoss, Abraham et al. 2014) and TRs have a myriad of target
genes (Yen, Feng et al. 2003) emphasizing the complexity of TR-mediated gene
regulation. It is important to note that low thyroid hormone could contribute to
hypomyelination observed in the premature aging syndromes like, Cockayne Syndrome
(Koob, Laugel et al. 2010, Revet, Feeney et al. 2012), as ligand-bound TR is an important
activator of myelin gene expression (Farsetti, Mitsuhashi et al. 1991, Ibarrola and
Rodriguez-Pena 1997, Dong, Yauk et al. 2009).
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The overall role of thyroid hormone in aging appears to be similar to that of IGF-1;
subclinical levels of thyroid hormone may lead to extended longevity (Gussekloo, van
Exel et al. 2004, Over, Mannan et al. 2010) but can be detrimental during the
developmental period. Low thyroid hormone and excessive Dio3 expression, the enzyme
responsible for deactivating thyroid hormone, have been reported in premature aging
mouse models and aged mice (Visser, Bombardieri et al. 2016). The mechanism by
which thyroid hormone exerts a protective effect in aging has yet to be elucidated. IGF-1
levels are controlled by GH, but there is evidence to suggest Igf1 expression may be
controlled by thyroid hormone, particularly in the prepubertal period (O'Shea, Bassett et
al. 2005, Wang, Shao et al. 2010, Xing, Govoni et al. 2012). TR is able to bind a thyroid
hormone response element in intron one of Igf1 to stimulate its expression (Xing, Govoni
et al. 2012). Mice deficient in thyroid hormone show greater than 50% decrease in Igf1
expression in liver and bone, and T4 treatment can reverse this effect (Xing, Govoni et al.
2012). These mice also exhibit phenotypes of premature aging, including skeletal
abnormalities and low IGF-1, both of which were rescued following treatment with
thyroid hormone (Xing, Govoni et al. 2012).

1.3 Myelination
1.3.1 Oligodendrocyte development
The balance of the four major cell types in the brain (neurons, microglia, astrocytes and
oligodendrocytes (OLs)) is essential for the development of a normal functioning nervous
system. Neural stem cells generate neurons, astrocytes and OLs in the CNS. After the
initial production of neurons, neural stem cells shift to a gliogenesis program to generate
astrocytes and OLs (Sauvageot and Stiles 2002). Astrocytes are involved in synapse
formation, regulation of blood flow, ion homeostasis, metabolism and blood brain barrier
function (Sofroniew and Vinters 2010). OLs are responsible for producing the myelin
sheath which is essential for proper signal propagation in neurons. (Stadelmann, Timmler
et al. 2019). Oligodendrocyte precursor cell (OPC) birth occurs early in development
followed by the migration and proliferation of OPCs. OPCs then go through several
stages of maturation ultimately differentiating into mature myelinating OLs. Lastly, the
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production of myelin occurs as OLs make contact with and ensheathe target axons with
their plasma membrane.
In the embryonic mouse brain, OPCs exhibit compensatory redundancy, by being
produced in three distinct waves. Beginning at E12.5, OPCs originate in the
subventricular zone of the medial ganglionic eminence and the anterior entopeduncular
area, migrating in a ventral to dorsal wave (Kessaris, Fogarty et al. 2006). OPC
generation continues to move dorsally towards the neocortex, in a medial wave, with
production stemming from the lateral and caudal ganglionic eminences at E15.5
(Kessaris, Fogarty et al. 2006). A final wave of OPC production occurs at birth from the
dorsal subventricular zone into the cortex (Kessaris, Fogarty et al. 2006). OPC tracing has
demonstrated that the P10 cortex is populated by OPCs from the medial and dorsal waves
of OPCs (Kessaris, Fogarty et al. 2006) (Figure 1-3), while the first ventral wave of OPCs
is completely lost in the postnatal brain. Interestingly, ventrally produced OPCs do
survive if the second or third waves are perturbed (Kessaris, Fogarty et al. 2006). The
overabundance of OPC production suggests a competitive and flexible system in which
the amount of myelin produced can be adjusted to suit unfavourable conditions, neuronal
activity or even diminished when there is a reduced need (Hill, Patel et al. 2014).
OPCs are generated from the commitment of proliferative neural stem cells through the
expression of the oligodendrocyte basic-helix-loop-helix (bHLH) transcription factors
Olig2 and Olig1 to generate OPCS (Figure 1-3). Olig2 is necessary for OPC generation
whereas Olig1 is involved in OL differentiation (Lu, Cai et al. 2001, Zhou, Choi et al.
2001, Othman, Frim et al. 2011). Knockout of Olig1/2 individually or together, results in
defects in myelin production (Lu, Sun et al. 2002, Zhou and Anderson 2002, Zhu, Zuo et
al. 2012). Olig2 is also transiently expressed in developing astrocytes (Cai, Chen et al.
2007). OPC migration is controlled by several signaling molecules, growth factors and
extracellular matrix components (de Castro and Bribián 2005, Elbaz and Popko 2019). Of
particular note is platelet derived growth factor (PDGF) (Fruttiger, Karlsson et al. 1999)
which is critical in general OPC development and is normally secreted by neurons and
astrocytes. Following OPC migration to the correct brain locations, OPCs rapidly
proliferate, mediated by PDGF signalling, and continue to divide until homeostasis is
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Figure 1-3 Developmental timeline of neuron, astrocyte and oligodendrocyte
production in the mouse brain.
Neurons, astrocytes and oligodendrocytes are all produced form the commitment of
neural stem cells that have the ability to self-renew or become committed to one of these
lineages. Neuron development occurs earliest in development starting at embryonic day
(E)8 continuing until just before birth at E20. Astrocyte development begins at E12 and
continues postnatally until P12. During this time, oligodendrocyte development also
occurs. At E15.5, the medial oligodendrocyte precursor cells are born, however, only a
portion go on to produce myelinating oligodendrocytes, represented by the dashed line in
the

developmental

timeline.

The

majority

of

oligodendrocytes

come

from

oligodendrocyte precursor cells that appear at birth (P0) which continue into myelinating
oligodendrocytes starting at P10 and throughout postnatal development. Additionally,
there is a resident population of oligodendrocyte precursors that exist in adulthood.
Astrocytes, oligodendrocyte precursors and myelinating oligodendrocytes express several
cell-type specific proteins which are listed below each cell type.
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reached (van Heyningen, Calver et al. 2001). Id2 (inhibitor of DNA binding 2) (Samanta
and Kessler 2004), Id4 (inhibitor of DNA binding 4) (Samanta and Kessler 2004), Hes1
(Hes family bHLH transcription factor 1) (Kondo and Raff 2000), Hes5 (Hes family
bHLH transcription factor 5) (Kondo and Raff 2000) and G protein-coupled receptor
(Gpr17) (Chen, Wu et al. 2009) are responsible for the prevention of premature
differentiation of OPCs. The rate of OPC cell division is dependent on location and
declines with age (Young, Psachoulia et al. 2013). OPCs make up ~5% of cells in the
adult brain and constitute the major dividing population in the adult CNS (Dawson, Polito
et al. 2003). OPCs in the adult CNS are important for normal myelin maintenance as well
as in remyelination in cases of injury (Rivers, Young et al. 2008, Kang, Fukaya et al.
2010, Young, Psachoulia et al. 2013). In the case of injury, demyelinated axons make
synaptic contacts with OPCs and the resulting neuronal activity via glutamate signalling
has been shown to cause OPC differentiation (Gallo, Zhou et al. 1996, Mangin, Li et al.
2012, Gibson, Purger et al. 2014, Gautier, Evans et al. 2015).
In addition to Olig2, several additional cofactors contribute to OL specification. Olig2
activates Sox10 (SRY-Box Transcription Factor 10), which participates in a positive feed
back loop with Olig2 to establish the OPC lineage (Finzsch, Stolt et al. 2008, Kuspert,
Hammer et al. 2011, Yu, Chen et al. 2013). Sox10 expression in primitive OPCs
(priOPCs) induces OPC development through the activation of chondroitin sulfate
proteoglycan (Cspg4; protein: neural glial antigen 2 (NG2)) and Pdgfrα (Pringle, Mudhar
et al. 1992, Nishiyama, Lin et al. 1996). NG2 is a surface type I transmembrane core
protein involved in cell migration and proliferation (Makagiansar, Williams et al. 2007).
PDGFRα promotes OPC proliferation, migration and survival (Noble, Murray et al. 1988,
Pringle, Collarini et al. 1989). NG2 and PDGFRα have been shown to interact and colocalize (Nishiyama, Lin et al. 1996, Nishiyama, Lin et al. 1996) providing further
evidence that they work together to maintain the OPC population. NG2 (Kucharova and
Stallcup 2010) and PDGFRα-null mice have a reduction in the OPC pool and subsequent
hypomyelination due to precocious OPC differentiation (Fruttiger, Karlsson et al. 1999).
Further commitment to the OL lineage starts with the generation of pre-OLs which, after
cell cycle exit, express myelin regulatory factor (Mrf) (Emery, Agalliu et al. 2009).
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Sox10 is responsible for the activation of Mrf and both proteins are responsible for the
activation of many other myelin critical genes (Hornig, Frob et al. 2013). As the OLs
mature and contact axons, they become highly branched and upregulate several myelin
sheath proteins while encompassing the axon. Several nuclear receptors are also
important for OL development (Elbaz and Popko 2019). There is an abundance of
evidence suggesting that TRs are important for the differentiation of OPCs. Myelination
is delayed in hypothyroid rats and accelerated in hyperthyroid rats (Walters and Morell
1981). Both TRα and TRβ are expressed in OLs in vitro (Baas, Fressinaud et al. 1994)
and in vivo (Carlson, Strait et al. 1994) and contribute to their differentiation. TRα1 is
involved in initial cell cycle exit (Billon, Jolicoeur et al. 2002) and TRβ1 in promoting
differentiation and myelination (Farsetti, Mitsuhashi et al. 1991, Billon, Tokumoto et al.
2001). In line with this, studies have shown that expression of essential myelin proteins,
myelin basic protein (MBP), myelin associated glycoprotein (MAG), proteolipid protein
(PLP) and 2,3’-Cyclic nucleotide 3’-phosphodiesterase (CNPase), are reduced in models
of hypothyroidism (Rodriguez-Peña, Ibarrola et al. 1993, Ibarrola and Rodríguez-Peña
1997, Barradas, Vieira et al. 2001). Furthermore, both TRs can directly bind and activate
the Mbp and Mag genes (Farsetti, Mitsuhashi et al. 1991, Ibarrola and Rodríguez-Peña
1997, Dong, Yauk et al. 2009).
Epigenetic regulation is critical for OPC formation, differentiation and subsequent
myelination. The OL lineage can be manipulated by changing histone acetylation state;
histone acetyltransferases (HATs) make chromatin more accessible, while the opposite is
true for histone deacetylases (HDACs) (Kouzarides 2007). HDAC1 and HDAC2 promote
OPC differentiation in the mouse CNS (Ye, Chen et al. 2009). Of note, only concurrent
deletion of HDAC1 and HDAC2 results in a defect in myelination, suggesting a
functional redundancy for these two proteins (Ye, Chen et al. 2009). At the onset of OPC
differentiation, HDAC1 is recruited to repress inhibitors of differentiation like Id2, Id4
and Hes5 (He, Dupree et al. 2007, Shen, Sandoval et al. 2008). HDAC3 supresses
neuronal specification (He, Dupree et al. 2007, Ye, Chen et al. 2009) and paradoxically,
has also been shown to promote Olig2 expression with the p300 HAT (Zhang, He et al.
2016). Additionally, the acetyltransferase CREB-binding protein (CBP) acetylates Olig1
and promotes OL differentiation (Dai, Bercury et al. 2015).
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Methylation states have not been fully characterized in OL development. Histone
demethylases have not been associated with OL development, however, during OL
differentiation the level of H3K9me3 increases (Sher, Boddeke et al. 2012, Liu, Magri et
al. 2015, He, Wang et al. 2017). Furthermore, EZH2, which catalyzes the trimethylation
of H3K27, has been shown to support OPC lineage commitment in neural stem cells
while suppressing astrocyte development (Sher, Rossler et al. 2008). In fact, the PRC2
complex, which contains EZH2, has been shown to control the balance of OPC
maintenance and OL differentiation, favoring the latter (He, Wang et al. 2017).

Several members of the ATP-dependent SWI/SNF chromatin remodeling family have
been implicated in OL development in a cascade of chromatin remodeling events. The
Snf2 chromatin remodeler CHD8 promotes the expression of the Smarca4 (Brg1) which
encodes the ATPase domain of the multi-subunit SWI/SNF chromatin remodeling
complex (Zhao, Dong et al. 2018). Brg1 is recruited to the Olig2 promoter (Matsumoto,
Banine et al. 2016) as well as other OL-differentiation genes (Yu, Chen et al. 2013). Brg1
and Olig2 then activate the chromatin remodeler CHD7 during OL differentiation (He,
Marie et al. 2016) and CHD7 triggers expression of Mrf and Olig1 to stimulate OL
maturation (He, Marie et al. 2016). This cascade of chromatin remodeling events ensures
the proper timing and region-specific progression of the OL lineage.

1.3.2 The fate potential of oligodendrocyte precursor cells
OPCs have been shown to become astrocytes (Raff, Miller et al. 1983, Rao and MayerProschel 1997) and neurons (Kondo and Raff 2000, Belachew, Chittajallu et al. 2003,
Liu, Han et al. 2007, Rivers, Young et al. 2008) under particular in vitro conditions. In
spite of this, there is limited evidence as to whether OPCs have an expanded fate
potential. There is in vivo evidence to suggest OPCs may be bipotential glial progenitors.
When cells of the OPC cell line CG4 are transplanted into glial deficient areas of the
mouse spinal cord, they develop into both astrocyte and OL-like cells (Franklin, Bayley
et al. 1995, Windrem, Nunes et al. 2004). Additionally, reports have suggested that 40%
of protoplasmic astrocytes specifically in the grey matter of the ventral posterior
forebrain, are derived from NG2-expressing cells, however, this was not observed at all
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in white matter tracts (Zhu, Bergles et al. 2008). Genetic manipulation has allowed the
mechanisms governing OPC potential to be further clarified. It was shown that deletion
of Olig2 or Hdac3 in OPCs results in ectopic astrocyte development in the dorsal cortex
at the expense of the OL lineage. (Cai, Qi et al. 2005, Zhu, Zuo et al. 2012, Zhang, He et
al. 2016, Zuo, Wood et al. 2018). These data suggest that OPCs have the ability to
differentiate into astrocytes in vitro but are restricted to the OL lineage in normal in vivo
conditions.

1.3.3 Myelin function and structure
White matter tracts in the CNS are made up of many myelinated axons with very few cell
bodies. Myelination begins at P10 and continues until 3 months of age in the mouse brain
(Hammelrath, Skokic et al. 2016). Myelination of axons occurs by the stacking of the OL
membrane, twisting around the axon and subsequent membrane expansion (Stadelmann,
Timmler et al. 2019). The membrane is then primarily compacted by MBP to prevent
current leakage along the axon and to allow for saltatory conduction of action potentials
(Salzer and Zalc 2016).
Myelin is also required for axon integrity and survival (Funfschilling et al., 2012; Saab et
al., 2016). OLs have been shown to produce energy for axons in times of high neuronal
activity (Lee, Morrison et al. 2012, Saab, Tzvetavona et al. 2016). As the compaction of
the myelin sheath prevents the axon from contacting nutrients, cytoplasmic channels
within the myelin sheath allow metabolic coupling between the axon and the OL
(Stadelmann, Timmler et al. 2019). OLs express MCTs (Lee, Morrison et al. 2012) which
transport lactate, pyruvate, ketone bodies and hydrogen ions across membranes (Pierre
and Pellerin 2005). Additionally, OLs can react to neuronal activity, by sensing axonal
glutamate release and responding with increased production of glucose transporters to
meet the energy needs of the neuron (Saab, Tzvetavona et al. 2016).
Myelin is unique in that it is composed of an unusually high amount of lipids (Norton and
Poduslo 1973) which make up about 70% of the myelin sheath (Salzer and Zalc 2016).
Electron microscopy has allowed myelin structure to be studied in depth. Myelin was first
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characterized as a multilayered stack of membranes which later become the cytoplasmic
(major dense line) and extracellular (interperiod line) membrane bilayers which occur in
repeating patterns of 12 nm (Salzer and Zalc 2016). The major dense line is a unique
structure in which there is a 3 nm wide compartment between two lipid bilayers (Salzer
and Zalc 2016). The major dense line is primarily stabilized by MBP which is essential
for the compaction of the two extracellular membrane bilayers (Salzer and Zalc 2016,
Raasakka, Ruskamo et al. 2017). MBP is a small, unstructured polypeptide chain that
assumes both α-helical and β-sheet structures upon interaction with the membrane
(Harauz, Ishiyama et al. 2004). This interaction is mediated by electrostatic forces
between the basic residues of MBP and negatively charged lipids of the membrane
(Musse, Gao et al. 2008, Nawaz, Kippert et al. 2009, Raasakka, Ruskamo et al. 2017).
Upon MBP binding, the membrane is compacted, resulting in protrusion of cytosol and
the exclusion of most proteins from the myelin sheath (Aggarwal, Yurlova et al. 2011).
To maintain cytoplasmic channels necessary for molecule transport, CNPase interacts
with actin to oppose MBP-mediated membrane compaction (Brunner, Lassmann et al.
1989, Snaidero, Velte et al. 2017). Myelin is also compacted by PLP, a transmembrane
protein within the myelin sheath (Boison, Bussow et al. 1995). Glycoproteins are myelin
minor proteins (Poduslo 1983) that mediate glial-glial and glial-neuron interactions. The
myelin sheath is attached to an axon via the paranodal axonal-glial junction (Salzer and
Zalc 2016). MAG coats the circumference of the adaxonal myelin membrane (Quarles
2007) and its dimerization restricts the cytosolic regions to a diameter of 10 nm (Pronker,
Lemstra et al. 2016). MAG also interacts with neuronal gangliosides (Schnaar and Lopez
2009) and activates extracellular signal-regulated kinase, which is involved in axonal
cytoskeleton maturation (Dashiell, Tanner et al. 2002). Similarly, MOG is expressed on
the surface of the myelin sheath (Brunner, Lassmann et al. 1989) and although its
structure (Martini and Schachner 1986) is known, its exact role within white matter
remains elusive. However, MOG is a member of the immunoglobulin superfamily
(Pham-Dinh, Mattei et al. 1993) and is a target for immune cells, resulting in
demyelination in experimental models of MS (Sun, Link et al. 1991) and in MS patients
(Weber, Derfuss et al. 2018).
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Both neuron and astrocyte communication are necessary to achieve a fully myelinated
brain. Electrical activity from neurons has been shown to induce OPC proliferation
(Gibson, Purger et al. 2014) and there is some evidence to show that electrical activity
induces myelination of certain axons (Gautier, Evans et al. 2015). Furthermore,
astrocytes secrete many signaling molecules during OL development and myelination,
including PDGF (Gard, Burrell et al. 1995) and ciliary neurotrophic factor (Stankoff,
Aigrot et al. 2002).

1.3.4 Myelin pathology in development
Myelin pathologies represent a heterogenous group of disorders with several etiologies
ranging from genetics to OL attack during inflammation. Disorders of the myelin sheath
can be classified in three categories; hypomyelination, where there is a permanent
deficiency in myelin production (Pelizaeus–Merzbacher Disease (Koeppen, Ronca et al.
1987)), dysmyelination, where there is abnormal deposition of myelin (Metachromatic
Leukodystrophy (Nandhagopal and Krishnamoorthy 2006)) or demyelination, where
myelin is formed but subsequently destroyed (Multiple Sclerosis (MS) (Karussis 2014)).
Hypomyelination and dysmyelination occur during development and demyelination
occurs later in life.
Hypomyelinating disorders are the largest category of leukoencephalopathies of unknown
origin and are often undiagnosed (van der Knaap, Breiter et al. 1999, Schiffmann and van
der Knaap 2009, Steenweg, Vanderver et al. 2010). It has been shown that
hypomyelinating disorders are easily identified by magnetic resonance imaging
(Schiffmann and van der Knaap 2009, Steenweg, Vanderver et al. 2010). They often stem
from mutations in genes involved in myelination like PLP1, (Pelizaeus–Merzbacher
disease) (Koeppen, Ronca et al. 1987) SOX10, (Waardenburg-Shah Syndrome) (ElmalehBerges, Baumann et al. 2013), and FAM126A (Hypomyelinating Leukodystrophy 5)
(Zara, Biancheri et al. 2006). Additionally, mutations in gap junctions (GJC2, Pelizaeus–
Merzbacher like Disease (Gotoh, Inoue et al. 2014); GJA1, Oculodentodigital Dysplasia
(Bugiani, Al Shahwan et al. 2006)), DNA excision repair (ERCC, Tay Syndrome
(Weeda, Eveno et al. 1997, Viprakasit, Gibbons et al. 2001), Cockayne Syndrome
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(Karikkineth, Scheibye-Knudsen et al. 2017)), RNA polymerase III (POLR3A,
Hypomyelinating Leukodystrophy 7 (Wolf, Vanderver et al. 2014); POLR3B,
Hypomyelinating Leukodystrophy 8 (Saitsu, Osaka et al. 2011)), as well as partial
deletion of the long arm of chromosome 18 (18q, Chromosome 18q Deletion Syndrome
(Chen, Lin et al. 2006)) have all been implicated in hypomyelinating disorders. In
addition to hypomyelination, clinical manifestations of these pathologies range from
dystonia, developmental anomalies, seizures, cataracts, hypotonia, motor delay and
cognitive impairment (Barkovich and Deon 2016). ATR-X syndrome patients display
hypomyelination (Wada, Ban et al. 2013, Lee, Lee et al. 2015) with a prevalence of 44%
in patients examined, with no correlation with mutation site (Wada, Ban et al. 2013).
White matter abnormalities were widespread and scattered (Wada, Ban et al. 2013, Lee,
Lee et al. 2015) or concentrated around the trigones of the lateral ventricle (Wada, Ban et
al. 2013).

1.4 Thesis Overview
The overall aim of this thesis was to determine if restoration of serum T4 levels in mice
with a forebrain and anterior pituitary specific deletion of Atrx (AtrxFoxG1Cre mice) would
rescue the premature aging phenotypes observed in this model. This hypothesis was
supported by the reported reduction in serum IGF-1 and T4 in other mouse models of
premature aging (Mariño, Ugalde et al. 2010, Xing, Govoni et al. 2012, Visser,
Bombardieri et al. 2016). Additionally, in one study, restoration of serum T4 levels
rescued premature aging phenotypes and IGF-1 levels (Xing, Govoni et al. 2012).
Despite complete restoration of serum T4 levels to that of controls, AtrxFoxG1Cre mice still
exhibited growth abnormalities, short lifespan, loss of subcutaneous fat and low glucose
levels. Accordingly, several thyroid hormone responsive genes, including Igf1, were not
re-established in the liver of AtrxFoxG1Cre mice following T4 treatment, nor were serum
IGF-1 levels. The lack of rescue of IGF-1 levels points to unexpected Cre-mediated Atrx
deletion in the liver of AtrxFoxG1Cre mice, the primary site of IGF-1 production. Indeed,
Atrx was absent in a subset of hepatocytes and in its absence, thyroid hormone mediated
gene expression could not occur for a subset of genes, indicating Atrx may be required for
their expression.
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I also observed drastic decreases of several myelin proteins in AtrxFoxG1Cre mice, a
phenotype also known to occur in models of premature aging. Myelin gene expression is
known to be activated by ligand-bound TR and in this case, T4 administration to
AtrxFoxG1Cre mice increased the number of mature OLs and myelin protein expression was
partially rescued. However, the number of OPCs did not increase in AtrxFoxG1Cre mice
treated with T4, hinting at an intrinsic role for ATRX in their development. Targeted
inactivation of Atrx in OPCs (AtrxSox10CreER mice) but not in neurons also caused
hypomyelination. Deletion of Atrx in OPCs resulted in a decrease in the fate-specifying
transcription factor Olig2. Mechanistically, ATRX occupies the Olig2 gene locus and
binds HDAC3, a known co-activator of Olig2 expression. Following Olig2
downregulation in ATRX-null OPCs, these cells lose several OPC markers and gain the
ability to differentiation intro astrocytes, causing the hypomyelination phenotype
observed in both AtrxFoxG1Cre mice and AtrxSox10CreER mice.
It has previously been shown in a mouse model of premature aging that T4 administration
can directly activate Igf1 expression and subsequently rescue premature aging
phenotypes. AtrxFoxG1Cre mice phenocopy models of premature aging and also display low
levels of both T4 and IGF-1. Based on this, I hypothesized that T4 administration to
AtrxFoxG1Cre mice would induce Igf1 transcription and salvage phenotypes of premature
aging. My results show that ATRX is required to facilitate transcription of several thyroid
hormone responsive genes, including Igf1, and in its absence, rescue of premature aging
phenotypes by T4 is perturbed. Despite the fact that T4 administration did not rescue
several premature aging phenotypes, hypomyelination was partially rescued in a T4dependent manner. This led to the discovery that ATRX is required in OPCs
independently of T4 to promote the expression of the key OL transcription factor Olig2,
maintain the OL lineage and drive myelination in the corpus callosum. Overall, this thesis
highlights the importance of ATRX in the prevention of premature aging, both dependent
and independent of thyroxine.
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Chapter 2

2

Inactivation of hepatic ATRX in AtrxFoxG1Cre mice prevents
reversal of aging-like phenotypes by thyroxine

Based on emerging evidence that T4 stimulates expression of IGF-1 in pre-pubertal mice,
we tested whether T4 supplementation in AtrxFoxG1cre mice could restore IGF-1 levels and
ameliorate premature aging-like phenotypes. Despite restoration of normal serum T4
levels, we did not observe improvements in circulating IGF-1. In the liver, thyroid
hormone target genes were differentially affected upon T4 treatment, with Igf1 and
several other thyroid hormone responsive genes failing to recover normal expression
levels. These findings hinted at Cre-mediated Atrx inactivation in the liver of Atrx
Foxg1cre mice, which we confirmed. Premature aging phenotypes observed in the Atrx
Foxg1cre mice can be explained in part by a role of ATRX in the liver to promote T4mediated Igf1 expression, thus explaining the inefficacy of T4 therapy observed in this
study.
This chapter has been published (Rowland, Jiang et al. 2018). Permissions for
reproduction are found in Appendix A.

2.1 Introduction
The α-Thalassemia/mental retardation X-linked (ATRX) chromatin remodeler is a
component of constitutive heterochromatin (McDowell, Gibbons et al. 1999, Baumann,
Schmidtmann et al. 2008, Goldberg, Banaszynski et al. 2010, Sadic, Schmidt et al. 2015,
Voon, Hughes et al. 2015) and is exclusively nuclear (McDowell, Gibbons et al. 1999).
The C-terminus of ATRX contains a Switch/Sucrose non-fermenting (Swi/Snf) domain
(Picketts, Higgs et al. 1996) which confers the ATPase and translocase activity of ATRX
necessary for nucleosome remodeling (Xue, Gibbons et al. 2003). The N-terminus of
ATRX contains an ADD domain (ATRX-DNTM3-DNTM3L) with homology to the
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DNA methyltransferase family and is capable of binding methylated histone tails within
chromatin (Aapola, Shibuya et al. 2000).
ATRX is essential for heterochromatin (Baumann, Schmidtmann et al. 2008, Law, Lower
et al. 2010) and telomere integrity (Law, Lower et al. 2010, Watson, Solomon et al.
2013), as well as normal gene expression (Levy, Fernandes et al. 2008, Bagheri-Fam,
Argentaro et al. 2011, Ratnakumar, Duarte et al. 2012, Levy, Kernohan et al. 2015, Li,
Syed et al. 2016). Deletion of ATRX in neuroprogenitor cells causes DNA damage at
telomeres and pericentromeric heterochromatin (Watson, Solomon et al. 2013). We have
previously shown that telomestatin-mediated stabilization of G-quadruplexes exacerbated
DNA damage and decreased viability of neuroprogenitors in the absence of ATRX
(Watson, Solomon et al. 2013). ATRX may be facilitating the progression of DNA
replication and transcriptional machinery through these non-canonical DNA structures
(Watson, Solomon et al. 2013, Levy, Kernohan et al. 2015).
We previously reported that postnatal health and longevity are severely affected in mice
with forebrain and anterior pituitary-specific deficiency for ATRX (AtrxFoxG1cre) (Watson,
Solomon et al. 2013). Many of the abnormalities detected in these mice resemble those
previously reported in mouse models of progeria, including low circulating levels of IGF1 (Niedernhofer, Garinis et al. 2006, van der Pluijm, Garinis et al. 2006, Varga, Eriksson
et al. 2006, Mariño, Ugalde et al. 2010, Kanfi, Naiman et al. 2012). Progeroid syndromes
are a group of disorders characterized by accelerated physiological aging. These heritable
disorders produce signs of premature aging in many, but not all tissues and therefore are
termed segmental progerias. It has been postulated that in progeroid syndromes,
mutations in genome repair genes result in increased genomic and heterochromatin
instability (Shumaker, Dechat et al. 2006, Liu, Barkho et al. 2011). This is paired with
the downregulation of genes involved in growth, such as Igf1, presumably in order to
survive the damage (Garinis, Uittenboogaard et al. 2009). However, if this occurs during
development, it is detrimental to the organism, resulting in metabolic defects and
premature aging. Several progeroid syndromes have been described, such as Cockayne
syndrome (Karikkineth, Scheibye-Knudsen et al. 2017), Werner syndrome (Oshima,
Sidorova et al. 2017) and Hutchinson-Gilford progeria (Gonzalo, Kreienkamp et al.
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2017).

Symptoms of these disorders typically include reduced growth, decreased

lifespan, bone and organ abnormalities and loss of subcutaneous fat.
The role of insulin signaling in aging and longevity is highly conserved (Giannakou and
Partridge 2007). IGF-1 is predominantly produced by the liver and important for stem
cell proliferation in many organs and some evidence points to depleted stem cell pools as
a main cause of aging (Burtner and Kennedy 2010, Guntur and Rosen 2013). A case in
point is Hutchinson-Gilford progeria, which is caused by mutations in Zmpste24, a
metallopeptidase involved in the processing of lamin A (Mariño, Ugalde et al. 2010).
When lamin A is mutated, the nuclear membrane is unable to form properly, resulting in
DNA damage and genome instability (Mariño, Ugalde et al. 2010). Zmpste24-null mice
exhibit accelerated aging phenotypes and low levels of circulating IGF-1 (Mariño,
Ugalde et al. 2010).

Remarkably, treatment of these mice with IGF-1 results in

amelioration of aging features and extends lifespan, demonstrating that reduction of IGF1 levels is a cause rather than an effect of premature aging (Mariño, Ugalde et al. 2010).
Xing et al. (2012) showed that mice deficient in thyroid hormone also exhibit premature
aging phenotypes associated with greater than 50% decrease in Igf1 expression in liver
and bone (Xing, Govoni et al. 2012). In this case, treatment with both the prohormone
thyroxine (T4) and the active hormone triiodothyronine (T3) rescued IGF-1 levels as well
as the phenotypic defects (Xing, Govoni et al. 2012). Thyroid hormone mediated gene
expression is regulated through the binding of T3 to the thyroid hormone receptors (TRs).
TRs act as transcription factors to either enhance or repress transcription depending on
whether T3 is bound or not (Xu, Glass et al. 1999, Grøntved, Waterfall et al. 2015).
Moreover, Visser et al. (2016) reported suppressed thyroid hormone signaling and
increased expression of the thyroid hormone deactivating enzyme deiodinase 3 (Dio3) in
mouse models of Xeroderma pigmentosa, Cockayne syndrome and in wild type aged
mice (Visser, Bombardieri et al. 2016). Taken together, this evidence suggests that
thyroid hormone signaling is implicated in progeria through the regulation of IGF-1 in
early postnatal development.
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Given that the AtrxFoxG1cre mice exhibit signs of accelerated aging as well as reduced
levels of T4 and IGF-1, we hypothesized that T4 treatment could rescue abnormalities in
these mice and perhaps extend longevity. Our findings demonstrate that, contrary to our
expectation, T4 administration does not rescue IGF-1 serum levels nor the associated
adverse phenotypes. Upon further investigation, we found that Atrx is partially deleted in
the liver of AtrxFoxG1cre mice and is required for the expression of a subset of thyroid
hormone responsive genes, including Igf1, providing a potential explanation for the lack
of rescue in this model system.

2.2 Materials and methods
2.2.1 Mouse husbandry and genotyping
Mice were exposed to 12-hour light/12-hour dark cycles and fed tap water and regular
chow ad libitum. The AtrxloxP mice have been described previously (Berube, Mangelsdorf
et al. 2005, Garrick, Sharpe et al. 2006). AtrxloxP mice, when mated to mice expressing
Cre

recombinase

under

the

control

of

the

Foxg1

promoter

(Foxg1KiCre,

RRID:MGI:3767191) (Hebert and McConnell 2000), produce male progeny with Atrx
deficiency in the forebrain and anterior pituitary (AtrxloxP;Foxg1KiCre or Atrx Foxg1cre
for simplicity, RRID:MGI:3530074). Ear or tail genomic DNA was used for genotyping.
Atrx, Cre, and Sry genotyping was performed by PCR as previously described (Berube,
Mangelsdorf et al. 2005).

2.2.2 Thyroxine injections
Control and AtrxFoxG1cre mice were injected subcutaneously from birth (P0) until P14 with
0.1, 0.5 or 1.0 mg/kg L-thyroxine (T4) (Sigma, T2376-100MG).

2.2.3 Measurements of T4, T3, IGF-1 and glucose
Plasma samples were collected from P14 mice. Blood was collected from the inferior
vena cava. EDTA pH 7.0 was added to the blood sample and centrifuged at 10000 RPM
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for 10 minutes at 4°C. Plasma supernatant was collected and kept frozen at –80°C.
Plasma T4 was assayed using a mouse T4 ELISA kit (Calbiotech, T4044T-100)
according to the manufacturers’ instructions. Plasma T3 was assayed using a mouse T3
ELISA kit (T3043T-100) according to the manufacturers’ instructions. Plasma IGF-1
content was measured using a mouse IGF-1 ELISA kit (R&D Systems, MG100)
according to the manufacturers’ instructions. Blood glucose levels were measured prior to
sacrifice using the ReliOn Prime Blood Glucose Meter according to the manufacturer’s
instructions.

2.2.4 Hematoxylin and eosin staining of skin sections
P20 mice were perfused with 4% paraformaldehyde before PBS washes and dehydration.
Skin tissue was flash-frozen in liquid nitrogen using Cryomatrix (ThermoFisher
Scientific) cryoprotectant (Berube, Jagla et al. 2002) and sectioned at 8µm (Leica CM
3050S). H&E staining was performed as follows: CAT hematoxylin (Biocare Medical)
for 2 minutes, wash for 30 seconds, Tasha’s bluing solution (Biocare Medical) for 30
seconds, wash for 10 minutes, eosin Y (Biocare Medical) for 2 minutes, 70% ethanol for
1 minute, 90% ethanol for 1 min, 100% ethanol for 4 min, Xylene for 15 minutes. Slides
were mounted with permount (Fisher Scientific).

2.2.5 Immunofluorescence and antibodies
P14 or P20 mice were perfused with 4% paraformaldehyde before PBS washes and
dehydration. Liver tissue was flash-frozen in liquid nitrogen using Cryomatrix
(ThermoFisher Scientific) cryoprotectant (Berube, Jagla et al. 2002) and sectioned and
sectioned at 8µm (Leica CM 3050S). For immunofluorescence staining of cryosections,
antigen retrieval was performed on slides by warming 10 mM sodium citrate pH 6
solution to approximately 95°C and microwaving slides in solution for 10 minutes on
low. After cooling, slides were washed, blocked with 10% normal goat serum (SigmaAldrich) for 1 hour and incubated with primary antibody overnight at 4°C. Slides were
washed in PBS and incubated with secondary antibody for 1 hour. Sections were
counterstained with DAPI (Sigma-Aldrich) and mounted with permafluor (ThermoFisher
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Scientific). The following primary antibodies were used: anti-ATRX, rabbit polyclonal
(1:75, Santa-Cruz Biotechnology, sc-15408, RRID:AB_2061023), anti-GFP, chicken
polyclonal (1:150, ThermoFisher Scientific, PA1-9533, RRID:AB_1074893), anti-RFP,
rabbit polyclonal (1:150, Rockland, 600-401-379, RRID:AB_2209751), anti-Albumin,
goat polyclonal (1:600, Bethyl, A90-134, RRID:AB_67120), anti-F4/80, rat monoclonal
(Abcam, ab6640, RRID:AB_1140040), anti-GFAP, mouse monoclonal (Sigma-Aldrich
Cat# G3893, RRID:AB_477010). The secondary antibodies used were goat anti-rabbitAlexa

Fluor

594

(1:800

dilution;

ThermoFisher

Scientific,

A-11012,

RRID:AB_2534079), goat anti-chicken-Alexa Fluor 488 (1:800 dilution; ThermoFisher
Scientific, A-11039, RRID:AB_2534096), goat anti-mouse-Alexa Fluor 488 (1:800
dilution; ThermoFisher Scientific, A-21121, RRID:AB_2535764) and goat anti-rat-Alexa
Fluor 488 (1:800 dilution; Thermo Fisher Scientific, A-11006, RRID:AB_2534074).

2.2.6 Microscopy, imaging and cell counts
Hematoxalin and eosin images were captured using a scanscope (Aperio CS model,
Leica). Scanscope console imaging software was used for automated image capture and
processing was performed using Volocity software (PerkinElmer). Immunofluorescence
images were captured using an inverted microscope (DMI 6000b, Leica). Digital
microscopy images were captured with a digital camera (ORCA-ER, Hamamatsu).
Openlab imaging software was used for manual image capture, and processing was
performed using Volocity software (PerkinElmer). Cell counts in the liver were
performed in a blinded and randomized manner for immunofluorescence staining of
ATRX in control or experimental cryosections using Volocity (PerkinElmer Demo
Version 6.0.1, RRID:SCR_002668). The counting area was recorded, and cells were
counted in 2-6 sections per biological replicate with 3 biological replicates for each
genotype.
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2.2.7 Quantitative reverse transcriptase PCR (qRT-PCR)
Total RNA was isolated from liver with the RNeasy Mini Kit (QIAGEN) and reverse
transcribed into cDNA as described previously (Jiao, Killela et al. 2012). Control
reactions without reverse transcriptase were prepared in parallel. cDNA was amplified
with gene-specific primers under the following conditions: 25–35 cycles of 95°C for 30
seconds, 60°C for 30 seconds, and 72°C for 1 minute. For qRT-PCR, cDNA was
amplified with iQ SYBR Green Master Mix (Bio-Rad) by using the standard curve
Ct method of quantification. Experiments were performed on a Chromo-4 thermocycler
(MJ Research) and analyzed with Opticon Monitor 3 and GeneX (Bio-Rad) software.
Gene expression analysis was repeated in duplicate for each sample. Conditions for
amplification were as follows: 35 cycles of 95°C for 10 seconds, 55°C for 20 seconds,
72°C for 30 seconds, and a final melting curve generated in increments of 0.5°C per plate
read. Primer sequences are listed in Table 1.

Gene Name
Igf1
Igf1r
Igf2r
Igfals
Igfbp1
Igfbp2
Igfbp3
Serpina7
Dio1
Dio3
Trβ
Prlr
Ghr
Thrsp

Forward Primer
ACC TCA GAC AGG CAT TGT GG
TGT GGT CAA GGA TGA ACC CG
GCA TCT TTC CAC CAG TTC CG
CAC ACA ACG CCA TCA CTA GC
AGC CCA GAG ATG ACA GAG GA
GCG GGT ACC TGT GAA AAG AG
GTG ACC GAT TCC AAG TTC CA
CCT TCC AAA AGA GGG ACA CA
GGA CAC AAT GCA GAA CCA GA
GTT TTT GGC TTG CTC TCA GG
CAG AAC CCA CGG ATG AGG AG
GCA TCT TTC CAG CAG TTC CG
ATT CAC CAA GTG TCG TTC C
ACG GAG CCC CTG ATC TCT AT

Reverse Primer
GTT TGT CGA TAG GGA CGG GG
CCT TGG GAT ACC ACA CCC AG
GCT CGT CCT CAT TGT CAT CC
CGT TGA AGA GGC CAA AGA AG
GTT GGG CTG CAG CTA ATC TC
AAC ACA GCC AGC TCC TTC AT
TGT CCT CCA TTT CTC TGC GG
CCA AGG TCA TAT GTG GCA GA
GCA AAG CTT TTC CAG GAC AG
CAA GTC CGA GCT GTG AA
GGC ATT CAC AAT GGG TGC TT
GCT CGT CCT CAT TGT CAT CC
TCC ATT CCT GGG TCC ATT CA
GGC TTC TAG GTC CAG CTC CT

Table 1 Primer sequences used for quantitative reverse transcriptase PCR
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2.2.8 Statistical analysis
Statistical analysis was performed using GraphPad Prism6 software (6.05; GraphPad
Software Inc.), and all results are expressed as the mean ± SEM unless indicated
otherwise. Two independent data sets were compared with the Student’s t test (unpaired,
2-tailed). Multiple independent data sets were compared with a one-way ANOVA with
post-hoc Tukey’s test. Statistical analyses of Kaplan-Meier survival curves were
performed using the log-rank test and the Gehan-Breslow-Wilcoxon test. A repeatedmeasures polynomial modeling analysis (SAS v.9.4, SAS Institute Inc., Cary, NC, USA)
was used to compare differences between groups in weight over time. P values of 0.05 or
less were considered to indicate significance.

2.2.9 Study approval
All procedures involving animals were conducted in accordance with the regulations of
the Animals for Research Act of the Province of Ontario and approved by the University
of Western Ontario Animal Care and Use Committee.

2.3 Results
2.3.1 T4 administration does not improve body growth of
AtrxFoxG1cre mice
We previously reported that AtrxFoxG1cre mice have reduced weight, length and a very
short lifespan associated with low T4 and IGF-1 (Watson, Solomon et al. 2013). To test
whether T4 injections in the postnatal period might ameliorate deleterious outcomes in
these mice, we established a protocol consisting of daily injections of three different
doses of L-thyroxine (T4) or PBS as a control, based on Xing et al. 2012 (Xing, Govoni
et al. 2012). Cohorts of AtrxFoxG1cre (indicated as cKO in figures) and control mice
(indicated as Ctrl in figures) were injected subcutaneously with 0.1, 0.5 or 1.0 mg/kg T4
daily from birth to P14. Atrx Foxg1cre mice injected with T4 did not show lifespan
extension at any dose of T4 (Figure 2-1A). Furthermore, injection protocols with 0.5 and
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Figure 2-1 T4 administration restores normal serum T4 levels in Atrx Foxg1cre
(cKO) mice but does not rescue life span or growth abnormalities.
(a) Kaplan-Meier curve depicting survival of Atrx Foxg1cre mice injected with various
amount of T4. (b) Serum T4 was recovered at P14 in Atrx Foxg1cre mice upon T4
treatment (0.1 mg/kg T4) (c) Body weight is not restored to control levels following T4
treatment, (d) Body weight and length were not recovered to control levels at P14 in Atrx
Foxg1cre mice following T4 treatment. Groups with the same letter have means that are
not significantly different. Groups with different letters have means that are significantly
different (p<0.05). Error bars represent SEM.
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1.0 mg/kg resulted in decreased average lifespan compared to Atrx Foxg1cre mice + PBS
(Figure 2-1A and 2-8). We thus used the lowest dose of T4 (0.01 mg/kg) for subsequent
analyses. We confirmed that at this lower dose, T4 levels were restored to control levels
and were significantly increased compared to sham-treated AtrxFoxG1cre mice (Figure 21B). If T4 levels in AtrxFoxG1cre mice differed from the control mean by more than 2
standard deviations, they were considered biological outliers and removed from the study
(Figure 2-9A). In order to determine whether serum T3 (the active form of thyroid
hormone) was increased after T4 treatment in AtrxFoxG1cre mice, a T3 ELISA was
performed (Figure 2-9B). However, due to the low levels of T3 in the serum (1 ng/mL)
we were unable to detect a change in any of the groups at this low level. As previously
reported, we observed that the weight of PBS-injected AtrxFoxG1cre mice was significantly
lower than PBS-injected control mice over time and this effect was not rescued following
T4 treatment (Figure 2-1C). Weight and length measurements at P14 show that both
PBS- or T4-injected AtrxFoxG1cre mice weigh less than half of controls and are shorter in
length (Figure 2-1D). These results indicate that, contrary to our expectation, restoration
of normal circulating T4 levels in AtrxFoxG1cre mice failed to improve their reduced size
and short lifespan.

2.3.2 Low subcutaneous fat and blood glucose are not improved
by T4 administration
The AtrxFoxG1cre mice were previously reported to have very low levels of subcutaneous
fat and serum glucose (Watson, Solomon et al. 2013). To measure the effects of T4
injections on these parameters, we examined skin sections and blood taken from P20
AtrxFoxG1cre mice treated with PBS or T4. These analyses confirmed our previous findings
that subcutaneous fat thickness was significantly reduced in AtrxFoxG1cre mice compared to
controls; however, it was not improved in T4-treated AtrxFoxG1cre mice and appears to be
further reduced (Figure 2-2A). In contrast, thickness of the dermal layer was not affected
by the deletion of Atrx or T4 treatment. A similar outcome was observed with serum
glucose level, which was significantly decreased in both PBS- and T4-treated Atrx
Foxg1cre mice compared to control mice (Figure 2-2B). Additionally, the liver and
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Figure 2-2 T4 administration in AtrxFoxG1cre (cKO) mice does not ameliorate
reduction in subcutaneous fat or serum glucose.
(a) H&E staining of P20 skin cryosections shows that subcutaneous fat (SF) is not
restored to control levels in AtrxFoxG1cre mice following T4 treatment (n=3). Dermal layer
(D) was unchanged between control and either PBS or T4 treated AtrxFoxG1cre mice as
previously reported (Scale bar = 200 µm). (b) Serum glucose at P14 was not restored to
control levels in AtrxFoxG1cre mice following T4 treatment. Groups with the same letter
have means that are not significantly different. Groups with different letters have means
that are significantly different (p<0.05). Error bars represent SEM.
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spleen of PBS-treated AtrxFoxG1cre mice were decreased in size when compared to control.
Upon T4 treatment, we observed a slight increase in liver and spleen weights (relative to
body weight) in AtrxFoxG1cre, but it was not significantly different from either PBS treated
or control mice (Figure 2-10). At P20, heart weight was unchanged in AtrxFoxG1cre mice
treated with PBS compared to control, however following treatment with T4, heart
weight increased significantly (Figure 2-10). In summary, subcutaneous fat and serum
glucose levels were not rescued by T4 treatment in AtrxFoxG1cre mice.

2.3.3 T4 administration fails to recover circulating and hepatic
IGF-1 levels
We confirmed that AtrxFoxG1cre serum IGF-1 level at P14 is 17.7% that of control mice
(Figure 2-3A). However, recovery of normal T4 circulating levels did not result in the
expected increase of serum IGF-1. Given that the liver is the major source of circulating
IGF-1, we next examined liver Igf1 expression by quantitative reverse transcriptase PCR
(RT-qPCR) and found that Igf1 expression is significantly decreased in the liver of
AtrxFoxG1cre mice, even after T4 supplementation (Figure 2-3A).
The decrease in serum IGF-1 in AtrxFoxG1cre mice could be due to alterations in Igf1
receptor (Igf1r) or Igf2 receptor (Igf2r) expression. IGF-1 binds Igf1r, which elicits an
intracellular response, whereas Igf2r acts as a scavenger receptor and no response occurs.
While Igf1r expression is not altered in the liver, Igf2r expression is decreased in the
AtrxFoxG1cre compared to control as previously reported (Watson, Solomon et al. 2013)
and not recovered by T4 treatment (Figure 2-3B). These data provide evidence that IGF-1
is able to bind Igf1r and is not subject to deactivation by high levels of Igf2r.
Serum IGF-1 could also be decreased due to gene expression alterations in IGF binding
proteins (IGFBPs) and acid labile subunit (IGFALS). Both IGFALS and IGFBPs bind
IGF-1, enhancing or diminishing IGF-1 signaling depending on the need of the cell.
Igfals and Igfbps are aberrantly expressed in livers of AtrxFoxG1cre mice compared to
controls. Igfals expression is significantly decreased in AtrxFoxG1cre mice + PBS compared
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Figure 2-3 T4 administration does not rescue decreased serum IGF-1 or
dysregulated gene expression in the liver of AtrxFoxG1cre (cKO) mice at P14.
(a) Serum IGF-1 and expression of liver Igf1 are not restored to control levels following
T4 treatment in AtrxFoxG1cre mice. (b) Igfr expression was not changed between control
and either PBS or T4 treated Foxg1cre mice. Igf2r expression was not restored to control
levels following T4 treatment in Atrx Foxg1cre mice. (c) Gene expression of IGF-1
complex proteins, Igfbp1 and Igfbp3 were not restored to control levels in AtrxFoxG1cre
mice, except in the case of Igfbp2 which was restored to control levels. qRT-PCR data
were normalized to β-actin expression, n=3-6. Groups with the same letter have means
that are not significantly different. Groups with different letters have means that are
significantly different (p<0.05). Error bars represent SEM.
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to control and is not rescued by T4 treatment. Igfbp1 and Igfbp2 expression are
significantly increased in AtrxFoxG1cre compared to control mice. Igfbp2, but not Igfbp1
expression is restored to control levels in AtrxFoxG1cre + T4. Low Igfbp2 expression has
been reported in hypothyroidism and its increase in expression is likely due to a feedback
mechanism following increased serum T4. Igfbp3 expression is decreased in the
AtrxFoxG1cre + PBS and not restored to control levels following T4 treatment (Figure 23C). These results indicate that despite restoring serum T4 levels, most genes involved in
IGF-1 signaling are still aberrantly expressed.

2.3.4 T4 administration restores thyroxine binding globulin gene
expression and a subset of thyroid hormone responsive
genes in the liver of AtrxFoxG1Cre mice
Alterations in the gene Serpina7 (thyroxine binding globulin (TBG)), one of the thyroid
hormone transport molecules, could also affect transport of T4. Serpina7 is significantly
increased in the AtrxFoxG1cre + PBS and is restored to control levels following treatment
with T4 (Figure 2-4A). We next examined the effect of T4 injections on the expression of
several thyroid hormone target genes in the liver of AtrxFoxG1cre mice. Dio1, which
converts T4 to its active form T3, is expressed at slightly decreased levels in AtrxFoxG1cre
liver, however not significantly. Dio3, the enzyme which converts T3 to the inactive
forms rT3 and T2, is normally expressed embryonically when precise control over
thyroid hormone signaling is crucial. Dio3 was reported to be reactivated in the liver of
two mouse models of premature aging and in normal mouse aging (Visser, Bombardieri
et al. 2016). Dio3 is slightly increased in AtrxFoxG1cre mice compared to control, however
not significantly (Figure 2-4B). Following T4 treatment Dio3 expression is highly
repressed and is significantly decreased in AtrxFoxg1Cre mice + T4 compared to AtrxFoxG1cre
mice + PBS, suggesting that T4 is converted to the T3 active form. Thyroid hormone
receptor β (Trβ), the active thyroid hormone receptor in the liver, is decreased in the
AtrxFoxG1cre + PBS compared to control. When treated with T4, Trβ expression is restored
to control levels and is significantly increased compared to AtrxFoxG1cre + PBS
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Figure 2-4 T4 administration restores thyroxine binding globulin gene expression
and a subset of thyroid hormone responsive genes in the liver of AtrxFoxG1cre (cKO)
mice at P14.
(a) Serpina7 (thyroxine binding globulin) gene expression is restored following T4
treatment. (b) Administration of T4 restores thyroid hormone responsive gene expression
of Dio1 and Trβ in AtrxFoxG1cre mice to that of control mice. In addition, there is a
dramatic repression of Dio3 expression in the liver of AtrxFoxG1cre mice at P14. (c) Despite
normal expression of Trβ, some thyroid hormone responsive genes are not rescued
following T4 treatment in Atrx Foxg1cre mice. qRT-PCR data were normalized to β-actin
expression, n=3-6. Groups with the same letter have means that are not significantly
different. Groups with different letters have means that are significantly different
(p<0.05). Error bars represent SEM.
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(Figure 2-4B). Despite proper regulation and activation of thyroid hormone in the liver,
expression of thyroid hormone responsive genes Prlr, Ghr and Thrsp were not restored to
control levels in AtrxFoxG1cre mice treated with T4 (Figure 2-4C). While the liver of
AtrxFoxG1cre mice should essentially be normal, all these results suggested that this is not
the case and that it fails to respond to normal thyroid hormone signaling. This prompted
us to investigate the possibility that Foxg1Cre expression might be spuriously activated in
the liver of these mice, causing Atrx gene inactivation.

Cre recombinase expression and Atrx deletion in the liver of
AtrxFoxG1Cre mice
We had previously verified by western blot analysis that ATRX protein levels were
normal in the liver in P20 AtrxFoxG1cre mice (Watson, Solomon et al. 2013). However,
given the results above, we re-examined the status of ATRX in the liver. To achieve this,
we introduced the ROSAmT/mG reporter allele into the AtrxFoxG1cre mice to allow
immunofluorescent detection of Cre-recombinase activity through the detection of green
fluorescent protein (GFP), while cells that have never been exposed to Cre-recombinase
activity display red fluorescent protein (RFP). Immunofluorescence detection of RFP and
GFP in liver cryosections at either P14 (Figure 2-5A) or P20 (Figure 2-5C) in Atrxwt/Y;
Foxg1cre; Rosa mTmG (controls) and Atrxf/Y;Foxg1cre;Rosa mTmG (cKO) mice
revealed the presence of many GFP+ cells in the liver. To verify that this resulted in loss
of ATRX protein, we performed immunofluorescence staining of ATRX in liver
cryosections at either P14 (Figure 2-5B) or P20 (Figure 2-5D). Quantification revealed a
significant reduction in the proportion of cells that express ATRX in the liver AtrxFoxG1cre
mice compared to controls at both P14 (Figure 2-5E) and P20 (Figure 2-5F). These
results indicate that Cre-mediated Atrx inactivation occurred in the liver of AtrxFoxG1cre
mice. However, at P20, we noted an increase in the total number of cells in the
AtrxFoxG1cre liver, and that many oblong-shaped cells expressed liver, and that many
oblong-shaped cells expressed high levels of ATRX when compared to control (Figure 25F). We speculate that these cells represent a regenerative event mediated by
proliferating ATRX+ Kupffer or stellate cells, likely explaining the lack of difference in
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Figure 2-5 Cre recombinase activation in the liver results in fewer hepatocytes that
express ATRX at P14 and P20 in AtrxFoxG1cre (cKO) mice.
(a) Co-immunofluorescence detection of RFP and GFP in liver cryosections at P14 in
ROSAmT/mG mice shows presence of GFP staining in AtrxFoxG1cre mice indicating Cre
recombinase activation. (b) Immunofluorescence staining of ATRX in liver cryosections
at P14. White box indicates area of zoom (n=3). Cell counts of ATRX staining revealed a
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significant reduction in % ATRX+ cells in AtrxFoxG1cre compared to control at P14 despite
equal number of cells. (c) Co-immunofluorescence detection of RFP and GFP in liver
cryosections at P20 in ROSAmT/mG mice shows presence of GFP staining in AtrxFoxG1cre
mice indicating Cre recombinase activation. (d) Immunofluorescence staining of ATRX
in liver cryosections at P20. White box indicates area of zoom (n=3). (e) Cell counts of
ATRX staining revealed a significant reduction in % ATRX+ cells in AtrxFoxG1cre mice
compared to control at P14. (f) At P20, there is a reduction in the % ATRX+ cells in
AtrxFoxG1cre mice compared to control and there is also an increase in the number of cells
in AtrxFoxG1cre mice when compared to control. AtrxFoxG1cre mice when compared to
control. Scale bar = 50 µm. (g) At P20, immunofluorescence staining in AtrxFoxG1cre mice
shows cells that do not express ATRX protein also costain with albumin, a marker of
hepatocytes and do not costain with F4/80 (Kupffer cell marker) or GFAP (stellate cell
marker). Scale bar = 5 µm. White arrows indicate cells that do not express ATRX.
Original magnification, 40x. Groups with the same letter have means that are not
significantly different. Groups with different letters have means that are significantly
different (p<0.05). Error bars represent SEM.
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the levels of ATRX protein previously observed in the P20 liver of AtrxFoxG1cre mice by
Western blot analysis (Watson, Solomon et al. 2013). Immunofluorescence detection of
ATRX and either albumin (hepatocyte marker), F4/80 (Kupffer cell marker) or GFAP
(stellate cell marker) in AtrxFoxG1cre mice revealed that cells lacking ATRX co-express
albumin but not F4/80 or GFAP, indicating that Cre-mediated Atrx deletion occurs in
hepatocytes (Figure 2-5G).

Increased expression of a subset of thyroid hormone responsive
genes upon T4 administration require ATRX expression
Several thyroid hormone responsive genes (Igf1, Prlr, Ghr and Thrsp) failed to respond
to T4 treatment in Atrx Foxg1cre mice, suggesting that their induction by T4 might
require ATRX. To test this, we compared the effect of T4 treatment of control and
AtrxFoxG1cre mice on the expression of Igf1, Prlr, Ghr and Thrsp in the liver. The results
show that these thyroid hormone responsive genes are induced by T4 in control mice, but
not in Atrx mutants (Figure 2-6), confirming a dependence on ATRX (Figure 2-7).

2.4 Discussion
Low serum IGF-1 has been implicated as a driver of premature aging syndromes
(Mariño, Ugalde et al. 2010, Xing, Govoni et al. 2012). More recently, thyroid hormone
signaling suppression has been linked to both premature aging and normal aging in mice
(Xing, Govoni et al. 2012, Visser, Bombardieri et al. 2016). Given the previous
observation that the AtrxFoxG1cre mice have both low T4 and IGF1 (Watson, Solomon et al.
2013), we tested the effects of T4 injections. However, despite recovery of normal T4
levels, the signaling that promotes Igf1 expression in the liver was found to be defective,
likely due to previously unrecognized Cre-mediated inactivation of the Atrx gene in the
liver. Thus, while several thyroid hormone target genes were responsive to T4 treatment,
several others, including Igf1, were not, suggesting that ATRX is required for the
induction of these genes in the liver. As a result, T4 administration does not rescue
decreased lifespan, reduced growth or other defects in AtrxFoxG1cre mice. Higher doses of
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Figure 2-6 A subset of thyroid hormone responsive genes are induced in the P14
liver in the presence of excess T4, in an ATRX-dependent manner.
Administration of T4 induces gene expression at or above the level of controls treated
with PBS (control set to 1) only when ATRX is present in Ctrl + T4 mice and not in
AtrxFoxG1cre + T4 mice at P14. qRT-PCR data were normalized to β-actin expression, n=36. Groups with the same letter have means that are not significantly different. Groups
with different letters have means that are significantly different (p<0.05). Error bars
represent SEM.

81

Figure 2-7 ATRX is required for the transcription of several thyroid hormone
responsive genes in the liver.
In the control, T4 is bound to thyroxine binding globulin (TBG) in the blood. It is
converted to T3 in the liver by Dio1. Both T4 and T3 can be inactivated by Dio3 to
produce the inactive molecules T2 and rT3. T3 binds its receptor Trβ (found as a
heterodimer with retinoid x receptor), which enters the nucleus, binds a thyroid hormone
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responsive element and initiates transcription. In AtrxFoxG1cre mice there is an increase in
TBG and a decrease in T4 in the serum. In the liver, there is a decrease in Dio1 and an
increase in Dio3. Any T4 present is likely converted to rT3. Low levels of Trβ acts as a
transcriptional repressor. Following treatment with T4 in Atrx Foxg1cre mice, there are
control levels of TBG and T4 in the blood. In the liver, Dio1 is at control levels and Dio3
is repressed. T4 is converted to T3 where it binds its receptor and transcription occurs
normally. This occurs for a subset of genes (Dio1 and Trβ). However, some genes (Igf1,
Prlr, Ghr and Thrsp) are still transcriptionally repressed following T4 treatment. This
suggests that ATRX is required for the transcription of some thyroid hormone responsive
genes.
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T4 that we initially tested (0.5 and 1.0 mg/kg daily) were likely inducing hyperthyroidism
in these small, young mice. The lowest dose, 0.1 mg/kg T4 daily, appeared to have
variable effects as some AtrxFoxG1cre mice injected received well above control levels or
levels similar to uninjected AtrxFoxG1cre mice. Whether this was experimental error or
AtrxFoxG1cre mice have variable absorption is unknown. Nevertheless, we used only
AtrxFoxG1cre mice that expressed control levels of serum T4 after treatment for subsequent
analyses. Our results suggest that restoring normal levels of serum T4 in AtrxFoxG1cre mice
does not ameliorate premature aging phenotypes. It is known that hyperthyroidism causes
increased metabolic rate, reduced bone density and osteoporosis (Williams and Bassett
2017). Due to the small size of the AtrxFoxG1cre mice (46.3% of control weight), it is
possible that AtrxFoxG1cre mice received levels of T4 that are too high for their body
weight and that a lower dose is necessary to eliminate induction of hyperthyroidism in
this model. Since Igf1r appears to be unaffected by deletion of ATRX, a future
experiment would be to directly inject IGF-1 in AtrxFoxG1cre mice. It has been shown in a
Hutchinson-Gilford Progeria mouse model that IGF-1 treatment extends lifespan and
delays onset of premature aging (Mariño, Ugalde et al. 2010).
The inefficacy of T4 treatment in our study could be explained by deletion of Atrx in the
liver of AtrxFoxG1cre mice, which was not previously reported. Dio1, Serpina7 and Trβ
transcript levels were normalized by T4 treatment, indicating that hepatic T3 is produced
and that thyroid signaling is at least partially intact. Conversely, several thyroid hormone
responsive genes, including Igf1, Prlr, Ghr and Thrsp were not rescued following T4
treatment. Furthermore, when controls were treated with T4, these genes all increased
compared to control levels. These data suggest that ATRX must be required for T3mediated transcription of a subset of genes in the liver.
It is still unknown why deletion of Atrx in the liver disrupts proper signaling and
production of IGF-1. ATRX contains several LXXLL-type motifs required to bind
hormone receptors and in the testes, it was shown that ATRX is able to bind the androgen
receptor, facilitating transcription of androgen receptor target genes (Bagheri-Fam,
Argentaro et al. 2011). Therefore, it is possible that ATRX binds and cooperates with the
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thyroid hormone receptor directly to modulate gene expression in the liver. Moreover, a
recent report strongly implicates ATRX in the regulation of gene expression in the liver
(Chatzinikolaou, Apostolou et al. 2017). It was shown that the nucleotide excision repair
(NER) structure-specific endonuclease ERCC1–XPF, a complex that is mutated in
premature aging, recruits the CTCF–cohesin complex, MBD2 and ATRX to promoters
and imprinting control regions (ICRs) to silence a subset of imprinted genes during
hepatic development (Chatzinikolaou, Apostolou et al. 2017).
ATRX deletion has been shown to result in DNA replication stress and telomere
abnormalities (Watson, Solomon et al. 2013). It is also possible that in addition to low
levels of IGF-1, DNA damage is accumulating in hepatocytes lacking ATRX and these
cells are dying or undergoing senescence, further exacerbating low levels of stem cells in
the liver. In the future, it will be necessary to investigate the full extent of ATRX function
in the liver and to further explore the link between ATRX and thyroid hormone mediated
transcription.
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2.5 Supplementary Figures

Figure 2-8 T4 supplementation does not improve lifespan in AtrxFoxG1cre (cKO) mice.
Average lifespan was not significantly changed between PBS and T4 treated AtrxFoxG1cre
mice. Error bars represent SEM.
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Figure 2-9 T4 supplementation results in variable serum T4 levels in AtrxFoxG1cre
(cKO) mice.
Variable serum T4 levels and unchanged serum T3 levels in AtrxFoxG1cre (cKO) mice upon
T4 supplementation. (a) Graph of Serum T4 levels in AtrxFoxG1cre mice following T4
treatment. Biological outliers are represented as squares and these mice were excluded
from further analyses. (b) Graph of serum T3 levels in AtrxFoxG1cre mice following T4
treatment. Groups with the same letter have means that are not significantly different.
Groups with different letters have means that are significantly different (p<0.05). Error
bars represent SEM.
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Figure 2-10 Liver and spleen abnormalities in AtrxFoxG1cre (cKO) mice are partially
rescued following T4 treatment.
Following T4 treatment in AtrxFoxG1cre mice, abnormal relative organ weights in the liver
and spleen are statistically similar to PBS treated control. There is an increase in relative
heart weight in T4 treated AtrxFoxG1cre mice compared to PBS treated control mice. There
was no significant difference in brain, thymus or kidneys relative weight. Groups with the
same letter have means that are not significantly different. Groups with different letters
have means that are significantly different (p<0.05). Data were normalized to body
weight, n=3-6. Error bars represent SEM.
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Chapter 3

3

Defective gliogenesis underlies aberrant myelination elicited
by ATRX deficiency

Hypomyelination has been reported in both mouse models and patients with premature
aging (Koob, Laugel et al. 2010, Revet, Feeney et al. 2012). Additionally, there is
deterioration of the myelin sheath consistent with axon degeneration present in normal
aging. The molecular mechanisms that control myelination during development are
incompletely resolved, however, it is well documented that ligand-bound TR directly
activates myelin gene expression and promotes oligodendrocyte differentiation (Farsetti,
Mitsuhashi et al. 1991, Billon, Tokumoto et al. 2001, Billon, Jolicoeur et al. 2002, Dong,
Yauk et al. 2009). As shown in chapter 2, postnatal systemic thyroxine administration can
improve, but not completely rescue myelin levels, pointing to additional roles of ATRX
in this process. Here, we show that inactivation of Atrx in postnatal OPCs increases
plasticity of these cells in vitro and in vivo, allowing a shift from a strict oligodendrocyte
differentiation program toward ectopic astrogliogenesis. Mechanistically, we provide
evidence that ATRX associates with HDAC3 to promote the expression of Olig2, a key
oligodendrocyte fate specification factor. These findings identify a role for ATRX in the
oligodendrocyte-astrocyte fate choice in the postnatal cortex.

3.1 Introduction
Myelin is an extension of the oligodendrocyte (OL) plasma membrane that wraps
itself around axons to increase conduction velocity, enabling efficient propagation of
action potentials. A series of events are necessary for the production of myelin, including
proliferation and migration of oligodendrocyte precursor cells (OPCs), recognition of
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recipient axons, membrane expansion, wrapping of axons and the appropriate production
of membrane components and myelin proteins for compaction (Nave and Werner 2014).
In the developing cortex, the generation of neurons by neural progenitor cells
eventually shifts towards production of astrocytes and then OLs (Sauvageot and Stiles
2002). The majority of primitive OPCs are generated postnatally from neural stem cells
through the expression of the oligodendrocyte basic-helix-loop-helix transcription factors
Olig1 and Olig2 (Zhou and Anderson 2002). Olig2 is required for OPC generation and
also suppresses the astrocytic lineage (Zhou, Choi et al. 2001, Cai, Chen et al. 2007, Zhu,
Zuo et al. 2012, Zuo, Wood et al. 2018). Downstream of Olig2, the SRY-box
transcription factor 10 (Sox10) participates in a positive feedback loop to establish the
OPC lineage (Finzsch, Stolt et al. 2008, Kuspert, Hammer et al. 2011, Yu, Chen et al.
2013). Notably, Sox10 activates several OPC-critical genes, including Chondroitin
sulfate proteoglycan (Cspg4; protein: neural glial antigen 2 (NG2)) and Platelet-derived
growth factor receptor α (Pdgfrα) (Pringle, Mudhar et al. 1992, Nishiyama, Lin et al.
1996, Nishiyama, Lin et al. 1996). NG2 is a surface type I transmembrane core protein
involved in cell migration and proliferation (Makagiansar, Williams et al. 2007), whereas
PDGFRα promotes OPC proliferation, migration and survival (Noble, Murray et al. 1988,
Pringle, Collarini et al. 1989). Further commitment to the OL lineage starts with the
generation of pre-OLs which, after cell cycle exit, express myelin regulatory factor
(MRF) (Emery, Agalliu et al. 2009). As OLs mature and contact axons, they become
highly branched and upregulate several myelin sheath proteins in order to encompass the
axon (Mitew, Hay et al. 2014, Nave and Werner 2014). The expression of myelin
proteins is complex and regulated by several different transcription factors including the
aforementioned Olig1 (Li, Lu et al. 2007), Sox10 (Stolt, Rehberg et al. 2002, Li, Lu et al.
2007) and MRF (Emery, Agalliu et al. 2009) but also Sp1 (Wei, Miskimins et al. 2004),
Nkx2.2 (Qi, Cai et al. 2001) and the ligand-bound thyroid hormone receptor (Farsetti,
Mitsuhashi et al. 1991, Ibarrola and Rodríguez-Peña 1997, Dong, Yauk et al. 2009).
Myelination has been studied extensively in the context of demyelinating diseases
like multiple sclerosis and leukodystrophies (Franklin and ffrench-Constant 2008).
However, myelin deficits are also frequently observed in neurodevelopmental cognitive

95

disorders like autism and schizophrenia and can contribute to intellectual disability
(Courchesne, Press et al. 1993, Wolkin, Rusinek et al. 1998, Iwase, Bérubé et al. 2017).
This is exemplified by the ATR-X syndrome, an intellectual disability disorder caused by
abnormalities in the ATRX chromatin remodeling protein (Gibbons, Picketts et al. 1995).
Affected boys often exhibit cognitive dysfunction, seizures and autistic features, among
other developmental defects (Gibbons, Picketts et al. 1995, Gibbons and Higgs 2000,
Wada, Ban et al. 2013, Lee, Lee et al. 2015, Giacomini, Vari et al. 2019). ATRX
syndrome patients also display abnormal myelination with a prevalence of 44% (Wada,
Ban et al. 2013, Lee, Lee et al. 2015) making white matter abnormalities a supporting
feature of the diagnostic criteria.
ATRX belongs to the Switch/Sucrose non-fermenting (Swi/Snf) family of
chromatin remodelers (Picketts, Higgs et al. 1996), and can regulate gene expression
through several mechanisms. In the newborn cortex, ATRX represses expression of
imprinted genes by fostering long-range chromatin interactions mediated by CCCTCbinding factor (CTCF) and cohesin (Kernohan, Jiang et al. 2010, Kernohan, Vernimmen
et al. 2014). In embryonic stem cells, it promotes maintenance of the repressive
H3K27me3 histone mark at polycomb target genes (Sarma, Cifuentes-Rojas et al. 2014).
On the other hand, ATRX can promote gene transcription through the incorporation of
histone H3.3 and facilitating RNA PolII elongation through G-rich sequences (Levy,
Fernandes et al. 2008, Levy, Kernohan et al. 2015). In testes, ATRX associates with the
androgen receptor and facilitates transcription of its target genes (Bagheri-Fam,
Argentaro et al. 2011). Additionally, ATRX was also reported to promote gene
expression at the α-globin cluster through the negative regulation of histone variant
macroH2A (Ratnakumar, Duarte et al. 2012).
The molecular or cellular basis for white matter abnormalities associated with
ATRX dysfunction has not yet been described. Here, we report that conditional deletion
of Atrx in the mouse forebrain and anterior pituitary causes hypomyelination. While
myelin levels and OL numbers were partially recovered upon administration of the
thyroid hormone thyroxine (T4) , this treatment failed to replenish OPCs, indicating that
ATRX might be required to maintain these progenitors independently of circulating T4
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levels. Indeed, targeted inactivation of Atrx in Sox10-expressing OPCs, but not in
neurons, resulted in CNS hypomyelination, revealing cell autonomous functions of
ATRX in OPCs. We demonstrate that ATRX-null OPCs tend to revert to a more
malleable state, and in so doing gain the ability to differentiate into astrocytes.
Mechanistically, we find that ATRX occupies the Olig2 gene locus and binds histone
deacetylase 3 (HDAC3), another regulator of OL versus astrocyte fate choice.

3.2 Methods
3.2.1 Animal husbandry and genotyping
Mice were exposed to 12-hour light/12-hour dark cycles and fed water and regular chow
ad libitum. The AtrxloxP mice have been described previously (Berube, Mangelsdorf et al.
2005) (MGI:3528480). Briefly, loxP sites flanking exon 18 allow for deletion of this
exon, destabilization of the mRNA and absence of the full-length ATRX protein (Berube,
Mangelsdorf et al. 2005). Mating AtrxloxP female mice to male mice expressing Cre
recombinase under the control of the Foxg1 promoter (129(Cg)-Foxg1tm1(cre)Skm/J,
RRID:IMSR_JAX:004337) (Hebert and McConnell 2000) yielded male progeny with
ATRX deficiency in the forebrain and anterior pituitary (AtrxloxP;FoxG1Cre
RRID:MGI:3530074) called AtrxFoxG1Cre for simplicity. Mating AtrxloxP female mice to
males expressing Cre recombinase under the control of the Nex gene promoter (Schwab,
Bartholomae et al. 2000, Goebbels, Bormuth et al. 2006) (Neurod6tm1(cre)Kan,
MGI:2668659) produced male progeny with ATRX deficiency in forebrain glutamatergic
neurons (AtrxloxP;NexCre or AtrxNexCre for simplicity). Mating AtrxloxP female mice to
males expressing Cre recombinase under the control of the Sox10 promoter (McKenzie,
Ohayon

et

al.

2014)

(CBA;B6-Tg(Sox10-icre/ERT2)388Wdr,

MGI:5634390,

RRID:IMSR JAX:027651), produced male progeny with Atrx deficiency in OPCs
(AtrxloxP;Sox10Cre or AtrxSox10Cre). Two Cre-sensitive reporter lines were bred into the
AtrxloxP mice to track Cre recombinase-expressing cells. The Sun1GFP allele (B6;129Gt(ROSA)26Sortm5(CAG-Sun1/sfGFP)Nat/J, MGI:5614796, RRID: IMSR_JAX:021039) encodes
the Sun1GFP fusion protein (located in the nuclear membrane) upon Cre-mediated
recombination (Mo, Mukamel et al. 2015) and the Tomato-Ai14 (Ai14) allele (B6.Cg-
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Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J,

MGI:3809524,

RRID:IMSR_JAX:007914)

(Madisen, Zwingman et al. 2010) expresses the tdTomato protein with red fluorescence
in the cytoplasm and nucleus upon Cre recombination. Ear punch genomic DNA was
used for PCR genotyping of the Atrx floxed or wildtype alleles using the primers 17F,
18R and neoR as described previously (Berube, Mangelsdorf et al. 2005). The
FoxG1Cre, NexCre, Sox10Cre, Tomato-Ai14 and Sun1GFP genotyping primers are listed
in Table 1.

3.2.2 Tamoxifen and thyroxine injections
Tamoxifen (10mg; Cat# T5648, Sigma) was dissolved in 100 µL 95% ethanol at 65°C for
10 mins, followed by dilution in 900 µL corn oil (Cat# C8267, Sigma). Lactating mothers
were injected intraperitoneally daily with 2 mg for two (mixed glial culture) or three
consecutive days (Harris, Buac et al. 2013). Subcutaneous injection of L-thyroxine (0.1
mg/kg; Sigma Cat# T2376-100MG) was performed daily on control and AtrxFoxG1Cre mice
from birth (P0) until P14 as done previously (Rowland, Jiang et al. 2018).

3.2.3 Microarray analysis
Total forebrain RNA (10 μg) was isolated from three P17 pairs of littermate matched
AtrxFoxG1Cre and control mice using the RNeasy Mini kit (Qiagen Cat# 74104). cRNA was
generated and hybridized to an Affymetrix Mouse Genome 430 2.0 Array at the London
Regional Genomics Center (London, Canada). Probe signal intensities were generated
using GCOS1.4 (Affymetrix Inc., Santa Clara, CA) using default values for the Statistical
Expression algorithm parameters and a Target Signal of 150 for all probe sets and a
Normalization Value of 1. Gene level data was generated using the RNA preprocessor in
GeneSpring GX 7.3.1 (Agilent Technologies Inc., Palo Alto, CA). Data were then
transformed (measurements less than 0.01 set to 0.01), normalized per chip to the 50th
percentile, and per gene to control samples. Probe sets representing Atrx transcripts were
removed (10 sets). The remaining probe sets were filtered by fold change ≥1.5 between
control and AtrxFoxG1Cre samples, and by confidence level of P<0.05. Significantly
overrepresented GO categories were determined using GeneSpring: probe sets were
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filtered by 1.5-fold change, P<0.05 and categorized as either up or downregulated. Where
there were multiple probe sets for a gene, duplicates were removed. P<0.001 was used as
the significance cut-off (Levy, Fernandes et al. 2008).

3.2.4 Western blot analysis
Protein was extracted from P14 or P20 mouse forebrain and homogenized in RIPA buffer
(150 mM NaCl, 1% NP-40, 50 mM Tris pH 8.0, 0.5% deoxycholic acid, 0.1% SDS, 0.2
mM PMSF, 0.5 mM NaF, 0.1 mM Na3VO4, 1x protease inhibitor cocktail (Millipore
Sigma Cat# 11873580001)). Homogenized tissue was incubated on ice for 20 minutes
and centrifuged for 20 minutes at 10000 RPM. Supernatant protein was quantified using
the Bradford assay (BioRad Cat# 500-0006). Protein (30 μg) was resolved on a 12%
SDS-PAGE and transferred to a 0.45 μm nitrocellulose membrane (BioRad Cat#
1620115). The membranes were probed with anti-MAG, mouse monoclonal (1:3000,
Abcam Cat# ab89780, RRID:AB_2042411), anti-MOG, rabbit polyclonal (1:3000,
Abcam Cat# ab32760, RRID:AB_2145529), or anti-MBP, rat monoclonal (1:3000,
Abcam Cat# ab7349, RRID:AB_305869) antibodies at 4°C overnight. This was followed
by incubation with the appropriate horseradish peroxidase–conjugated secondary
antibody for 1 hour at room temperature: mouse-HRP (1:3,000, Santa Cruz Cat# sc516102, RRID:AB_2687626), rabbit-HRP (1:5000, Jackson ImmunoResearch Cat# 111036-003, RRID:AB_2337942) or rat-HRP (1:3,000, Santa Cruz Cat# sc-2006,
RRID:AB_1125219). The membrane was incubated in enhanced chemiluminescent
(ECL) (Thermo Fisher Cat# 34095) before exposure using film (Progene Cat# 39-20810)
or Universal Hood III (BioRad Cat# 731BR00882) and analyzed with Image Lab
(BioRad, Version 4.1, 2012).

3.2.5 Immunofluorescence
P14 or P20 mice were transcardially perfused with PBS followed by 4%
paraformaldehyde. Brains were dissected and fixed in 4% paraformaldehyde overnight.
The next day, brains were washed 3x 5 min in PBS and dehydrated in 30% sucrose until
tissue had sunk. Fixed brain tissue was flash-frozen on dry ice using Cryomatrix
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cryoprotectant (ThermoFisher Cat# 6769006) and cryosectioned coronally at 8 µm
thickness (Leica CM 3050S) on superfrost slides (Thermo Fisher Cat# 22-037-246) and
stored at -80°C with a desiccant (VWR, 61161-319). For immunofluorescence staining of
cryosections, slides were rehydrated in 1x PBS for 5 minutes, washed with PBS + 0.1%
TritonX100 (Millipore Sigma Cat# T8787), blocked with 10% normal goat serum diluted
in washing solution (Millipore Sigma Cat# G9023) for 1 hour and incubated with primary
antibody overnight at 4°C. Slides were washed 3 times for 5 min with PBS and incubated
with secondary antibody for 1 hour in the dark followed by 2x 5 min PBS washes.
Sections were counterstained with 1 µg/mL DAPI (Millipore Sigma Cat# D9542) for 5
min, washed for 5 min with PBS and mounted with Permafluor (Thermo Fisher Cat# TA006-FM) followed by imaging. Primary mixed glial cultures were fixed for
immunofluorescence staining at 3DIV or 9DIV with 3% PFA at room temperature for 15
minutes. Cells were permeabilized with PBS + 0.1% TritonX100 (Millipore Sigma Cat#
T8787), blocked with PBS + 10% normal goat serum (Millipore Sigma Cat# G9023) for
1 hour and incubated with primary antibody overnight at 4°C. The next day, flasks were
washed 3x 5 minutes with PBS and incubated with secondary antibody diluted in
blocking solution for 1 hour at room temperature. Cells were then counter-stained with 1
µg/mL DAPI (Millipore Sigma Cat# D9542) for 5 min, washed for 5 min with PBS and
mounted with Permafluor (Thermo Fisher Cat# TA-006-FM) followed by imaging. The
following primary antibodies were used: anti-MOG, rabbit polyclonal (1:200, Abcam
Cat# ab32760, RRID:AB_2145529), or anti-MBP, rat monoclonal (1:50, Abcam Cat#
ab7349, RRID:AB_305869),

anti-ATRX, rabbit polyclonal (1:75, Santa Cruz

Biotechnology Cat# sc-15408, RRID:AB_2061023), anti-Olig2, rabbit polyclonal (1:200,
Millipore Cat# AB9610, RRID:AB_570666), anti-S100β, rabbit polyclonal (1:200,
Agilent Cat# Z0311, RRID:AB_10013383), anti-GFAP, rabbit polyclonal (1:200, Agilent
Cat# Z0334, RRID:AB_10013382), Anti-NG2, rabbit polyclonal (1:200, Millipore Cat#
AB5320, RRID:AB_11213678), Anti-Pdgfrα, rabbit polyclonal (Abcam Cat# ab65258,
RRID:AB_1141669) and Anti-APC, mouse monoclonal (Abcam Cat# ab16794,
RRID:AB_443473). The secondary antibodies used were goat anti-rabbit-Alexa Fluor
594 (1:800, Thermo Fisher Scientific, A-11012, RRID:AB_2534079), goat anti-rabbitAlexa Fluor 488 (1:800, Thermo Fisher Scientific Cat# A-11008, RRID:AB_143165),
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goat anti-mouse-Alexa Fluor 594 (1:800 Thermo Fisher Scientific Cat# A-21125,
RRID:AB_2535767), goat anti-mouse-Alexa Fluor 488 (1:800, Thermo Fisher Scientific
Cat# A-11001, RRID:AB_2534069) and goat anti-rat-Alexa Fluor 488 (1:800, Thermo
Fisher Scientific, A-11006, RRID:AB_2534074).

3.2.6 Microscopy, imaging and cell counts
Immunofluorescence images were captured using an inverted microscope (DMI 6000b,
Leica) outfitted with a digital camera (ORCA-ER, Hamamatsu). Openlab software
(PerkinElmer Version 5.0, RRID:SCR_012158) was used for image capture. Image
processing was performed using Volocity (PerkinElmer Demo Version 6.0.1,
RRID:SCR_002668) and Adobe Photoshop. Cell counts of the mouse corpus callosum
were performed in a blinded and randomized manner for immunofluorescence staining of
Olig2, PDGFRα, APC, Sun1GFP, S100β and GFAP in control or experimental
cryosections using Volocity (PerkinElmer Demo Version 6.0.1, RRID:SCR_002668).
The corpus callosum was outlined and the area recorded. Cells were counted in 2-10
sections per biological replicate and 3-4 biological replicates were counted for each
genotype.

3.2.7 Isolation of nuclei tagged in specific cell types (INTACT)
method
To circumvent the problems associated with mechanical purification techniques, the
INTACT method (Mo, Mukamel et al. 2015) followed by fluorescence-activated nuclei
sorting (FANS) was used to enrich for Sun1-GFP+ OPC nuclei. Control or AtrxSox10Cre
forebrain tissue was homogenized in 500 µL homogenization buffer (20 mM Tricine
KOH, 25 mM MgCl2, 250 mM sucrose, 1 mM DTT, 0.15 mM spermine, 0.5 mM
spermidine, 0.1% IGEPAL-630, 1x protease inhibitor cocktail (Millipore Sigma Cat#
11873580001), 1 uL/mL RNase inhibitor (Thermo Fisher Scientific Cat# 10777019).
Samples were diluted to 7.5 mL with homogenization buffer and filtered through a 40 µm
strainer. Filtered samples were layered on top of 7.5 mL cushion buffer consisting of 0.5
mM MgCl2, 0.88 M sucrose, 0.5 mM DTT, 1x protease inhibitor cocktail (Millipore
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Sigma Cat# 11873580001), 1 uL/mL RNase inhibitor (Thermo Fisher Scientific Cat#
10777019) and centrifuged at 2800 g for 20 mins at 4°C. Nuclei were collected as a
pellet, incubated for 10 min in 500 µL 4% FBS, 0.15 mM spermine, 0.5 mM spermidine,
1x protease inhibitor cocktail (Millipore Sigma Cat# 11873580001) and 1 uL/mL RNase
inhibitor (Thermo Fisher Scientific Cat# 10777019) in PBS and resuspended by gentle
pipetting. Nuclei were sorted using a Sony SH800 Cell Sorter and Sun1GFP + nuclei were
collected. Total RNA was immediately isolated from GFP+ nuclei with a single cell RNA
purification kit (NorgenBiotek Cat# 51800).

3.2.8 Quantitative reverse transcriptase-PCR (qRT-PCR)
cDNA was prepared using 100 ng RNA from FANS-purified GFP+ nuclei or from the
optic tract (RNeasy Mini kit; Qiagen Cat# 74104) and 1.5 µL 100 ng/uL of random
hexamer (Integrated DNA Technologies Cat# 51-01-18-26) were diluted to 12 µL with
RNAse free water. Samples were heated to 65°C followed by addition of 4 µL first strand
buffer (Thermo Fisher Scientific Cat# 18064014), 2 µL 100 mM DTT (Thermo Fisher
Scientific Cat# 18064014), 0.8 µL 25 mM dNTPs, 0.5 µL RNaseOut (Thermo Fisher
Scientific Cat# 10777019), 0.5 uL SuperScript II Reverse Transcriptase (Thermo Fisher
Scientific Cat# 18064014) and 0.5 µL RNAse free water per sample. Samples were then
incubated at 30°C for 10 minutes then 42°C for 45 minutes and stored at -20°C. cDNA
was amplified with gene-specific primers under the following conditions: cDNA was
amplified with iQ SYBR Green Master Mix (BioRad Cat# 1708884) using the standard
curve Ct method of quantification. Experiments were performed on a Chromo-4
thermocycler (MJ Research/BioRad) and analyzed with Opticon Monitor 3 and GeneX
(BioRad) software. Technical duplicates were completed for each sample. Conditions for
amplification were as follows: 40 cycles of 95°C for 10 seconds, 55-60°C for 20 seconds,
72°C for 30 seconds, and a final melting curve generated in increments of 0.5°C per plate
read. Primer sequences are listed in Table 2.
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Gene Name
AtrxWT
Atrxfloxed
FoxG1Cre
NexCre
Sox10Cre
Sun1GFP
Ai14Tomato
Gapdh
Atrx
Olig2
Sox10
Pdgfrα
Olig1
Gpr17
Cspg4
Mag
Mog
Mbp
Plp
Gfap
S100β

Forward Primer
AGA AAT TGA GGA TGC TTC ACC
AGA AAT TGA GGA TGC TTC ACC
TGA CCA GAG TCA TCC TTA GCG
TGA CCA GAG TCA TCC TTA GCG
CAC CTA GGG TCT GGC ATG T
AAG GGA GCT GCA GTG GAG TA
GGC ATT AAA GCA GCG TAT CC
CAA CGA CCC CTT CAT TGA CCT
AGA AAT TGA GGA TGC TTC ACC
GCA GCG AGC ACC TCA AAT CT
CTA CAGG GAG TGC CCA CCT GG
GTC AGG CCA CT AAA GAG GTC A
CTC GCC CAG GTG TTT TGT TG
TCACAGCTTACCTGCTTCCC
CTCAAGATGGGAGCCTCAGC
CAG AGA GCC ACT GCC TTC AA
AGA GGC AGC AAT GGA GTT GA
CAT TGG GTC GCC ATG GGA AA
GGC CAC TGG ATT GTG TTT CT
AAA CCA GCC TGG ACA CCA AA
TGA AGC CAG AGA GGA CTC CA

Reverse Primer
TGA ACC TGG GGA CTT CTT TG
CCA CCA TGA TAT TCG GCA AG
AAT GCT TCT GTC CGT TTG CC
AAT GCT TCT GTC CGT TTG CC
CAG GTT TTG GTG CAC AGT CA
CGG GCC ATT TAC CGT AAG TTA T
CTG TTC CTG TAC GGC ATG G
ATC CAC GAC CGA CAC ATT GG
TGA ACC TGG GGA CTT CTT TG
AGA TCA TCG GGT TCT GGG GA
GCT CTG TCT TTG GGG TGG TT
CGT GCA AGT TGA CAG CTT CC
CGA CGT GCC TTG CTA CCT AT
TTGTCCGCATTGCTCAGAGT
ACAAAGGCGTCTGTCTGTGT
TCA AAG GCC ACA GAG GTT C
TGC GAT GAG AGT CAG CAC AC
AGC CTC TCC TCG GTG AAT CT
GAA AGC ATT CCA TGG GAG AA
ACA CCT CAC ATC ACC ACG TC
CCA GGA AGT GAG AGA GCT CG

P1 Promoter

ATT CCC CGT CTC ACT CCG TA

TAG CGG GGC TGC TAA AGA AG

P2 Proximal

GCC TGA CGC TAC AGT GAC AA

TAG CGG GGC TGC TAA AGA AG

P3 Exon1

CTG CCT CCA CCC AGC TA TAA

GGT GTT GGC TCG GTC TGT AA

P4 Exon2

ATC TTC CTC CAG CAC CTC CT

GTT CGC GGC TGT TGA TCT TC

P5 3'UTR

TAG GAG ACT CCC AGG AAC CG

GAC CAC AGG ACC CTA AGT GC

P6 3'UTR2

CCT CCC ACA CAC ACA CCT TT

AGG TGG AAG GTT AGG AGG CA

Application
Genotyping
Genotyping
Genotyping
Genotyping
Genotyping
Genotyping
Genotyping
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCR
ChIP qRTPCR
ChIP qRTPCR
ChIP qRTPCR
ChIP qRTPCR
ChIP qRTPCR
ChIP qRTPCR

Table 2 List of primer sequences

3.2.9 Mixed glial cells primary culture
Cre recombination was induced by IP injection of 2 mg tamoxifen to lactating mothers
for two consecutive days (P0-P1) (Harris, Buac et al. 2013). At P3, mouse cortices were
dissected into MEM and tissue dissociated by pipetting with a P1000. Samples were then
incubated at 37°C with OPC papain solution (Worthington Cat# LS003124) for 20
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minutes with constant inversion to prevent tissue aggregation. Papain was deactivated for
10 min at room temperature followed by trituration with a flame polished Pasteur pipette.
Samples were centrifuged at 300 g for 5 minutes and pellets resuspended in 1 mL mixed
glial culture media consisting of DMEM supplemented with 10% FBS (Gibco Cat #
12483020), 1% Penicillin-Streptomycin (Gibco Cat # 15070063), 1% AntibioticAntimycotic (Gibco Cat # 15240062) and 1% GlutaMax (Gibco Cat # 35050061). The
cell suspension from each tube was added to a pre-equilibrated poly-L-lysine (1 mg/mL)
coated 6 well plate in 1 mL of media. Flasks were incubated at 8.5% CO2 in a tissue
culture incubator for 3 hours to allow cells to attach to the poly-L-lysine substrate
followed by a full media change. A 2/3 volume media change was performed every three
days (Chen, Balasubramaniyan et al. 2007, O'Meara, Ryan et al. 2011).

3.2.10 Co-immunoprecipitation
P20 control mouse forebrain protein (1 mg), 50 µL protein G Dynabeads (Invitrogen
Cat# 10009D) and 5 µg either anti-HDAC3, mouse monoclonal (Millipore Sigma Cat#
05-813, RRID: AB_310021) or anti-IgG, rabbit polyclonal (Thermo Fisher Scientific
Cat# 02-6102, RRID:AB_2532938) diluted in PBS + 0.1% Tween-20 were incubated
with rotation at 4°C overnight. The Dynabeads-Ab-Ag complex was washed three times
with PBS and the antigen was eluted from the beads with 30 µl SDS sample buffer (100
mM Tris (pH 6.8), 4% sodium dodecyl sulfate (SDS), 0.2% bromophenol blue, 20%
glycerol, 200 mM β-mercaptoethanol) heated for 10 min at 70°C with agitation. Input
protein (100 µg) was treated the same. Samples were resolved on 6% SDS-PAGE and
transferred onto a 0.45 μm nitrocellulose membrane (BioRad Cat# 1620115). The
membrane was probed with anti-ATRX, rabbit polyclonal (1:1000, Abcam Cat#
ab97508, RRID:AB_10680289) at 4°C overnight. This was followed by rabbit-anti-HRP
(1:5000, Jackson ImmunoResearch Cat# 111-036-003, RRID:AB_2337942) conjugated
secondary antibody for 1 hour at room temperature. The membrane was treated with
enhanced chemiluminescent (ECL) (Thermo Fisher Cat# 34095) before exposure with a
Hood III (BioRad Cat# 731BR00882) and analyzed with Image Lab (BioRad, Version
4.1, 2012).
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3.2.11 Chromatin immunoprecipitation in cultured OPCs
Cortices from 15 control P0.5 pups were dissected and OPCs were grown for 9 DIV in a
mixed glial co-culture as described in the mixed glial co-culture section. OPCs were then
physically separated from resident astrocytes by shaking overnight in a tissue culture
incubator at 5% CO2 (Chen, Balasubramaniyan et al. 2007, O'Meara, Ryan et al. 2011).
OPCs were pooled, homogenized and passed through a 70 µm strainer. To crosslink
chromatin, the sample was diluted to 20 mL with PBS with 0.02 M EGS (ethylene glycol
bis(succinimidyl succinate)) (Thermo Fisher Scientific Cat # 21565) and incubated at
room temperature for 45 min with constant mixing (Truch, Telenius et al. 2018). This
was followed by the addition of 1% formaldehyde and incubation at room temperature
for 20 minutes with constant mixing. To quench crosslinking, 0.125 M glycine was added
for 2 minutes at room temperature and samples were centrifuged at 700 g for 5 minutes.
Pellets were washed twice with 10 mL cold PBS and stored at -80°.
Chromatin was sonicated following lysis with a Bioruptor Pico Sonication Device
(Diagenode Cat# B01060010) for 6 cycles. For ChIP, 50 µL protein G Dynabeads
(Invitrogen Cat# 10009D) were prepared with either 10 µg anti-ATRX rabbit polyclonal
antibody (Abcam Cat# ab97508, RRID:AB_10680289) or anti-IgG rabbit polyclonal
antibody (Thermo Fisher Scientific Cat# 02-6102, RRID:AB_2532938) for 4 hours with
rotation at 4°C. Chromatin lysate (50 µg per IP) was precleared with 100 uL protein G
Dynabeads (Invitrogen Cat# 10009D) for 1 hour at 4°C. Precleared lysate and antibodybound beads were combined and incubated at 4°C overnight with rotation. The next day,
beads were washed five times and eluted for 15 minutes at room temperature followed by
a second elution for 20 minutes at 65°C (Truch, Telenius et al. 2018). Crosslinking was
reversed by adding 5M NaCl at 65°C for 4 hours. Samples were treated with 1 µL 10
mg/mL RNase A at 37°C for 30 min then 1 µL 20 µg/mL proteinase K for 1 hour at
45°C. 1/10th of precleared chromatin lysate was treated the same and used as input. DNA
was purified (QIAquick PCR Purification Kit, Qiagen Cat# 28104) and amplified by
qRT-PCR with iQ SYBR Green Master Mix (BioRad Cat# 1708884) by using the
standard curve Ct method of quantification. Experiments were performed on a Chromo-4
thermocycler (MJ Research/BioRad) and analyzed with Opticon Monitor 3 and GeneX
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(BioRad) software. qRT-PCR was repeated in duplicate for each sample as a technical
replicate. Conditions for amplification were as follows: 40 cycles of 95°C for 10 seconds,
55-60°C for 20 seconds, 72°C for 30 seconds, and a final melting curve generated in
increments of 0.5°C per plate read. Amplified DNA was resolved on a 1.5% agarose gel
to confirm correct product size. Primer sequences are listed in Supplementary Table 1.

3.2.12 Statistical analysis
Statistical analysis was performed using GraphPad Prism6 software (6.05; GraphPad
Software Inc.) and all results are expressed as the mean ± SEM. Two independent data
sets were compared with the Student’s t test (unpaired, 2-tailed). Multiple independent
data sets were compared with a one-way ANOVA with post-hoc Tukey’s test. P values of
0.05 or less were considered to indicate significance.

3.2.13 Study approval
All procedures involving animals were conducted in accordance with the regulations of
the Animals for Research Act of the Province of Ontario and approved by the University
of Western Ontario Animal Care and Use Committee.

3.3 Results
3.3.1 Decreased myelination in the AtrxFoxG1Cre forebrain
Our previous studies have shown that postnatal health and longevity are adversely
affected in mice with forebrain and anterior pituitary-specific deficiency for ATRX
(AtrxFoxG1cre mice) (Watson, Solomon et al. 2013, Rowland, Jiang et al. 2018). AtrxFoxG1cre
mice have a shortened lifespan, growth and hormone abnormalities, including low
circulating levels of IGF-1 and T4 and exhibit aberrant gene expression in the liver
(Watson, Solomon et al. 2013, Rowland, Jiang et al. 2018). To identify potential
forebrain related differences in transcription between control and AtrxFoxG1Cre we
performed a microarray analysis on forebrain tissue of 3 littermate-matched pairs of P17
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control and AtrxFoxG1Cre mice. The microarray analysis identified a potential effect of
ATRX loss of function on myelination, as several central nervous system related
phenotypes including abnormal myelination, demyelination and abnormal OL
morphology/physiology were enriched in pathway analysis (Figure 3-1A). The genes
significantly downregulated in the abnormal myelination and demyelination categories
included 25 genes associated with abnormal myelination (Figure 3-1B). Based on several
eports of aberrant myelination in ATR-X patients (Wada, Ban et al. 2013, Lee, Lee et al.
2015), we explored a possible loss of myelination in these mice, examining levels of
well-established myelin markers, including myelin associated glycoprotein (MAG),
myelin oligodendrocyte glycoprotein (MOG) or myelin basic protein (MBP) in control
and AtrxFoxG1Cre forebrain protein extracts. Western blot analysis demonstrates that,
similar to the lower mRNA levels, the level of these myelin proteins is significantly
decreased in AtrxFoxG1Cre forebrain compared to littermate matched controls (n=4 each
genotype; Student’s T-test, MAG p<0.05) (Figure 3-1C). Immunofluorescence staining
of brain cryosections reinforced these findings, showing qualitative decreased level of
MOG and MBP in the corpus callosum and adjacent cortex of AtrxFoxG1Cre compared to
control mice at P20 (Figure 3-1D). These data demonstrate that the AtrxFoxG1Cre mice
display severe hypomyelination.

3.3.2 Postnatal thyroxine treatment partially restores OLs, but
not OPCs in AtrxFoxG1Cre mice
We previously determined that circulating levels of the thyroid hormone T4 in
AtrxFoxG1Cre mice are less than half that of controls, most likely stemming from the
deletion of Atrx in the anterior pituitary in these mice (Watson, Solomon et al. 2013,
Rowland, Jiang et al. 2018). The thyroid hormone receptor is a transcription factor that
requires its ligand, triiodothyronine (T3), to promote the expression of several myelin
genes (Farsetti, Mitsuhashi et al. 1991, Ibarrola and Rodríguez-Peña 1997, Dong, Yauk et
al. 2009). Based on this, we tested whether postnatal injections of the prohormone T4
could rescue hypomyelination in AtrxFoxG1Cre mice. We performed daily injections of 0.1
mg/kg L-thyroxine (T4) or PBS from P0 to P14, as outlined in Figure 3-2A, a dose
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Figure 3-1 The mouse forebrain lacking ATRX expression is hypomyelinated.
(a) Microarray analysis of P17 control and AtrxFoxG1Cre forebrain tissue reveals a
significant downregulation (p<0.05) of genes related to myelination, axon degeneration
and abnormal nerve conduction. (b) List of downregulated genes involved in myelination.
(c) Western blot analysis of P20 forebrain extracts shows significantly decreased levels of
MAG, MOG and MBP proteins in AtrxFoxG1Cre compared to control mice (n=4 for each
genotype) after normalization to Actin protein levels. Error bars represent +/- SEM and
asterisks indicate p<0.05 (Student’s T-test). (d) Immunofluorescence microscopy of P20
brain cryosections stained with anti-MOG (green) and anti-MBP (red) antibodies confirm
decreased levels of these myelin proteins in the cortex (Ctx) and corpus callosum (CC)
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(outlined in white dashed line) areas of the forebrain in AtrxFoxG1Cre mice compared to
controls (Ctrl). Scale bar, 500 µm.
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Figure 3-2 Postnatal thyroxine treatment partially rescues the number of APC+ OLs
and the expression of myelin proteins in the ATRX-null forebrain but does not
restore the number of Pdgfrα+ OPCs.
(a) Outline of experimental design. Each arrow represents a subcutaneous (SC) injection
of 0.1 mg/kg T4 or PBS to AtrxFoxG1Cre and control pups. Analyses were then performed
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at P14. (b-c) Quantification of immunostained P14 cryosections demonstrate that the
reduced number of Olig2+ and Pdgfrα+ cells observed in the AtrxFoxG1Cre CC is not
rescued by T4 treatment (n=3 each group). (d) The number of APC+ cells are partially
rescued upon T4 treatment (n=3 each group). (e) qRT-PCR shows that transcript levels of
several myelin genes are decreased in the P14 AtrxFoxG1Cre forebrain and partially restored
to control levels following T4 treatment (n=3-5 for each group). (f) Western blot analysis
of MAG, MOG and MBP shows decreased protein levels in P14 AtrxFoxG1Cre compared to
control forebrain extracts and partial rescue upon T4 treatment. Graphs show
quantification of 3 trios, normalized to Actin protein levels. (g) Immunofluorescence
staining of P14 brain cryosections highlight the decreased expression of MOG (green)
and MBP (red) protein levels in the AtrxFoxG1Cre cortex (Ctx) and corpus callosum (CC)
(outlined in white dashed line) that are ameliorated following T4 treatment. Scale bar,
500 µm. In all graphs, error bars represent +/-SEM, and groups with different letters
significantly differ from one another (one-way ANOVA with post-hoc Tukey HSD;
p<0.05).
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previously shown to successfully elevate circulating T4 to control levels in AtrxFoxG1Cre
mice (Rowland, Jiang et al. 2018).
We first quantified the number of OLs after T4 treatment by immunofluorescence
staining of P14 brain cryosections, using an antibody specific for the pan-OL marker
Olig2. We find that the proportion of Olig2+ cells (representing all OPCs and OLs) is
significantly decreased in the AtrxFoxG1Cre corpus callosum (25.7% of total DAPI+ cells)
when compared to controls (43.2% of total DAPI+ cells) and this is partially recovered in
AtrxFoxG1Cre mice treated with T4 (31.4%) (n=3 for each genotype; p<0.05, one-way
ANOVA) (Figure 3-2B). We also counted the proportion of OPCs or OLs in the corpus
callosum of control and AtrxFoxG1Cre brain cryosections at P14, identified by PDGFRα and
adenomatous polyposis coli (APC) staining, respectively. The proportion of differentiated
APC+ OLs is decreased in the AtrxFoxG1Cre corpus callosum (11.3%) compared to controls
(28.2%) and was partially recovered (19.6%) following T4 treatment (n=3 for each
genotype; p<0.05 one-way ANOVA) (Figure 3-2D). While the proportion of PDGFRα+
OPCs is lower in AtrxFoxG1Cre mice (11.5%) compared to controls (24.6%) it is not
improved upon T4 treatment (11%) (n=3 each genotype; p<0.05, one-way ANOVA)
(Figure 3-2C).
To determine if T4 administration increases the expression of myelin genes, we
performed qRT-PCR using primer pairs specific for several established myelin genes:
Mag, Mog, Mbp and Plp1 (proteolipid protein 1). The level of RNA transcripts is
generally elevated in T4- vs PBS-treated AtrxFoxG1Cre mice, but rescue is only partial and
does not reach control levels (n=3-4 each genotype; Mag, Mog, Plp p<0.05 by one-way
ANOVA) (Figure 3-2 E) Given that RNA transcript levels are not always representative
of protein levels, we also examined how T4 injections affect myelin protein expression.
Western blot analysis of MAG, MOG and MBP reveals a significant albeit partial rescue
of the level of these proteins upon T4 treatment in AtrxFoxG1Cre forebrain extracts (n=3
each genotype p<0.05 by one-way ANOVA) (Figure 3-2 F). The results were similar by
immunofluorescence staining of MOG and MBP in AtrxFoxG1Cre forebrain cryosections
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with or without T4 supplementation (Figure 3-2 G). Taken together, these experiments
suggest that hypomyelination in AtrxFoxG1Cre mice is due to a reduced number of OPCs
and OLs. T4 treatment stimulates OL differentiation by promoting myelin gene
expression but does not ameliorate OPC numbers, thus explaining the incomplete effect
of T4 treatment on the extent myelination.

3.3.3 Targeted deletion of Atrx in neurons does not affect
myelination
The results of the T4 treatment suggested that ATRX is likely required in the central
nervous system to support normal myelination either cell autonomously or in other cell
types to provide trophic support to OPCs. To resolve whether ATRX regulates
myelination intrinsically in OPCs or indirectly via neuronal signaling (or both), we used
different Cre driver lines to inactivate ATRX specifically in each cell type. We generated
mice that lack ATRX in forebrain excitatory neurons using the NexCre driver mice for
AtrxloxP recombination (Goebbels, Bormuth et al. 2006). We confirmed the absence of
ATRX nuclear protein in cortical neurons by co-immunofluorescent staining of ATRX
and the neuronal marker NeuN (Figure 3-3A). We next examined myelin protein
expression in the forebrain of these mice by immunofluorescence staining of P20 brain
cryosections and observed no obvious difference in MBP and MOG protein between
control and AtrxNexCre mice (Figure 3-3B). Furthermore, MAG, MOG and MBP protein
levels are also similar to controls when assessed by immunoblot of P20 AtrxNexCre
forebrain extracts (n=3 each genotype) (Figure 3-3C). These findings show that ATRX is
not required in neurons of the developing brain for proper signaling to OPCs and for
normal initiation of the myelination program.

3.3.4 Inducible postnatal inactivation of ATRX in OPCs
We next sought to establish whether deletion of ATRX specifically in OPCs causes
depletion of the OPC/OL pool leading to hypomyelination. ATRX deletion in OPCs was
achieved using the tamoxifen inducible Sox10CreERT2 allele, which upon mating with
AtrxLoxP mice produced AtrxSox10-iCreERT2 (AtrxSox10Cre) mice
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Figure 3-3 Myelination appears normal in mice with Atrx deletion in forebrain
excitatory neurons.
(a) Immunofluorescence staining of P20 brain cryosections shows absence of ATRX
protein (red) in NeuN expressing neurons (green) in the cortex of AtrxNexCre mice. Scale
bar, 100 µm. (b) MBP and MOG immunofluorescence staining of P20 AtrxNexCre and
control cortex (Ctx) and corpus callosum (CC) (outlined in white dashed line). Scale bar,
100 µm. (c) Western blot analysis of MAG, MOG and MBP and quantification below
shows similar levels of these proteins in the P20 AtrxNexCre mouse forebrain compared to
controls when normalized to Actin protein levels (p>0.05 Student’s T-test). Error bars
represent +/-SEM, n=3 each genotype.
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(McKenzie, Ohayon et al. 2014). The Cre-sensitive nuclear membrane Sun1GFP reporter
was also introduced in the AtrxSox10Cre mice to facilitate fate tracking of Cre-expressing
cells (Figure 3-4 A) (Mo, Mukamel et al. 2015). Cre recombination was induced by daily
intraperitoneal injections of nursing mothers for three successive days (pups at P1-P3)
(Harris, Buac et al. 2013) and the mice were analyzed at P20 or P35 (Figure 3-4B). The
absence of ATRX protein was confirmed in AtrxSox10Cre OPCs by immunofluorescence
staining of ATRX and imaging in parallel with the endogenous Sun1GFP reporter (Figure
3-4C). To confirm depletion of Atrx, we obtained OPC nuclei from P20 forebrain of
control and AtrxSox10Cre mice and enriched for Sun1GFP+ nuclei using FANS (Figure 34D). qRT-PCR analysis confirmed a 74.2% decrease in Atrx transcript levels AtrxSox10Cre
Sun1GFP+ nuclei compared to control Sun1GFP+ nuclei (n=4 each genotype; Student’s
T-test, p<0.05) (Figure 3-4E). These results confirm that Atrx gene deletion in OPCs
leads to a reduction of ATRX protein and transcript levels in AtrxSox10Cre mice.

3.3.5 Loss of the Olig2 fate specification factor in ATRX-null
OPCs.
At all stages of development, OPCs and OLs express Olig2, an essential regulator of OL
lineage specification (Lu, Sun et al. 2002, Takebayashi, Nabeshima et al. 2002, Zhou and
Anderson 2002). Olig2 suppresses astrocytic fate (Cai, Chen et al. 2007, Zhu, Zuo et al.
2012, Zuo, Wood et al. 2018) and promotes OPC differentiation via regulation of the
chromatin remodeling complex Smarca4/Brg1 (Yu, Chen et al. 2013). Upon staining with
Olig2, we were surprised to see that in the AtrxSox10Cre corpus callosum, a large proportion
of Sun1GFP+ ATRX-null OPCs do not express the Olig2 protein (47.9%) compared to
Sun1GFP+ control OPCs (12.1%) (n=3-4 each genotype; Student’s T-test, p<0.05)
(Figure 3-5A, B). Similarly, qRT-PCR performed on sorted AtrxSox10Cre Sun1GFP+ nuclei
confirms a 58% reduction in Olig2 RNA transcripts compared to Sun1GFP+ control
nuclei (n=3 each genotype; Student’s T-test, p<0.05) (Figure 3-5C).
Loss of Olig2 expression in ATRX-null OPCs is also observed in primary glial cell
cultures. Cre-mediated recombination was induced by tamoxifen injections to nursing
mothers for two days (age of pups P0-P1). P3 cortices of AtrxSox10Cre or control mice that
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Figure 3-4 ATRX is absent in Sox10-expressing cells following tamoxifen injection
to nursing mothers.
(a) Diagram of the Cre-sensitive Sun1GFP nuclear membrane reporter. (b) Nursing
mothers were injected daily with tamoxifen (Tam) for three days (P1-P3 of pups, as
indicated by black arrows) and pups were sacrificed for analysis at P20. (c)
Immunofluorescence microscopy of P20 Atrxwt/y;Sox10Cre+ corpus callosum shows
expression of the Sun1GFP fusion protein in the nuclear membrane of OPCs upon Tam
induced Sox10Cre-mediated excision of the upstream polyA transcriptional stop
sequence (left). P20 Atrxfl/y;Sox10Cre+ treated with Tamoxifen also express Sun1GFP but
lack expression of nuclear ATRX (right). Scale bar, 100 µm. (d) Isolation of nuclei
expressing Sun1GFP via FACS sorting. (e) qRT-PCR analysis shows that Atrx transcript
levels are significantly decreased in P20 AtrxSox10Cre isolated nuclei (n= 4 for each
genotype; Student’s T-test p<0.05).
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Figure 3-5 ATRX-null OPCs fail to express Olig2 and exhibit altered morphology.
Fate mapping of ATRX-null Sun1GFP+ OPCs reveals frequent loss of the Olig2
transcription factor (white arrowheads). Scale bar, 100µm. (b) Quantification of
Sun1GFP+ OPCs that lack Olig2 staining (right) (Ctrl n=4; AtrxSox10Cre n=3; Student’s ttest; p<0.05). (c) qRT-PCR analysis demonstrates significantly decreased Olig2 transcript
levels in Sun1GFP+ AtrxSox10Cre sorted nuclei compared to Sun1GFP+ control nuclei (n= 4
for each genotype; Student’s T-test; p<0.05). (d) Diagram of the Cre sensitive Ai14 allele
encoding the tdTomato fluorescent reporter. (e) Experimental timeline of Tamoxifen
(Tam) injections to nursing mothers at P0 and P1 (black arrows). Primary mixed glial
cultures of cortices were established at P3 and maintained for 9 days in vitro (DIV). (f, g)
Control and AtrxSox10Cre Ai14+ (red) primary cultures at 9DIV immunostained for Olig2
(green) reveal limited overlap of ATRX-null Ai14+ OPCs with Olig2 and flattened cell
morphology. Scale bar, (f) 500 µm (g) 100 µm. In all graphs, error bars represent +/-SEM
and asterisks indicate p<0.05 (Student’s T-test).
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also express the Ai14-TdTomato reporter (Figure 3-5D) (Madisen, Zwingman et al.
2010) were dissociated and cells grown in mixed glial co-culture in which OPCs are
expanded on top of an astrocyte monolayer (Chen, Balasubramaniyan et al. 2007,
O'Meara, Ryan et al. 2011) (Figure 3-5E). After 9 days in vitro (DIV), we observed that
many ATRX-null Ai14+ cells do not express Olig2and display an elongated and flattened
morphology unlike the typically rounded shape of OPCs (Figure 3-5F, G). These results
establish that ATRX-null OPCs fail to express Olig2 in vivo and in vitro and start to
display an atypical flattened morphology.

3.3.6 Inactivation of Atrx downregulates the expression of OPCspecific genes
To further characterize ATRX-null OPCs and investigate the downstream consequences
of Olig2 loss of expression, we evaluated the transcript level of known OPC-specific
markers. We extracted RNA from ATRX-null or control Sun1GFP+ OPC nuclei sorted
from cortical samples. RT-qPCR analysis reveals a dramatic reduction in the expression
of OPC markers Pdgfrα, Cspg4 (NG2) and Gpr17 in ATRX-null OPCs (Figure 3-6A)
(n=3-4 each genotype; Student’s T-test, p<0.05). The OPC-expressed genes Olig1 and
Sox10 were similarly reduced but did not reach the significance threshold of P<0.05
(Figure 3-6A) (n=3 each genotype; p>0.05 Student’s T-test). Moreover, Sun1GFP+
ATRX-null OPCs in the corpus callosum stain less frequently for PDGFRα (24.9%)
compared to controls (41.1%) (Figure 3-6B) (n=3 each genotype; p<0.05, Student’s Ttest). Immunofluorescence staining was also performed on mixed glial cultures at either
early (3DIV) or late (9DIV) timepoints to examine OPC development over time as
depicted in Figure 3-6C. At 3DIV, many ATRX-null Ai14+ cells still express PDGFRα
despite the onset of an abnormal flattened and elongated morphology (Figure 3-6D).
Conversely, NG2 is not expressed in ATRX-null Ai14+ cells at 3DIV, even in cells
displaying the typical round OPC morphology (Figure 3-6E). These data suggest that
downregulation of NG2 precedes that of PDGFRα in ATRX-null OPC. At 9DIV,
however, there is a striking increase in ATRX-null Ai14+ cells displaying atypical
morphology coupled with NG2 and PDGFRα loss (Figure 3-6F). We also noted that at
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Figure 3-6 Loss of OPC identity after induction of Atrx deletion in Sox10+ cells.
(a) Transcriptional analysis of AtrxSox10Cre sorted Sun1GFP+ nuclei shows downregulation
in OPC markers compared to control (n=3-4 each genotype; asterisks indicate p<0.05,
Student’s t-test). (b) PDGFRα immunostaining (red) shows decrease proportion of
Sun1GFP+ PDGFRα+ cells in the corpus callosum of AtrxSox10Cre compared to control
mice. Scale bar, 100 µm (n=3 each genotype; Student’s t-test; p<0.05). (c) Timeline of
tamoxifen injection and primary culture performed for panels (d) to (g). (d)
Immunofluorescence staining for PDGFRα (green) shows all Ai14+ (red) cells are
PDGFRα+ at 3DIV, even in cells starting to undergo morphological changes (e)
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Immunofluorescence staining for NG2 shows Ai14+ (red) cells do not express NG2
(green) following 3DIV. (f) Loss of PDGFRα+ (green) staining in ATRX-null OPCs (red)
at 9DIV. (g) Ki67 staining (green) reveals diminished proliferative capacity in ATRXnull OPCs (red). Scale bar, 100 µm. In all graphs, error bars represent +/-SEM.
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9DIV, there are fewer ATRX-null Ai14+ cells that stain positively for the proliferation
marker Ki67, which could stem from the reduction of the growth promoting factor
PDGFRα (Figure 3-6G). We conclude that ATRX ablation in postnatal Sox10-expressing
OPCs leads to a reduction in the expression of OPC markers and a loss of progenitor
identity.

3.3.7 Postnatal Atrx inactivation in OPCs results in fewer
myelinating OLs and hypomyelination.
Considering the reduction in the normal OPC pool in the AtrxSox10Cre mice, we predicted a
consequent decrease in the number of differentiated and myelinating OLs. To establish
whether this is the case, we performed Immunofluorescence staining for APC, a marker
of differentiated OLs in P20 control and AtrxSox10Cre cortical sections.

There is a

significant reduction in the number of Sun1GFP+ ATRX-null OPCs that co-express APC
(41%) compared to Sun1GFP+ control OPCs (61.4%) (Figure 3-7A) (n=3 each genotype;
p<0.05 Student’s T-test), indicative of limited capacity of ATRX-null OPCs to
differentiate into OLs. RNA transcript levels of the OL-specific genes Mag, Mog, Mbp
are also decreased in P35 AtrxSox10Cre optic tract (n=3-4 each genotype; Mog, Mbp p<0.05
Student’s T-test) (Figure 3-7B). Furthermore, immunofluorescence staining for MOG and
MBP in brain cryosections at P20 show decreased level of these myelin proteins in the
corpus callosum and cortex of AtrxSox10Cre mice compared to controls (Figure 3-7C).
Reduced myelin protein expression in AtrxSox10Cre mice was confirmed by western blot
analysis of MAG, MOG and MBP (n=4 each genotype; MOG, MBP p<0.05 Student’s Ttest) (Figure 3-7D). These results demonstrate that ATRX-null OPCs either do not
survive or have lost the ability to differentiate into mature OLs, leading to reduced
myelination.

3.3.8 ATRX-null OPCs undergo ectopic astrogliogenesis
Ablation of the transcription factor Olig2 in OPCs in the postnatal cortex has been
reported to induce abnormal OPC differentiation to that of astrocytes
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Figure 3-7 Reduced capacity of ATRX-null OPCs to differentiate into OLs leads to
hypomyelination.
(a) Cell counts show significantly fewer Sun1GFP+ cells that co-stain for the mature OL
marker APC (red) in the P20 AtrxSox10Cre corpus callosum compared to controls. Scale bar,
100 µm (n=3 each genotype; p<0.05 Student’s T-test). (b) qRT-PCR analysis of Mag,
Mog and Mbp shows reduced RNA transcript levels in AtrxSox10Cre P35 optic tract
compared to controls

(n=3-4 each genotype; p<0.05 Student’s T-test). (c)

Immunofluorescence staining of myelin proteins MOG (green) and MBP (red) shows
decreased protein levels in P20 AtrxSox10Cre cortex (Ctx) and corpus callosum (CC)
(outlined in white dashed line) compared to controls. Scale bar, 500 µm. (d) Western blot
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analysis of MAG, MOG and MBP (left) and quantification (right) reveals decreased
expression of these proteins in P20 AtrxSox10Cre mouse forebrain extracts compared to
controls after normalization to actin (n=4 each genotype; p<0.05 Student’s T-test). In all
graphs, error bars represent +/-SEM and asterisks indicate significance of p<0.05.
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(Cai, Chen et al. 2007, Zhu, Zuo et al. 2012, Zuo, Wood et al. 2018). This, combined
with the observation that many ATRX-null OPCs take on an atypical morphology
reminiscent of astrocytes in vivo and in vitro, prompted us to investigate whether ATRXnull OPCs were adopting a more malleable state conducive to alternative fate
specification. To answer this question, we performed immunofluorescence staining of
known astrocyte markers in control and AtrxSox10Cre and control brain cryosections at P20.
We observe increased S100 calcium-binding protein β (S100β) staining in the corpus
callosum and cortex of in AtrxSox10Cre mice (Figure 3-8A). Cells co-expressing the
endogenous Sun1GFP and S100β (by immunostaining) were counted and the results
show a 19.9% increase in the number of Sun1GFP+ cells that co-express S100β in
AtrxSox10Cre compared to control corpus callosum (n=3 each genotype; Student’s T-test,
p<0.05) (Figure 3-8B). However, S100β can sometimes stain OLs (Hachem, Aguirre et
al. 2005) and indeed we observed a high proportion of control Sun1GFP+ OPCs that
expressed S100β (34.2%). We thus repeated this analysis using glial fibrillary acidic
protein (GFAP), another astrocyte marker. Similar to the results obtained for S100β, we
observed increased GFAP staining in the cortex of AtrxSox10Cre mice (Figure 3-8C). Cell
counts of GFAP+Sun1GFP+ cells showed a 15.2% increase in the proportion of
Sun1GFP+ cells that co-stain with GFAP in AtrxSox10Cre compared to control corpus
callosum (n=3 each genotype; Student’s T-test, p<0.05) (Figure 3-8D).
Utilizing the Ai14 reporter to assess AtrxSox10Cre cell morphology, we can easily see that a
subset of ATRX-null Ai14+ cells display arborized morphology typical of protoplasmic
astrocytes as previously observed in Olig2 knockout mice (Zhu, Zuo et al. 2012, Zuo,
Wood et al. 2018) (Figure 3-8E). These cells co-express GFAP (Figure 3-8E), indicating
that ATRX-null OPCs have gained the ability to undergo astrocyte differentiation in vivo.
To confirm this finding, we established primary glial cultures from control and
AtrxSox10Cre pups after 2 days of feeding from tamoxifen-injected mothers. After just
3DIV many AtrxSox10Cre derived cells (Ai14+) co-express GFAP which is not the case in
control cells (Figure 3-8F). By 9DIV, these cells display clear astrocyte morphology,
adhering to the plate unlike the rounded and raised OPC morphology in controls (Figure
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Figure 3-8 A subset of ATRX-null OPCs express astrocyte markers and adopt an
astrocytic morphology in vivo and in vitro.
(a) Immunofluorescence staining of the astrocyte marker S100β reveals increased levels
In the P20 AtrxSox10Cre mouse corpus callosum (CC) and cortex (Ctx) compared to
controls. Scale bars,100 µm. (b) Quantification of the number of Sun1GFP + OPCs that
stain positive for S100β shows a significant overlap compared to control (n= 3-4 for each
genotype). (c) Immunofluorescence staining of the astrocyte marker GFAP reveals
increased levels In the P20 AtrxSox10Cre mouse corpus callosum (CC) and cortex (Ctx)
compared to controls. Scale bars, 100 µm. (d) Quantification of the number of Sun1GFP+
OPCs that stain positive for GFAP shows a significant overlap compared to control (n=
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3-4 for each genotype). (e) Immunofluorescence microscopy detects co-staining of the
Cre-sensitive Ai14 reporter (red) and the astrocyte marker GFAP (green) in the
AtrxSox10Cre mouse brain in vivo (white arrowheads and higher magnification image on
the right. (f, g) Overlap of Ai14 (red) and GFAP (green) is also observed in AtrxSox10Cre
OPCs at 3DIV (f) and more drastically at 9DIV (g) (white arrow heads indicate
Sun1GFP+GFAP+ cells) but not in control cells. Scale bars, 100 µm. In all graphs, error
bars represent +/-SEM and asterisks indicate significance (p<0.05 Student’s T-test).
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3-8G). These results strongly suggest that a portion of ATRX-null OPCs have gained the
ability to generate astrocytes.

3.3.9 ATRX interacts with HDAC3 and occupies the Olig2 gene
locus
The histone deacetylase 3 (HDAC3) has been shown to directly promote the expression
of Olig2 in OPCs (Zhang, He et al. 2016). Deletion of Hdac3 results in decreased Olig2
expression, and an increased number of astrocytes at the expense of OLs (Zhang, He et
al. 2016) similar to what we observed upon Atrx deletion in postnatal OPCs. We thus
hypothesized that ATRX might directly bind and activate the Olig2 gene in conjunction
with HDAC3. Chromatin immunoprecipitation followed by quantitative PCR at various
points along the Olig2 gene (Figure 3-9A) in control cultured primary OPCs reveals
occupancy of ATRX specifically at the promoter, exon 1 and 3’ UTR of the gene (Figure
3-9B). Furthermore, HDAC3 and ATRX can be reproducibly co-immunoprecipitated in
control forebrain extracts (n=3) (Figure 3-9C). These results indicate that ATRX directly
binds to the Olig2 gene and can interact with HDAC3, suggesting that they may coactivate Olig2 expression to maintain OPC fate specification and suppress astrocytic fate
(Figure 3-9D).

3.4 Discussion
Chromatin remodelers have emerged as critical factors in the regulation of the OL lineage
progression and myelination, however, many questions remain as to the exact
mechanisms by which they exert their effects. In the present study, we report key
advances in our understanding of ATRX-mediated regulation of myelin development
through both systemic and cell-autonomous mechanisms. Mice lacking Atrx in all cells of
the forebrain and anterior pituitary exhibit reduced myelination that could be partially
rescued by early postnatal administration of thyroxine. Cell type specific inactivation of
ATRX in OPCs, but not in neurons, also led to hypomyelination. We determined that
ATRX directly binds to the Olig2 gene and interacts with HDAC3, previously identified
as an Olig2 gene activator. Consequently, Olig2 is not expressed in many ATRX-null
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Figure 3-9 ATRX interacts with HDAC3 and occupies the Olig2 gene locus.
(a) Schematic representation of the of the Olig2 gene locus. (b) ATRX ChIP-qPCR
analysis reveals direct binding to the Olig2 promoter, exon 1 and 3’UTR in chromatin
prepared from cultured wildtype OPCs. ChIP with IgG was performed in parallel as a
control (n=2). The location of the primer pairs used for qRT-PCR (P1-P6) are indicated
as boxes in (a). (c) Co-immunoprecipitation of ATRX and HDAC3 in P20 wildtype
mouse forebrain extracts (n=3). (d) Proposed model of ATRX function in OPCs. Neural
stem cells (NSCs) commit to the OL lineage by expressing the transcription factor Olig2
in primitive OPCs (PriOPCs). Olig2 expression is maintained in OPCs by HDAC3 and
ATRX. ATRX deletion in Sox10+ OPCs in the postnatal cortex prevents expression of
Olig2 and several OPC-specific markers, leading to increased fate malleability and
ectopic astrogliogenesis.
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OPCs, leading to a more permissive precursor state, perhaps through modified chromatin
accessibility, allowing for ectopic astrogliogenesis (Figure 3-9D).
We first demonstrated that myelination is abnormally decreased in AtrxFoxG1Cre mice,
which have low levels of circulating T4 (Watson, Solomon et al. 2013, Rowland, Jiang et
al. 2018). The thyroid hormone receptor is a transcriptional activator for several myelin
genes, promoting differentiation of OPCs (Farsetti, Mitsuhashi et al. 1991, Ibarrola and
Rodríguez-Peña 1997, Dong, Yauk et al. 2009). Following T4 supplementation in
AtrxFoxG1Cre mice there was a significant yet partial rescue in myelin gene and protein
expression. Whereas the number of APC-positive differentiated OLs increased following
T4 administration, the number of PDGFRα-positive OPCs was not restored to that of
controls.

Furthermore,

production

of

Olig2-expressing

OLs

following

T4

supplementation in AtrxFoxG1Cre mice was not observed, indicating that ATRX may be
essential for OPC production or survival in a mechanism distinct from T4 regulation.
Neuronal communication with OLs is emerging as a key regulator of myelination.
Neurons have been proposed to be necessary for adaptive myelination (Barres and Raff
1993, Gibson, Purger et al. 2014) and electrical activity from neurons has been shown to
induce OPC proliferation and remyelination (Gautier, Evans et al. 2015). Due to the fact
that ATRX is deleted in all cell types of the forebrain of AtrxFoxG1Cre mice, it was
conceivable that deletion of Atrx in neurons could result in a reduction of the OPC pool.
Nonetheless, deletion of ATRX in neurons did not result in defects in the development of
white matter, pointing to a role for ATRX in the regulation of OPCs and OLs cellautonomously. We therefore deleted Atrx specifically in OPCs postnatally by
administering tamoxifen to nursing mothers. Lineage tracing in vivo and in vitro revealed
that ATRX-null OPCs lack Olig2 and NG2 (Cspg4), with a more progressive loss of
PDGFRα expression. This might be due to the fact that Cspg4 is directly regulated by
HDAC3/p300 (Zhang, He et al. 2016) and Olig2 (Wang, Pol et al. 2014, Gotoh, Wood et
al. 2018) whereas Pdgfrα is regulated by Sox10 (Finzsch, Stolt et al. 2008), which is
activated by Olig2 (Kuspert, Hammer et al. 2011). PDGFRα is essential for OPC
proliferation and its eventual loss likely contributes to the reduction in Ki67+ cells in
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AtrxSox10Cre cultured OPCs at 9DIV. This depletion of the OPC pool explains the
reduction in myelinating OLs and hypomyelination observed in AtrxSox10Cre mice. The
absence of key fate determinants like Olig2, Sox10, NG2 and PDGFRα may allow
ATRX-null OPCs to acquire an expanded fate potential as they are no longer expressing
OL lineage proteins.
In support of this, we observed that ATRX-null OPCs are able to adopt an astrocytic fate
that is reminiscent of the effects of Olig2 deletion in the postnatal cortex (Zhu, Zuo et al.
2012, Zuo, Wood et al. 2018). The timing of Olig2 ablation has been shown to reflect the
number of OPCs that differentiate into astrocytes. When Olig2 is deleted constitutively in
NG2 expressing cells beginning at E16.5 there is almost complete conversion of these
cells to astrocytes (Zhu, Zuo et al. 2012). However, deletion of Olig2 at P2 or P18 results
in a 50% and 25% conversion to astrocytes, respectively (Zhu, Bergles et al. 2008, Zuo,
Wood et al. 2018). It is likely if we deleted Atrx earlier in development we may see an
increase in OL fate conversion to the astrocyte lineage in vivo. Our in vitro system is
designed for the mass production of OPCs and allows for more cell division than would
normally be observed in vivo, especially considering proliferation capacity declines with
age (Young, Psachoulia et al. 2013). Correspondingly, AtrxSox10Cre mixed glial cultures
have a drastic increase in OPC-derived astrocytes over a period of 9DIV.
The OL to astrocyte fate change could potentially be mediated by changes in the
chromatin landscape. It was shown that deletion of HDAC3 leads to a reduction in Olig2
expression, a loss of OLs and a concomitant increase in the number of astrocytes (Zhang,
He et al. 2016). In addition to direct activation of Olig2 with the histone acetyltransferase
(HAT) p300, HDAC3 also inhibits transcription of astrocyte genes when not bound to
p300 (Zhang, He et al. 2016). When HDAC3 is deleted, p300 is able to bind Stat3 to
activate genes in the astrocyte lineage (Zhang, He et al. 2016). We show that ATRX can
bind to both HDAC3 and the Olig2 gene locus indicating that ATRX may work in
conjunction with HDAC3 and p300 to activate Olig2 expression. This was unexpected as
histone deacetylation usually results in chromatin compaction and gene repression
(Ruthenburg, Li et al. 2007). Unconventionally, HATS and HDACs are found together,
primarily at actively transcribed genes and very rarely at repressed genes (Wang, Zang et
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al. 2009). It is possible that at the Olig2 gene, HDAC3 functions to remove acetyl groups
added by p300 during transcriptional initiation and elongation to help maintain an
appropriate level of acetylation and to reset chromatin modifications after gene
activation.
The finding that OPCs lacking ATRX aberrantly differentiate into astrocytes could also
have important implications in our understanding of ATRX loss of function in
astrocytomas (Abedalthagafi, Phillips et al. 2013). In fact, a recent report described a
patient with an oligodendroglioma that transitioned into astrocytoma upon loss of ATRX
(Kim, Jang et al. 2019). Additionally, this is the first report investigating the regulation of
myelination by ATRX linking hypomyelination to intellectual disability in ATR-X
syndrome patient. In addition to potential benefits of thyroxine administration, our study
highlights a novel role for ATRX in the oligodendrocyte-astrocyte lineage choice during
postnatal cortical development.

3.5 References
Abedalthagafi, M., J. J. Phillips, G. E. Kim, S. Mueller, D. A. Haas-Kogen, R. E.
Marshall, S. E. Croul, M. R. Santi, J. Cheng, S. Zhou, L. M. Sullivan, M. Martinez-Lage,
A. R. Judkins and A. Perry (2013). "The alternative lengthening of telomere phenotype is
significantly associated with loss of ATRX expression in high-grade pediatric and adult
astrocytomas: a multi-institutional study of 214 astrocytomas." Mod Pathol 26(11): 14251432.
Bagheri-Fam, S., A. Argentaro, T. Svingen, A. N. Combes, A. H. Sinclair, P. Koopman
and V. R. Harley (2011). "Defective survival of proliferating Sertoli cells and androgen
receptor function in a mouse model of the ATR-X syndrome." Hum Mol Genet 20(11):
2213-2224.
Barres, B. A. and M. C. Raff (1993). "Proliferation of oligodendrocyte precursor cells
depends on electrical activity in axons." Nature 361(6409): 258-260.
Berube, N. G., M. Mangelsdorf, M. Jagla, J. Vanderluit, D. Garrick, R. J. Gibbons, D. R.
Higgs, R. S. Slack and D. J. Picketts (2005). "The chromatin-remodeling protein ATRX
is critical for neuronal survival during corticogenesis." J Clin Invest 115(2): 258-267.
Billon, N., C. Jolicoeur, Y. Tokumoto, B. Vennström and M. Raff (2002). "Normal
timing of oligodendrocyte development depends on thyroid hormone receptor alpha 1
(TRalpha1)." The EMBO journal 21(23): 6452-6460.

131

Billon, N., Y. Tokumoto, D. Forrest and M. Raff (2001). "Role of thyroid hormone
receptors in timing oligodendrocyte differentiation." Dev Biol 235(1): 110-120.
Cai, J., Y. Chen, W.-H. Cai, E. C. Hurlock, H. Wu, S. G. Kernie, L. F. Parada and Q. R.
Lu (2007). "A crucial role for Olig2 in white matter astrocyte development."
Development 134(10): 1887.
Chen, Y., V. Balasubramaniyan, J. Peng, E. C. Hurlock, M. Tallquist, J. Li and Q. R. Lu
(2007). "Isolation and culture of rat and mouse oligodendrocyte precursor cells." Nat
Protoc 2(5): 1044-1051.
Courchesne, E., G. A. Press and R. Yeung-Courchesne (1993). "Parietal lobe
abnormalities detected with MR in patients with infantile autism." AJR Am J Roentgenol
160(2): 387-393.
Dong, H., C. L. Yauk, A. Rowan-Carroll, S.-H. You, R. T. Zoeller, I. Lambert and M. G.
Wade (2009). "Identification of Thyroid Hormone Receptor Binding Sites and Target
Genes Using ChIP-on-Chip in Developing Mouse Cerebellum." PLOS ONE 4(2): e4610.
Emery, B., D. Agalliu, J. D. Cahoy, T. A. Watkins, J. C. Dugas, S. B. Mulinyawe, A.
Ibrahim, K. L. Ligon, D. H. Rowitch and B. A. Barres (2009). "Myelin gene regulatory
factor is a critical transcriptional regulator required for CNS myelination." Cell 138(1):
172-185.
Farsetti, A., T. Mitsuhashi, B. Desvergne, J. Robbins and V. M. Nikodem (1991).
"Molecular basis of thyroid hormone regulation of myelin basic protein gene expression
in rodent brain." J Biol Chem 266(34): 23226-23232.
Finzsch, M., C. C. Stolt, P. Lommes and M. Wegner (2008). "Sox9 and Sox10 influence
survival and migration of oligodendrocyte precursors in the spinal cord by regulating
PDGF receptor alpha expression." Development 135(4): 637-646.
Franklin, R. J. M. and C. ffrench-Constant (2008). "Remyelination in the CNS: from
biology to therapy." Nature Reviews Neuroscience 9: 839.
Gautier, H. O. B., K. A. Evans, K. Volbracht, R. James, S. Sitnikov, I. Lundgaard, F.
James, C. Lao-Peregrin, R. Reynolds, R. J. M. Franklin and R. T. Káradóttir (2015).
"Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyte
progenitors." Nature communications 6: 8518-8518.
Giacomini, T., M. S. Vari, S. Janis, G. Prato, L. Pisciotta, A. Rocchi, A. Michelucci, M.
Di Rocco, P. Gandullia, G. Mattioli, O. Sacco, G. Morana and M. M. Mancardi (2019).
"Epileptic Encephalopathy, Myoclonus-Dystonia, and Premature Pubarche in Siblings
with a Novel C-Terminal Truncating Mutation in ATRX Gene." Neuropediatrics 50(5):
327-331.
Gibbons, R. J. and D. R. Higgs (2000). "Molecular-clinical spectrum of the ATR-X
syndrome." Am J Med Genet 97(3): 204-212.

132

Gibbons, R. J., D. J. Picketts and D. R. Higgs (1995). "Syndromal mental retardation due
to mutations in a regulator of gene expression." Hum Mol Genet 4 Spec No: 1705-1709.
Gibbons, R. J., D. J. Picketts, L. Villard and D. R. Higgs (1995). "Mutations in a putative
global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia
(ATR-X syndrome)." Cell 80(6): 837-845.
Gibson, E. M., D. Purger, C. W. Mount, A. K. Goldstein, G. L. Lin, L. S. Wood, I.
Inema, S. E. Miller, G. Bieri, J. B. Zuchero, B. A. Barres, P. J. Woo, H. Vogel and M.
Monje (2014). "Neuronal activity promotes oligodendrogenesis and adaptive myelination
in the mammalian brain." Science 344(6183): 1252304.
Goebbels, S., I. Bormuth, U. Bode, O. Hermanson, M. H. Schwab and K. A. Nave
(2006). "Genetic targeting of principal neurons in neocortex and hippocampus of NEXCre mice." Genesis 44(12): 611-621.
Gotoh, H., W. M. Wood, K. D. Patel, D. C. Factor, L. L. Boshans, T. Nomura, P. J.
Tesar, K. Ono and A. Nishiyama (2018). "NG2 expression in NG2 glia is regulated by
binding of SoxE and bHLH transcription factors to a Cspg4 intronic enhancer." 66(12):
2684-2699.
Hachem, S., A. Aguirre, V. Vives, A. Marks, V. Gallo and C. Legraverend (2005).
"Spatial and temporal expression of S100B in cells of oligodendrocyte lineage." Glia
51(2): 81-97.
Harris, M. L., K. Buac, O. Shakhova, R. M. Hakami, M. Wegner, L. Sommer and W. J.
Pavan (2013). "A Dual Role for SOX10 in the Maintenance of the Postnatal Melanocyte
Lineage and the Differentiation of Melanocyte Stem Cell Progenitors." PLOS Genetics
9(7): e1003644.
Hebert, J. M. and S. K. McConnell (2000). "Targeting of cre to the Foxg1 (BF-1) locus
mediates loxP recombination in the telencephalon and other developing head structures."
Dev Biol 222(2): 296-306.
Ibarrola, N. and A. Rodríguez-Peña (1997). "Hypothyroidism coordinately and
transiently affects myelin protein gene expression in most rat brain regions during
postnatal development." Brain Research 752(1): 285-293.
Iwase, S., N. G. Bérubé, Z. Zhou, N. N. Kasri, E. Battaglioli, M. Scandaglia and A. Barco
(2017). "Epigenetic Etiology of Intellectual Disability." The Journal of Neuroscience
37(45): 10773.
Kernohan, K. D., Y. Jiang, D. C. Tremblay, A. C. Bonvissuto, J. H. Eubanks, M. R.
Mann and N. G. Berube (2010). "ATRX partners with cohesin and MeCP2 and
contributes to developmental silencing of imprinted genes in the brain." Dev Cell 18(2):
191-202.

133

Kernohan, K. D., D. Vernimmen, G. B. Gloor and N. G. Berube (2014). "Analysis of
neonatal brain lacking ATRX or MeCP2 reveals changes in nucleosome density, CTCF
binding and chromatin looping." Nucleic Acids Res 42(13): 8356-8368.
Kim, J. H., W. Y. Jang, T. Y. Jung, S. Jung, K. K. Kim, H. S. Kim, E. H. Kim, M. C. Lee,
K. S. Moon and K. H. Lee (2019). "Recurrent Glioma With Lineage Conversion From
Oligodendroglioma to Astrocytoma in Two Cases." Front Oncol 9: 828.
Koob, M., V. Laugel, M. Durand, H. Fothergill, C. Dalloz, F. Sauvanaud, H. Dollfus, I. J.
Namer and J. L. Dietemann (2010). "Neuroimaging in Cockayne syndrome." AJNR Am J
Neuroradiol 31(9): 1623-1630.
Kuspert, M., A. Hammer, M. R. Bosl and M. Wegner (2011). "Olig2 regulates Sox10
expression in oligodendrocyte precursors through an evolutionary conserved distal
enhancer." Nucleic Acids Res 39(4): 1280-1293.
Lee, J. S., S. Lee, B. C. Lim, K. J. Kim, Y. S. Hwang, M. Choi and J.-H. Chae (2015).
"Alpha-thalassemia X-linked intellectual disability syndrome identified by whole exome
sequencing in two boys with white matter changes and developmental retardation." Gene
569(2): 318-322.
Levy, M. A., A. D. Fernandes, D. C. Tremblay, C. Seah and N. G. Bérubé (2008). "The
SWI/SNF protein ATRX co-regulates pseudoautosomal genes that have translocated to
autosomes in the mouse genome." BMC Genomics 9(1): 468.
Levy, M. A., K. D. Kernohan, Y. Jiang and N. G. Bérubé (2015). "ATRX promotes gene
expression by facilitating transcriptional elongation through guanine-rich coding
regions." Human Molecular Genetics 24(7): 1824-1835.
Li, H., Y. Lu, H. K. Smith and W. D. Richardson (2007). "Olig1 and Sox10 interact
synergistically to drive myelin basic protein transcription in oligodendrocytes." J
Neurosci 27(52): 14375-14382.
Lu, Q. R., T. Sun, Z. Zhu, N. Ma, M. Garcia, C. D. Stiles and D. H. Rowitch (2002).
"Common developmental requirement for Olig function indicates a motor
neuron/oligodendrocyte connection." Cell 109(1): 75-86.
Madisen, L., T. A. Zwingman, S. M. Sunkin, S. W. Oh, H. A. Zariwala, H. Gu, L. L. Ng,
R. D. Palmiter, M. J. Hawrylycz, A. R. Jones, E. S. Lein and H. Zeng (2010). "A robust
and high-throughput Cre reporting and characterization system for the whole mouse
brain." Nat Neurosci 13(1): 133-140.
Makagiansar, I. T., S. Williams, T. Mustelin and W. B. Stallcup (2007). "Differential
phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell
proliferation and migration." J Cell Biol 178(1): 155-165.

134

McKenzie, I. A., D. Ohayon, H. Li, J. P. de Faria, B. Emery, K. Tohyama and W. D.
Richardson (2014). "Motor skill learning requires active central myelination." Science
346(6207): 318-322.
Mitew, S., C. M. Hay, H. Peckham, J. Xiao, M. Koenning and B. Emery (2014).
"Mechanisms regulating the development of oligodendrocytes and central nervous system
myelin." Neuroscience 276: 29-47.
Mo, A., E. A. Mukamel, F. P. Davis, C. Luo, G. L. Henry, S. Picard, M. A. Urich, J. R.
Nery, T. J. Sejnowski, R. Lister, S. R. Eddy, J. R. Ecker and J. Nathans (2015).
"Epigenomic Signatures of Neuronal Diversity in the Mammalian Brain." Neuron 86(6):
1369-1384.
Nave, K. A. and H. B. Werner (2014). "Myelination of the nervous system: mechanisms
and functions." Annu Rev Cell Dev Biol 30: 503-533.
Nishiyama, A., X. H. Lin, N. Giese, C. H. Heldin and W. B. Stallcup (1996). "Colocalization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in
the developing rat brain." J Neurosci Res 43(3): 299-314.
Nishiyama, A., X. H. Lin, N. Giese, C. H. Heldin and W. B. Stallcup (1996). "Interaction
between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required
for optimal response to PDGF." J Neurosci Res 43(3): 315-330.
Noble, M., K. Murray, P. Stroobant, M. D. Waterfield and P. Riddle (1988). "Plateletderived growth factor promotes division and motility and inhibits premature
differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell." Nature
333(6173): 560-562.
O'Meara, R. W., S. D. Ryan, H. Colognato and R. Kothary (2011). "Derivation of
enriched oligodendrocyte cultures and oligodendrocyte/neuron myelinating co-cultures
from post-natal murine tissues." J Vis Exp(54).
Picketts, D. J., D. R. Higgs, S. Bachoo, D. J. Blake, O. W. Quarrell and R. J. Gibbons
(1996). "ATRX encodes a novel member of the SNF2 family of proteins: mutations point
to a common mechanism underlying the ATR-X syndrome." Hum Mol Genet 5(12):
1899-1907.
Pringle, N., E. J. Collarini, M. J. Mosley, C. H. Heldin, B. Westermark and W. D.
Richardson (1989). "PDGF A chain homodimers drive proliferation of bipotential (O-2A)
glial progenitor cells in the developing rat optic nerve." Embo j 8(4): 1049-1056.
Pringle, N. P., H. S. Mudhar, E. J. Collarini and W. D. Richardson (1992). "PDGF
receptors in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression
appears to be restricted to glial cells of the oligodendrocyte lineage." Development
115(2): 535-551.

135

Qi, Y., J. Cai, Y. Wu, R. Wu, J. Lee, H. Fu, M. Rao, L. Sussel, J. Rubenstein and M. Qiu
(2001). "Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain
transcription factor." Development 128(14): 2723-2733.
Ratnakumar, K., L. F. Duarte, G. LeRoy, D. Hasson, D. Smeets, C. Vardabasso, C.
Bönisch, T. Zeng, B. Xiang, D. Y. Zhang, H. Li, X. Wang, S. B. Hake, L. Schermelleh,
B. A. Garcia and E. Bernstein (2012). "ATRX-mediated chromatin association of histone
variant macroH2A1 regulates α-globin expression." Genes & Development 26(5): 433438.
Revet, I., L. Feeney, A. A. Tang, E. J. Huang and J. E. Cleaver (2012). "Dysmyelination
not demyelination causes neurological symptoms in preweaned mice in a murine model
of Cockayne syndrome." Proceedings of the National Academy of Sciences 109(12):
4627-4632.
Rowland, M. E., Y. Jiang, F. Beier and N. G. Bérubé (2018). "Inactivation of hepatic
ATRX in Atrx Foxg1cre mice prevents reversal of aging-like phenotypes by thyroxine."
Aging 10(6): 1223-1238.
Ruthenburg, A. J., H. Li, D. J. Patel and C. D. Allis (2007). "Multivalent engagement of
chromatin modifications by linked binding modules." Nat Rev Mol Cell Biol 8(12): 983994.
Sarma, K., C. Cifuentes-Rojas, A. Ergun, A. Del Rosario, Y. Jeon, F. White, R. Sadreyev
and J. T. Lee (2014). "ATRX directs binding of PRC2 to Xist RNA and Polycomb
targets." Cell 159(4): 869-883.
Sauvageot, C. M. and C. D. Stiles (2002). "Molecular mechanisms controlling cortical
gliogenesis." Curr Opin Neurobiol 12(3): 244-249.
Schwab, M. H., A. Bartholomae, B. Heimrich, D. Feldmeyer, S. Druffel-Augustin, S.
Goebbels, F. J. Naya, S. Zhao, M. Frotscher, M. J. Tsai and K. A. Nave (2000).
"Neuronal basic helix-loop-helix proteins (NEX and BETA2/Neuro D) regulate terminal
granule cell differentiation in the hippocampus." J Neurosci 20(10): 3714-3724.
Stolt, C. C., S. Rehberg, M. Ader, P. Lommes, D. Riethmacher, M. Schachner, U.
Bartsch and M. Wegner (2002). "Terminal differentiation of myelin-forming
oligodendrocytes depends on the transcription factor Sox10." Genes Dev 16(2): 165-170.
Takebayashi, H., Y. Nabeshima, S. Yoshida, O. Chisaka, K. Ikenaka and Y. Nabeshima
(2002). "The basic helix-loop-helix factor olig2 is essential for the development of
motoneuron and oligodendrocyte lineages." Curr Biol 12(13): 1157-1163.
Truch, J., J. Telenius, D. R. Higgs and R. J. Gibbons (2018). "How to Tackle Challenging
ChIP-Seq, with Long-Range Cross-Linking, Using ATRX as an Example." Methods Mol
Biol 1832: 105-130.

136

Wada, T., H. Ban, M. Matsufuji, N. Okamoto, K. Enomoto, K. Kurosawa and N. Aida
(2013). "Neuroradiologic Features in X-linked α-Thalassemia/Mental Retardation
Syndrome." American Journal of Neuroradiology 34(10): 2034-2038.
Wang, J., S. U. Pol, A. K. Haberman, C. Wang, M. A. O'Bara and F. J. Sim (2014).
"Transcription factor induction of human oligodendrocyte progenitor fate and
differentiation." Proc Natl Acad Sci U S A 111(28): E2885-2894.
Wang, Z., C. Zang, K. Cui, D. E. Schones, A. Barski, W. Peng and K. Zhao (2009).
"Genome-wide mapping of HATs and HDACs reveals distinct functions in active and
inactive genes." Cell 138(5): 1019-1031.
Watson, L. A., L. A. Solomon, J. R. Li, Y. Jiang, M. Edwards, K. Shin-ya, F. Beier and
N. G. Berube (2013). "Atrx deficiency induces telomere dysfunction, endocrine defects,
and reduced life span." The Journal of Clinical Investigation 123(5): 2049-2063.
Wei, Q., W. K. Miskimins and R. Miskimins (2004). "Sox10 acts as a tissue-specific
transcription factor enhancing activation of the myelin basic protein gene promoter by
p27Kip1 and Sp1." J Neurosci Res 78(6): 796-802.
Wolkin, A., H. Rusinek, G. Vaid, L. Arena, T. Lafargue, M. Sanfilipo, C. Loneragan, A.
Lautin and J. Rotrosen (1998). "Structural magnetic resonance image averaging in
schizophrenia." Am J Psychiatry 155(8): 1064-1073.
Young, K. M., K. Psachoulia, R. B. Tripathi, S.-J. Dunn, L. Cossell, D. Attwell, K.
Tohyama and W. D. Richardson (2013). "Oligodendrocyte dynamics in the healthy adult
CNS: evidence for myelin remodeling." Neuron 77(5): 873-885.
Yu, Y., Y. Chen, B. Kim, H. Wang, C. Zhao, X. He, L. Liu, W. Liu, L. M. Wu, M. Mao,
J. R. Chan, J. Wu and Q. R. Lu (2013). "Olig2 targets chromatin remodelers to enhancers
to initiate oligodendrocyte differentiation." Cell 152(1-2): 248-261.
Zhang, L., X. He, L. Liu, M. Jiang, C. Zhao, H. Wang, D. He, T. Zheng, X. Zhou, A.
Hassan, Z. Ma, M. Xin, Z. Sun, M. A. Lazar, S. A. Goldman, E. N. Olson and Q. R. Lu
(2016). "Hdac3 Interaction with p300 Histone Acetyltransferase Regulates the
Oligodendrocyte and Astrocyte Lineage Fate Switch." Dev Cell 36(3): 316-330.
Zhou, Q. and D. J. Anderson (2002). "The bHLH transcription factors OLIG2 and OLIG1
couple neuronal and glial subtype specification." Cell 109(1): 61-73.
Zhou, Q., G. Choi and D. J. Anderson (2001). "The bHLH transcription factor Olig2
promotes oligodendrocyte differentiation in collaboration with Nkx2.2." Neuron 31(5):
791-807.
Zhu, X., D. E. Bergles and A. Nishiyama (2008). "NG2 cells generate both
oligodendrocytes and gray matter astrocytes." Development 135(1): 145-157.

137

Zhu, X., H. Zuo, B. J. Maher, D. R. Serwanski, J. J. LoTurco, Q. R. Lu and A. Nishiyama
(2012). "Olig2-dependent developmental fate switch of NG2 cells." Development
139(13): 2299-2307.
Zuo, H., W. M. Wood, A. Sherafat and R. A. Hill (2018). "Age-Dependent Decline in
Fate Switch from NG2 Cells to Astrocytes After Olig2 Deletion." The Journal of
Neuroscience 38(9): 2359-2371.

138

Chapter 4

4

Discussion and Future Directions

4.1 Thesis Summary
This thesis describes the role of ATRX in the prevention of premature aging phenotypes
by the maintenance of cell type specific gene expression programs, which is partially
mediated by activated thyroid hormone receptor. Aging is known to be caused by DNA
damage and telomere abnormalities (López-Otín, Blasco et al. 2013) both of which are
observed following Atrx deletion in neuroprogenitor cells (Watson, Solomon et al. 2013).
We can now add transcriptional regulation of Igf1 in the liver and Olig2 in OPCs to the
list of evidence to support that ATRX is necessary for the prevention of premature aging
phenotypes.
In chapter two I built upon previous work that demonstrated mice lacking ATRX in all
cells of the forebrain and anterior pituitary (AtrxFoxG1Cre) exhibit premature aging-like
phenotypes (Watson, Solomon et al. 2013) (Figure 4-1). Aging phenotypes were
accompanied by low circulating levels of IGF-1 and T4 (Watson, Solomon et al. 2013).
Based on evidence that T4 activates expression of Igf1 (Xing, Govoni et al. 2012), T4
was administered to AtrxFoxG1cre mice during the prepubertal period. Despite restoration of
normal serum T4 levels, circulating IGF-1 was not recovered, nor was expression of Igf1
and several other thyroid hormone responsive genes. Unexpected Cre-mediated Atrx
inactivation in the liver likely explains the inefficacy of T4 treatment, indicating Atrx
plays a role in the activation of some thyroid hormone responsive genes, like Igf1.
Chapter 3 focuses on a more in-depth investigation of the only aging phenotype that was
ameliorated by T4 treatment, hypomyelination (Figure 4-1). I found that AtrxFoxG1Cre mice
exhibit hypomyelination and T4 treatment led to increased OL differentiation and partial
rescue of myelination. However, the number of OPCs was still reduced, suggesting
additional, T4-independet mechanisms for ATRX in myelin production. Specific
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Figure 4-1 Thyroxine-Dependent and -Independent Effects on Premature Aging
Phenotypes in ATRX Mutant Mice.
Despite restoration of normal serum T4 levels in AtrxFoxG1Cre mice, circulating IGF-1 was
not recovered, nor were several phenotypes of premature aging (left). AtrxFoxG1Cre mice
also display the premature aging phenotype hypomyelination and T4 treatment led to a
partial rescue of myelination (left). However, myelination rescue was partial suggesting
additional, T4-independet mechanisms for ATRX in myelin production. Specific
inactivation of Atrx in postnatal OPCs results in a failure to induce Olig2 expression,
ectopic astrogliogenesis and consequently, hypomyelination (right).

140

inactivation of Atrx in postnatal OPCs results in ectopic astrogliogenesis, a reduction in
the number of OLs and consequently, hypomyelination. ATRX associates with HDAC3
to directly activate expression of the fate specifying transcription factor Olig2.
Taken together, this thesis highlights the role of ATRX maintaining normal gene
expression in the liver and the OL lineage (Figure 4-1). It also expands upon many
controversial mechanisms in the literature, including Igf1 regulation, OPC multipotency
and HDAC-mediated gene activation.

4.2 The role of ATRX in IGF-1 signaling and the prevention of
premature aging phenotypes
Watson et al. previously described the AtrxFoxG1Cre mice with Atrx deficiency in the
forebrain and anterior pituitary resulting in low serum T4 and IGF-1 (Watson, Solomon
et al. 2013). AtrxFoxG1Cre mice display many phenotypes of premature aging, including
short lifespan and growth abnormalities (Watson, Solomon et al. 2013). Several lines of
evidence led us to attempt T4 supplementation to reverse phenotypes in AtrxFoxG1Cre mice.
First, the features of AtrxFoxG1Cre mice are comparable to mice deficient for the Zmpste
gene important for the processing of Lamin A (Mariño, Ugalde et al. 2010).
Supplementing Zmpste-/- mice with IGF-1 restored their somatotrope axis and drastically
improved phenotypes of aging and extending longevity (Mariño, Ugalde et al. 2010).
Second, mice lacking the receptor for TSH (Tshr-/-), have low T4, IGF-1 and growth
abnormalities, all of which were rescued following prepubertal T4 treatment (Xing,
Govoni et al. 2012). Third, several reports revealed that thyroid hormone is able to
control Igf1 expression in the early postnatal stages of life (O'Shea, Bassett et al. 2005,
Wang, Shao et al. 2010, Xing, Govoni et al. 2012). Thus, we hypothesized that the low
T4 observed in AtrxFoxG1Cre mice may be directly responsible for the reduction in serum
IGF-1 and subsequent premature aging phenotypes, and that T4 injections would reverse
these effects.
Contrary to our expectations, prepubertal T4 administration did not restore hepatic Igf1
transcription, serum IGF-1 levels or phenotypes of premature aging in AtrxFoxG1Cre mice
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(except for hypomyelination, discussed below). Upon further investigation, we found that
Atrx is unexpectedly absent in a subset of hepatocytes due to off-target Cre expression
from the Foxg1Cre allele. Moreover, it appears that ATRX is actually required in
hepatocytes for the expression of a subset of thyroid hormone responsive genes in the
liver, including Igf1, thus explaining the ineffectiveness of T4 treatment. ATRX is known
to bind another nuclear hormone receptor in the testes, the androgen receptor, to facilitate
transcription of its target genes (Bagheri-Fam, Argentaro et al. 2011). It is possible that
ATRX is able to bind TRs in a similar fashion, to facilitate transcription of its target
genes. With that said, we were unable to co-immunoprecipitate ATRX and Trβ in control
liver extracts (data not shown) and further studies are needed to determine if this
interaction does indeed occur.
The role of ATRX in IGF-1 signaling, could be clarified by generating mice with targeted
inactivation of Atrx in hepatocytes, the cell type that produces and secretes IGF-1 into the
serum. Hepatocyte-specific deletion of Igf1 results in an 80% reduction in serum IGF-1,
however, body weight and length were unaffected in the mice (Yakar, Liu et al. 1999),
unlike what is observed in whole body knockout of Igf1 (Liu, Baker et al. 1993, PowellBraxton, Hollingshead et al. 1993) and in our multiple organ ATRX-deficient mice. The
absence of deleterious effects on growth following liver deletion of Igf1 emphasizes the
importance of IGF-1 production at the tissue level. In light of this, it is possible that Atrx
deletion in hepatocytes would not be sufficient to elicit an aging phenotype.
The NER protein ERCC1 plays a key role in DNA repair, and has been linked to both
progeria in humans (Niedernhofer, Garinis et al. 2006) and in mice (McWhir, Selfridge et
al. 1993, Weeda, Donker et al. 1997, Dolle, Kuiper et al. 2011). It is therefore quite
intriguing that ERCC1 colocalizes with ATRX, CTCF and cohesin to repress imprinted
genes in the liver (Chatzinikolaou, Apostolou et al. 2017). The authors propose that in
hepatocytes lacking Ercc1, persistent DNA damage elicits changes to chromatin
structure, mediated by CTCF and ATRX, which adversely affect gene expression in the
liver (Chatzinikolaou, Apostolou et al. 2017). We have reported a similar role for ATRX
in the silencing of imprinted genes in the brain, although without the link to ERCC1
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(Kernohan, Jiang et al. 2010, Kernohan, Vernimmen et al. 2014). It is plausible that
ATRX works with ERCC1 in multiple tissue types to maintain chromatin structure as
well as normal gene expression programs, and that dysfunction in either protein results in
premature aging-like phenotypes.

4.3 The role of ATRX in myelination
A common symptom of aging is the gradual decline in white matter (Bartzokis, Beckson
et al. 2001, Bartzokis, Cummings et al. 2003). The structure of the aged myelin sheath
has dense cytoplasm, vesicular inclusions, multilamellar myelin fragments and membrane
ballooning, all indicative of axon degeneration (Stadelmann, Timmler et al. 2019). OLs
are highly susceptible to DNA damage and the latter is often associated with
hypomyelination (Tse and Herrup 2017). Additionally, myelin defects have been
observed in both patients (Koob, Laugel et al. 2010, James and Jose 2017) and mouse
models of Cockayne Syndrome (Revet, Feeney et al. 2012) further implicating impaired
genomic maintenance to the age-related decline in myelination. Neonatal hypothyroidism
has been shown to cause hypomyelination which can be reversed with thyroxine
treatment (Jagannathan, Tandon et al. 1998). Lastly, ATR-X syndrome patients display
abnormal myelination (Wada, Ban et al. 2013, Lee, Lee et al. 2015) but it has not been
reported whether patients display low levels of thyroid hormone or IGF-1. While
thyroxine treatment did not improve IGF-1 dependent aging-related phenotypes, it did
ameliorate myelination in the AtrxFoxG1Cre mice due to the direct transcriptional effects of
ligand-bound TRs on OL differentiation (Farsetti, Mitsuhashi et al. 1991, Billon,
Tokumoto et al. 2001, Billon, Jolicoeur et al. 2002) and myelin gene expression (Farsetti,
Mitsuhashi et al. 1991, Rodriguez-Peña, Ibarrola et al. 1993, Dong, Yauk et al. 2009). In
spite of this, myelin restoration in AtrxFoxG1Cre mice by thyroid hormone was partial,
indicating that ATRX is required independently of circulating T4 levels to control myelin
production.
To address the potential requirement for ATRX in cells of the nervous system, we
characterized myelination in two mouse models where ATRX is conditionally ablated
directly in OPCs, or in neurons. The observation that Atrx deletion in neurons does not
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result in hypomyelination during the developmental period does not rule out the
possibility that ATRX is required in neurons for the maintenance of the myelin sheath.
Axons are very important for maintaining myelination throughout life although the exact
mechanisms by which this occurs in the CNS have yet to be deciphered (Bercury and
Macklin 2015). For example, in diseases like Niemann-Pick type C disease (Yu and
Lieberman 2013) and Charcot–Marie–Tooth disease (Juárez and Palau 2012), mutations
in genes essential for neuron function and survival result in demyelinating neuropathy.
Recently, we demonstrated that deletion of Atrx in adult forebrain glutamatergic neurons
using the CaMKII-Cre driver results in a reduction of corpus callosum volume as
observed by magnetic resonance imaging in 9-month-old mice (data not shown). It is
plausible that AtrxNexCre mice may exhibit similar phenotypes of myelin deterioration later
in life. Additionally, we cannot rule out that myelin defects in AtrxFoxG1Cre mice are in part
due to deletion of Atrx in astrocytes or microglia causing non cell-autonomous effects on
OPCs and/or OLs. This idea could be tested in the future to better differentiate the role of
ATRX in each cell type with respect to myelin development.

4.4 The role of ATRX in the OPC-to-astrocyte fate switch
The investigation of the cell-autonomous effects of ATRX deletion on myelination was
especially insightful, leading to the discovery that ATRX is important in the OL and
astrocyte fate choice. We found that ATRX directly controls expression of the OL fate
specifying transcription factor Olig2, potentially in concert with HDAC3. Consequently,
the loss of ATRX in OPCs leads to ectopic astrogliogenesis, a reduction in both OPCs
and OLs, with subsequent hypomyelination. It is well documented that OLs can become
astrocytes in vitro (Raff, Miller et al. 1983) and research is ongoing to determine the
degree of plasticity that OPCs exhibit under normal conditions in vivo (Rivers, Young et
al. 2008, Kang, Fukaya et al. 2010). Under normal in vivo conditions, OPCs have been
shown to become astrocytes with high prevalence in the ventral forebrain (Zhu, Bergles
et al. 2008). While a small number of OPCs can become astrocytes in the dorsal cortex,
this is restricted to areas of grey matter and has not been observed at all in areas of white
matter (Zhu, Bergles et al. 2008). OL to astrocyte fate switch is documented in areas of
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grey matter of the dorsal cortex following deletion of Olig2 (Zhu, Zuo et al. 2012, Zuo,
Wood et al. 2018) or Hdac3 (Zhang, He et al. 2016). Following deletion of Atrx, we
provide compelling evidence that ectopic astrocyte production can occur in the corpus
callosum, the largest white matter tract in the brain.
The brain is a heterogenous tissue and is comprised of several highly interconnected cell
types. With this in mind, it is difficult to perform molecular experiments that are cell-type
specific. To evaluate the transcriptional effects of ATRX loss in OPCs, we employed
FANS to specifically isolate Sun1GFP+ control Sun1GFP+ Atrx-null nuclei. Using this
strategy, we could detect decreases expression of several OPC-specific genes (Olig2,
Pdgfrα, Cspg4, Gpr17) in ATRX-null OPCs, however, we were unable to detect a
difference in expression of astrocyte-related genes (Gfap, Nfia). This may be due to the
fact that there is a relatively small proportion of ectopic astrocytes (18.6%), making gene
expression changes difficult to detect. Single-cell RNA sequencing may be a more
effective way to determine gene expression changes in both the OPC, astrocyte and
potentially unknown populations of nuclei that are generated following ATRX deletion in
OPCs.
It is unclear whether Atrx-null, OPC-derived astrocytes are functional and
indistinguishable from control astrocytes. In mixed glial culture, OPCs proliferate on top
of an astrocyte monolayer which facilitate their growth by secretion of several growth
factors and signaling molecule. PDGF and other growth factor levels could be measured
from the media of both AtrxSox10Cre and control cultures to determine if there is
discrepancy in growth factor secretion by ATRX-null OPC-derived astrocytes.
In AtrxSox10Cre mice, around 50% of ATRX-null OPCs in the corpus callosum still express
Olig2 and go on to produce normal, myelinating OLs. In addition to this, in the adult
brain OPCs make up 5% of the total cells (Dawson, Polito et al. 2003). Resident adult
OPCs proliferate and differentiate following myelin injury or neurodegeneration (Kang,
Fukaya et al. 2010), contributing to remyelination in the CNS (Gautier, Evans et al.
2015). The next step will be to determine if the hypomyelination observed at P20 in
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AtrxSox10Cre mice persists into adulthood or if remyelination occurs due to the large
number of OPCs still present. Regardless of the potential for remyelination, the behaviour
of these mice can be evaluated at different points in development to determine if
hypomyelination affects cognitive functions. Deletion of Olig2 in differentiated but
immature OLs leads to memory deficits, elevated glutamate levels and anxiety-like
behaviours (Chen, Zhang et al. 2015, Chen, Wang et al. 2019). If these aberrant
behaviours are observed in our model, it may be indicative of intellectual disability and
autistic-like features observed in ATR-X syndrome patients.

4.5 The proposed mechanisms by which ATRX promotes Olig2
expression in OPCs
The discovery that ATRX may work together with HDAC3 to control Olig2 expression
was unexpected, as histone deacetylation usually results in chromatin compaction and
gene repression (Ruthenburg, Li et al. 2007). Nevertheless, HATs and HDACs are often
found together at actively transcribed genes although the role of HDACs in gene
activation is still under investigation (Wang, Zang et al. 2009). It has it has been proposed
that, following gene activation, the transcriptional machinery alters chromatin structure
and that acetylation needs to be reset to allow for gene reactivation (Wang, Kurdistani et
al. 2002). It appears the role of HDACs at active genes is to maintain the proper level of
acetylation to promote gene expression (Wang, Zang et al. 2009), however, more
research is needed to confirm this hypothesis.
What is a potential mechanism by which ATRX, HDAC3 and p300 may control the
expression of certain genes like Olig2? In OPCs, HDAC3 was shown to only activate
genes like Olig2 when bound with the HAT p300 (Zhang, He et al. 2016). The exact role
of H3.3 at enhancers and active genes is still under investigation. In a recent report, it was
shown that deletion of H3.3 negatively impacts p300 enzymatic activity and that
phosphorylation of H3.3S31, allows H3.3 to become a nucleosomal cofactor for p300 to
promote enhancer acetylation (Martire, Gogate et al. 2019). Deletion of ATRX could
potentially result in a failure to deposit H3.3 which is predicted to cause a reduction in
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p300 activity and a subsequent decrease in Olig2 gene expression due to presence of
HDAC3 without HAT p300. This mechanism provides an explanation for the
controversial ability of OPCs to become astrocytes only in certain conditions.
It will be important to understand if the recruitment of p300, HDAC3 and H3.3 is
perturbed by deletion of Atrx in OPCs. Our ATRX ChIP experiment was performed on
control OPCs physically purified from mixed glial cultures. ATRX-null OPCs that take
on an astrocyte fate, change morphology and adhere to the surface of the culture dish and
can no longer be separated from control astrocytes. A method to investigate the role of
ATRX in p300, HDAC3 and H3.3 recruitment, would be to use FANS to obtain purified
nuclei in control and AtrxSox10Cre brain extracts. It will also be valuable to investigate
chromatin accessibility using assay for transposase-accessible chromatin using
sequencing (ATAC-seq). If HDAC3 activity is enhanced and/or p300 activity is
attenuated at Olig2 following ATRX deletion, this will correspond to less accessible
chromatin and fewer reads using ATAC-seq.

4.6 ATRX, HDAC3 and p300 may work together to maintain the
balance of gene activation and repression in several tissues
The data in this thesis are provocative and provide key new information regarding ATRX
function, bringing to the front new ideas and hypotheses. For example, there may be a
common mechanism by which ATRX, HDAC3 and p300 function to regulate the
development not only of OPCs, but also of thyrotropes in the pituitary and hepatocytes in
the liver. We previously reported perturbed gene expression of both Atrx and Tshβ in the
pituitary as well as serum levels of TSH in AtrxFoxG1Cre mice (Watson, Solomon et al.
2013). Diminished TSHβ serum levels are predicted to reduce circulating T4 in
AtrxFoxG1Cre mice because TSHβ activates T4 production in the thyroid. Unliganded TRs
repress target genes through the recruitment of NCoR co-repressor protein which exerts
its effects in complex with HDAC3 to enhance deacetylation and gene repression (Li,
Wang et al. 2000). HDAC3-NCoR have been shown to repress expression of Pit1 (Xu,
Lavinsky et al. 1998), the transcription factor responsible for the production of
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thyrotropes in the pituitary and expression of Tshβ (Scully and Rosenfeld 2002). NCoR
and unliganded TR have also been shown to repress transcription of several thyroid
hormone responsive genes in the liver (Astapova, Lee et al. 2008). Lastly, HDAC3 has
been shown to induce expression of Olig2 when coupled with p300 (Zhang, He et al.
2016). With this in mind, one could envision a scenario in which ATRX is in complex
with HDAC3 and p300 to activate genes in multiple tissues. In the absence of ATRX,
p300 activity is reduced and HDAC3 deacetylation activity is enhanced, leading to
abnormal gene inhibition in the pituitary (Pit1), the liver (Igf1, Ghr, Prlr) and in the brain
(Olig2), ultimately causing premature aging phenotypes.

4.7 Thesis conclusions
Premature aging research has focused on elucidating the mechanisms behind
evolutionarily conserved genetic and biochemical pathways that control the aging process
to ultimately extend lifespan. The insulin and IGF-1 signaling pathway has been broadly
studied in both premature aging and normal aging and its manipulation can either reduce
or extend lifespan in several model organisms (López-Otín, Blasco et al. 2013). On the
other hand, although hypothyroidism has been observed in aging and premature aging
models, the exact reason for this is still under investigation (Gussekloo, van Exel et al.
2004, Atzmon, Barzilai et al. 2009, Over, Mannan et al. 2010, Visser, Bombardieri et al.
2016).
To assess the reported role of thyroid hormone mediated activation of Igf1 expression and
rescue of premature aging phenotypes (Xing, Govoni et al. 2012), I directly injected mice
with T4. Despite restoration of T4 levels to that of controls, AtrxFoxG1Cre mice still
displayed several premature aging phenotypes. The lack of rescue was due to a failure to
recover IGF-1 serum levels and Igf1 transcript levels in the liver. To determine if thyroid
hormone signaling was intact in the AtrxFoxG1Cre liver, the main site of IGF-1 production, I
assessed transcript levels of several genes normally activated by ligand-bound TR.
Results showed that although T4 injections was able to activate transcription of several
genes that were not expressed in AtrxFoxG1Cre livers, other genes were still
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transcriptionally repressed, including Igf1. This unexpected result prompted investigation
into the liver and the discovery that ATRX was absent from a subset of hepatocytes in the
AtrxFoxG1Cre liver particularly at P14. This result was quite unexpected as ATRX levels
were reported to be that of control in AtrxFoxG1Cre livers at P20 (Watson, Solomon et al.
2013) and likely reflects proliferation or infiltration of ATRX+ immune cells in the liver
that occurs sometime between P14 and P20. This suggests that ATRX may be required in
the liver to co-activate Igf1, potentially by binding liganded TR, similar to the reported
mechanism with AR in the testes (Bagheri-Fam, Argentaro et al. 2011). By understanding
the molecular mechanisms that control premature aging, we can begin to determine what
causes normal aging and ultimately ameliorate symptoms in progeroid syndromes and in
normal aging.
Both Cockayne syndrome patients (Koob, Laugel et al. 2010) and ATR-X syndrome
patients (Wada, Ban et al. 2013, Lee, Lee et al. 2015) display hypomyelination which
could contribute to cognitive deficits seen in these syndromes. Additionally, ligandbound thyroid hormone has been shown to directly activate MBP and MAG expression as
well as induce differentiation of OLs independently of IGF-1 (Farsetti, Mitsuhashi et al.
1991). Thyroxine administration did improve hypomyelination and increase the number
of differentiated OLs in AtrxFoxG1Cre mice. T4 supplementation is a conceivable treatment
for ATR-X syndrome patients displaying hypomyelination and as more patient data
becomes available, we will be able to determine if they exhibit low serum T4. Due to the
fact that the rescue in myelination was partial, I hypothesized ATRX may be required
cell-autonomously in the brain to promote OL development. Atrx deletion in OPCs
resulted in Olig2 downregulation allowing for astrocyte differentiation at the expense of
the OL production. Although it is well established that OPCs have the potential to
become astrocytes in vitro (Raff, Miller et al. 1983, Franklin, Bayley et al. 1995), there
have been very few cases this has been demonstrated in vivo (Zhu, Bergles et al. 2008,
Zhu, Zuo et al. 2012, Zhang, He et al. 2016, Zuo, Wood et al. 2018). The fact that
ATRX-null OPCs can become astrocytes provides evidence that OPCs are indeed able to
commit to the astrocyte lineage under certain conditions. ATRX is also able to directly
bind the Olig2 locus potentially in conjunction with HDAC3 to activate its expression,
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promote the development of the OL lineage and drive CNS myelination. The discovery
that ATRX is essential for Olig2 transcription has implications not only for ATR-X
syndrome patients but also patients with astrocytoma as a recent report described an
oligodendroglioma that converted to astrocytoma upon loss of ATRX (Kim, Jang et al.
2019). One potential explanation is that the cell of origin for many ATRX-null
astrocytomas might be OPCs that acquire an astrocytic fate.
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